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Abstract
5-Aminolevulinic acid (ALA), one of the body’s naturally occurring molecules in 
the biosynthetic pathway to haem, is being used in Photodynamic Therapy (PDT), 
a new approach to the treatment of cancer.
It is a highly reactive molecule, which, upon standing in solution, dimerises to 
give 2,5-di-((5-carboxyethyl) pyrazine. This reaction, and other similar ones, have 
been studied in some detail as it remains a major problem in the clinic, lowering 
the dose of active drug being administered and forming a molecule of which the 
toxicology is not known.
The initial product of dimérisation is a dihydropyrazine, which is immediately 
oxidised in air to give a pyrazine. The chemistry of dihydropyrazines has also been 
investigated.
The chemical synthesis of ALA itself has been optimised and derivatives of the 
molecule have been prepared to try to prevent this dimérisation from occurring 
and, potentially, increase the tissue selectivity of the drug. Twelve derivatives of 
ALA have been prepared and biologically tested for their activity in PDT.
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Chapter 1 
Introduction
1.1 General Introduction
In the UK over 190 000 new skin tumours are diagnosed every year. This figure is 
rising, as is the death rate fi-om them.'°^ Two thousand four hundred new cases of 
oral cancer are reported each year in the UK alone and the prognosis is no better 
than it was forty years ago.*^  ^Lung cancer is the main cause of cancer deaths in 
the Western World and, for the majority of patients, conventional treatment fails 
and tumours continue to progress.^^^ Cancer causes more deaths among children 
under 15 years of age than any other disease, and over half the deaths of people 
aged less than 65. Most of the diseases that were common killers in the nineteenth 
and early twentieth centuries, such as leprosy, bubonic plague (black death) and 
tuberculosis are now curable and have been more or less eradicated. Cancer still 
remains a major problem. Currently, there are three main approaches to the 
treatment of cancer. These are radiotherapy, chemotherapy and surgical excision, 
all of which are harsh. Radiotherapy and chemotherapy are non-selective, killing 
cells other than tumour cells, and causing many further side effects. Surgical 
excision is not possible in many cases, but where it is it leads to severe 
mutilation.
A relatively new and promising approach in the treatment of cancer is 
photodynamic therapy (PDT) and involves the use of a drug which is activated by 
light. It is an area where much research is being targeted. Many light sensitive 
drugs, known as photosensitisers, are being tested for potential use in areas such 
as dermatology and gynaecology, but the majority of work is aimed at the 
selective detection and destruction of cancerous tumours.
1.2 What is Cancer?
Any multicellular organism can contract cancer and it is not a recently discovered 
disease. Ancient Egyptians in 1600 BC were aware of tumours and documented 
them in hieroglyphics. Autopsies on mummies have shown bone lesions and 
cancerous growths have been found even in dinosaur bones.
It was Hippocrates who first used the term ‘carcinoma’ to describe a growth 
which spread and then destroyed a patient. In the nineteenth century, scientists 
such as Pasteur were researching the topic but believed that tumours were 
infectious. By 1914, however, it was known that certain groups of chemicals 
caused cancer. Today we know that both chemicals, and other infectious agents 
can cause malignant tumours to develop.
The words ‘cancer’ and ‘tumour’ are used commonly to refer to cancer. The 
medical term is ‘neoplasm’. Tumours can be either benign or malignant. Benign 
tumours do not metastasise, i.e. they do not have secondary growths originating 
fi-om the primary tumour. They are encapsulated, or contained, and grow very 
slowly. Malignant tumours are much more dangerous as they do metastasise. 
They are not contained in one small area but rapidly spread to other parts of the 
body. Cancer is, therefore, defined as a malignant neoplasm. The term tumour is 
very general and refers to any abnormal mass of tissue. Neoplasms are tumours 
but so are any other swellings or lumps, e.g. scars or bruises.
1.3 The History of Photodynamic Therapy
The use of light in medicine originated in Ancient Greece 4000 years ago. Plants 
containing psoralins (Fig. 1.1) were ingested and, when activated by sunlight, 
brought about repigmentation of the skin.’®^
Figure 1.1 - A psoralin (7H-furo[3,2-g][l]benzopyran-7-one)
The Greek physician Herodotus first documented the healing property of light and 
named it Heliotherapy.'^^ This 4000 year old treatment, now known as PUVA 
(Psoralin and UVA light) is still used today for vitilago, psoriasis, acne, eczema, 
herpes simplex virus (HSV) and a wide range of other dermatological 
diseases.
In the 1890s Finsen treated lupus vulgaris, a tubercular skin complaint (TB) with 
light from a carbon arc lamp. Queen Alexandra helped him to establish the 
treatment in the UK at the London Hospital in Whitechapel, where they had a 
Hght department by the early 1900s. Finsen won the Nobel prize in 1903 and the 
original Hght source is now on display in London’s Science Museum.
The most promising areas of photomedicine, however, involve the use of a 
combination of Hght and a photosensitising drug. It was beHeved, in the nineteenth
century, that all effective drugs were coloured.’®^ Even now, the most effective 
sensitisers are porphyrins, the word coming from the Greek, ]Jop(pvpo<j 
(porphuros), meaning purple. Two years after X-rays were discovered at the turn 
of the twentieth century, Raab found that acridine dye (Fig. 1.2), in the presence 
of light, killed Paramecia cells. This was the first published example of a chemical 
showing a photosensitising effect.^
CIH.H2N" NH2.HCI
Figure 1.2 - An acridine dye (acridine yellow G)
A few years later, in 1903, the first clinical example of photodynamic therapy 
involved the treatment of a 70 year old woman with a facial tumour. Von 
Tappeiner and Jesionek used a 5 % solution of eosin dye (Fig. 1.3).
COONa
.NO.
NaQ-
Figure 1.3 - An eosin dye (4’5’dibromo-2’7’-dinitrofluorescein)
This was painted onto the growth at intervals over a two month period. During 
this time the patient was exposed to both sunlight and light from a lamp. This 
resulted in regression of the tumour and very little scarring. Although they
showed some positive results, these original photosensitisers, eosin and acridine, 
are no longer used due to their carcinogenic nature. The term ‘photodynamic 
therapy’ was introduced by von Tappeiner. It arises from the German term 
photodynamische Wirkung and describes the damage of living tissue using a drug 
and l i g h t . V o n  Tappeiner also discovered the necessity for oxygen in a 
photodynamic reaction.
The first use of porphyrins in PDT was demonstrated by Meyer-Betz in 1913. He 
injected himself with 200 mg of haematoporphyi'in (Hp) (Fig. 1.4) and felt no ill- 
effects until he spent ten minutes in the sunlight. This caused him to suffer 
extreme swelling and a painful, disfiguring oedema. He remained sensitive to light 
for several months. It is, therefore, not surprising that PDT has made
little progress until recently.
HO.
OHNH
NH
Figure 1.4 - Haematoporphyrin (Hp).
Policard, in 1925, studied the ability of porphyrins to produce a phototoxic 
r eac t ion .Auler  and Banzer in 1942 discovered that Hp accumulated to a
greater extent in tumour cells than healthy ones^ ®^  and this led to the idea of using 
porphyrias for cancer therapy.**®
Work in the early 1950s by Schwartz showed that Hp, itself, was not the cause of 
the long term effects in Meyer-Betz’s self-experiment. They were due to 
oligomeric mixtures in the material which had been extracted from blood. He 
formed a compound known as haematoporphyrin derivative (HpD)**  ^ which was 
shown to have a better tumour localising effect than haematoporphyrin itself.
Single case studies of HpD as a cancer treatment began in the early 1970s,**  ^but 
it was not until 1976 that the first systematic studies on PDT in the clinic were 
initiated by Dougherty at the Rosewell Park Cancer Institute, Buffalo, USA.*®^  
He found that further purification of HpD by gel exclusion chromatography 
removed the monomers leaving an oligomeric substance now known as Photofrin 
I I ®  (pp[).*®^  PII has regulatory approval from health boards in the US, Canada, 
Japan and Europe for use in PDT. Many new second generation photosensitisers 
are undergoing clinical trials and PDT has become a fourth option for the 
treatment of cancer. Interest in the area has, therefore, increased very rapidly and 
now over 10 000 papers have been published.
1.4 Photochemistry - How Does Photodynamic Therapy Work?
Photochemical processes in biology can be divided into two categories. The first 
concerns positive uses, such as photosynthesis and vision which are advantageous 
to the organism. The other area, which includes the photodynamic effect, can be 
thought of as destructive to the organism. PDT, however, can be used to our 
advantage.*®®
It involves a two step process. The first of these requires the introduction of a 
light sensitive compound, or a pro-drug into the affected area. This can be done 
either orally or intravenously by systemic administration. In the case of skin 
cancer, topical application, in a cream, is a direct form of administration. There 
must then be an appropriate time interval before the tumour is irradiated with 
light. This is to allow maximum build-up of the photosensitising agent within the 
tumour. Light can be delivered directly or via a fibre optic and must be at the 
correct wavelength to activate the drug (Fig. 1.5).
Tumour
Drug-light 
interval 
( -3 -9 6  h) 
------
^  Systemic 
administration 
of photosensitizer
Irradiation of 
tumour with 
appropriate 
dose of visible 
light via 
fibre optic
Necrosed
tumour
Figure 1.5 - Schematic diagram of PDT.
The light is absorbed by the pbotosensitiser allowing three competing processes to 
occur. It can fluoresce, or the activated molecule can be destroyed by a 
pbotobleacbing process. The third possibUity involves a type I or II photochemical 
reaction and this is the basis for PDT destruction in tumours (Fig. 1.6).^*^
Crossover
Light
AbsorbanceFluorescence
Substrate
Oxidised
Substrate
Sensitiser 
ground state
Sensitiser triplet 
state
Sensitiser singlet 
state
Figure 1.6 - Schematic representation of photochemistry involving a pbotosensitiser.
1.4.1 Fluorescence
After absorption of a photon of light, photosensitisers are converted to an excited 
singlet state, which is very short lived. From this state they can decay back to the 
ground state and, in doing so, emit light. This emission is known as 
fluorescence*’"^ and, as it is easily detected, it can be used clinically in 
photodynamic detection (FDD) of tumours”  ^ which will be discussed later in 
Section 1.11.
1.4.2 Photobleaching
Photobleaching effects hinder PDT and are caused by a photoinduced chemical 
reaction.”  ^During light exposure, photosensitisers can be gradually destroyed by 
singlet oxygen, or other free radicals, yielding products which can no longer 
contribute to PDT.” "*
1.4.3 Type I and II Photochemical Processes
The excited singlet state of a pbotosensitiser can undergo an inter-system 
crossover converting it to a triplet state. This is a spin-forbidden process but, 
although forbidden processes are less likely to occur, a good pbotosensitiser wiU 
undergo the reaction readily. The sensitiser excited state relaxes by two different 
mechanisms, either by phosphorescence or by spin exchanging with another 
molecule which is in its triplet state. As phosphorescence is also a forbidden 
process, the triplet state can last for microseconds, so is regarded as fairly long- 
lived and can react with other molecules surrounding it.” ^
A type I photochemical reaction involves the interaction of this triplet state with a 
biologically active molecule. This occurs by either electron or hydrogen transfer 
and results in the formation of radicals of the sensitiser. These can react with 
molecular oxygen producing hydroxyl radicals, hydrogen peroxide and superoxide 
anions.” "* Although photosynthesis makes use of this,***^  type I reactions play a 
very minor role in PDT.
The major mechanism for tumour destruction is due to a type II photochemical 
process (Fig. 1.7).
D -t-ho D*(S) absorption
D*(S) D*(T) intersystem crossing
D*(T) + 02(T) ^  D(S) + 02*(S) energy transfer
0 2 *(S) ^  0 2 (T) deactivation
02*(S) + X -------- ^  X' reaction
Figure 1.7 - The type II photochemical process. D is the light absorber (dye) in the ground state, 
D* (S) is the excited singlet state of D, D* (T) is the excited triplet state of D, O2 (T) is the
ground triplet state of Oj, Og* (S) is oxygen in its excited singlet state and X is the target of
oxidation.
This involves a spin exchange reaction directly between the excited state of the 
pbotosensitiser and triplet oxygen, the ground state of molecular oxygen. This 
results in the generation of the highly reactive singlet oxygen species which 
undergoes many chemical reactions. In biological molecules these consist mainly 
of oxidations and cycloadditions which are very disruptive to biological processes 
(Fig. 1.8).
As proteins and unsaturated lipids, the main constituents of cell membranes, 
contain many double bonds, they are good targets for singlet oxygen attack. 
Sulfur containing amino acids are oxidised to sulfoxides. Histidine and tryptophan
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react to produce endoperoxides, releasing hydroxyl radicals, which react with 
DNA.
cholesterol
CgHj7
*02
OOH
NHR
CO2R
tiyptophan
*02
NHR
CO2R
Orfx") O2 O N.HN
O''N '
guanine
Figure 1.8 - Some chemical reactions involving biological molecules and singlet oxygen
As the pbotosensitiser transfers its energy to molecular oxygen it is not destroyed. 
It can return to its ground state to absorb another photon and repeat the cycle, 
acting as a catalyst (Fig. 1.6).*”
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PDT, therefore, requires only a photo sensitising drug, light, and the presence, of 
molecular oxygen to destroy tumours.
1.5 Light Sources and Penetration
The ideal pbotosensitiser is one which can be activated at wavelengths in the red 
to near infrared region of the spectrum, as light of longer wavelengths penetrates 
deeper into the tumour (Fig. 1.9).^'^ Even at this wavelength the maximum depth 
of tumour necrosis in most tissues is only approximately five millimetres.^’^
I//MW
nm 800700 600 500 400
membrane
blood1 cm
artery
Figure 1.9 - Representation of a tumour section showing light penetration.
The exact wavelength required for photosensitisation varies from drug to drug, 
e.g. PH and Protoporphyrin DC (PpDC) absorb at 630 nm, phthalocyanines at 675 
nm and benzoporphyrin derivative (BPD) at 690 nm.” ^
Originally, sunlight was used to activate the sensitiser but due to its low intensity 
at 630 nm and problems with control and delivery, it is no longer commonly 
applied.” * Slide projectors and gas discharge lamps were also among the original 
sources used.” ’ The two main categories of light delivery systems in PDT today, 
however, use more sophisticated wavelength filtered lamps and lasers.” *
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Lasers are the most common source of light used in the activation of 
photosensitisers.’’’* Laser beams of a single wavelength can be delivered through 
single optical fibres easily, allowing light to be delivered to the tumour directly. 
The most commonly used lasers in PDT are argon ion- and copper vapour- 
pumped dye systems. These are very expensive, bulky, slow to warm up and 
require highly trained operators. New technology is producing laser diode arrays 
which are much more transportable and ready for use in a shorter time but, as yet, 
they cannot produce light in the 630 nm region.’”^
Extensive work is also underway in the development of non-laser light sources. 
Arc lamps and fluorescent bulbs are inexpensive but cannot be used with fibre 
optics. The light must be filtered to give the correct wavelength to maximise 
absorption of the pbotosensitiser and tissue penetration.” ^
One non-laser lamp for use in PDT which costs one twentieth of the price of a 
laser is being developed at the Paterson Institute in Manchester. It has been used 
to treat two hundred cases of skin cancer successfully using an arc of 
concentrated light which is cooled down then channelled through a series of 
optics, taking just forty-five minutes.’^ ”
As new photosensitisers which absorb at higher wavelengths are discovered, 
research into new laser and non-laser light sources is vital for PDT.'^’
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1.6 Photosensitisers
1.6.1 First Generation Photosensitisers
1.6.1.1 Haematoporphyin (Hp)
Hp (Fig. 1.4) was first isolated from dried blood in 1841 and was one of the first 
compounds to be tested as a pbotosensitiser. It was thought that tumours could 
take up and retain the drug more readily than normal cells.
Experiments in the 1950s, however, showed that it was not haematoporphyrin 
which caused the long-term effects that were observed, e.g. in Meyer-Betz’s self­
experiment. It was an ohgomeric mixture of porphyrins, resulting from the 
extraction method used to isolate Hp from blood, that was the photosensitising 
agent. This mixture is now known as Haematoporphyrin derivative (HpD).” ^
1.6.1.2 Haematoporphyrin Derivative (HpD)
Schwartz prepared the first batch of HpD by treating HP with sulfuric acid in 
acetic acid. This acetylated the alcohol groups of Hp. He then treated the 
acetylated mixture with sodium hydroxide to form the oligomer known as HpD 
(Fig. 1.10).
HpD is a mixtur e of non-metallic oligomeric porphyrins, each molecule containing 
up to eight porphyrin building blocks.”’^  In 1966, a woman with breast cancer was 
treated with limited success using HpD and light and this experiment was the first 
clinical example of the use of PDT in cancer therapy.”  ^ The selectivity of HpD
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into tumours over normal tissue is only about two or three to one in most 
organs”  ^but haematoporphyrin based drugs are not toxic in the absence of light 
and have been used to treat almost 10 000 p a t i e n t s .T h e  therapy has been 
shown to be successful. Eleven out of twelve patients suffering from cancer of the 
larynx who were treated with HpD showed a complete response, i.e. total 
regression, after only one course of PDT.’^ '’ HpD is still one of the most 
frequently used photosensitisers.”*^
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Hp
AcO.
OAcNH
NH
CH2CH2CO2H CH2CH2CO2H
NaOH
CH2CH2CO2H
CH2CH2CO2H CH2CH2CO2H
CH2CH2CO2H CH2CH2CO2H
CH2CH2CO2H CH2Œ 2CO2H 
Figure 1.10 - Chemical synthesis of HpD.
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1.6.1.3 Photofrin II® (Porfimer Sodium) (PH)
The active compound in HpD was isolated using gel exclusion chromatography at 
the beginning of the 1980s. It consists of a mixture of haematoporphyrin 
molecules which are linked together by ether bonds and is known as Photofrin II® 
or Porfimer Sodium (PII) (Fig. 1.11). It is thought to consist of 
dihaematoporphyrin ether (DHE) although this has not been confirmed.PII  is 
purer than HpD but still contains a complex mixture of compounds as shown by 
hplc traces.*
■NH
NHNH
HN-=rN HN-HN-
CO,HGOgH
Figure 1.11 - The major component of PII. = CH(OH)CH3 or CH^CHg
In 1993, PII gained the first health agency approval for unrestricted use in PDT 
for the treatment of bladder cancer in Canada. It now has regulatory approval 
for use in lung cancer in the Netherlands*^^ and oesophageal cancers in the US, 
Japan'^’ and France but has not yet been approved for use in the UK.*^ ®
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PII uptake into tumour tissues is comparable with HpD but, of all the currently 
used drugs, it can kill tumours of a greater depth.*PII  can be very effective. It 
was used to treat eleven patients with mouth cancer resulting in a one hundred 
percent success rate.*^^
1.6.2 Second Generation Photosensitisers
The newer photosensitisers are known as second generation sensitisers and are 
nearly all synthesised chemically, hence their structures are known. They include 
the chlorins, phthalocyanines and 5-aminolevulinic acid (ALA) induced 
protoporphyrin IX (PpIX). These compounds are based mainly upon cyclic 
tetrapyrrole structures and are designed to absorb light in the red region of the 
spectrum. *^^
1.6.2.1 Chlorins
Chlorins are reduced, hydrophilic porphyrins which can be derived from 
chlorophyll A. (Fig, 1.12)'“
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Phytyl O
Figure 1.12 - The structure of chlorophyll A.
Phytyl = CH3[CH(CH3)CH2CH2CH2]3C(CH3)CHCH2
This class of sensitiser includes chlorin ee (Fig. 1.13a), MACE (a mono amide 
with L-Aspartic acid) (Fig. 1.13b) and mTHPC (meso-Tetrakis-m-hydroxyphenyl 
chlorin), commercially known as Foscan (Fig 1.13c). Benzoporphyrin derivative 
(BPD) (Fig. 1.13d) is also chlorin,^®^  as are the purpurins (Fig 1.13e).^^“
As Chlorins are reduced porphyrins, they tend to oxidise. Exocyclic rings or bulky 
groups next to the reduced pyrrole ring are usually added to attempt to block this, 
e.g. the hydroxyphenyl group in Foscan,^
Foscan is proving to be a very active pbotosensitiser which can produce tumour 
deaths at depths of ten millimetres.'^^ Phase I clinical trials are underway,
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Figure 1.13 - The chlorins. a - chlorin eg, b - MACE, c - mTHPC, d - BPD and e - a purpurin
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1.6.2.2 Phthalocyanines
Phthalocyanines are synthetic porphyrins which can be chelated with metals, 
especially aluminium and zinc, to enhance their phototoxicity (Fig. 1.14).^ ^®
Figure 1.14 - An aluminium sulfonated phthalocyanine. R = H or SO3H
These compounds have been used commercially, as pigments, since the 1930s but 
have recently been shown to exhibit photobiological activity, particularly against 
tumom‘s.^ °^
Phthalocyanines that are substituted with sulfonated groups become water 
soluble. The less sulfonated compounds, however, are more lipophilic and are 
better at penetrating cell membranes, making them more active derivatives.
Some phthalocyanines have tumour-to-tissue ratios of eight to one in certain cell 
types and have been shown to be effective photosensitisers.^
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1.6.2.3 Other Photosensitisers
A variety of non-porphyrin based photosensitisers have been tested for potential 
use in PDT. These include psoralen derivatives (Fig. 1.15a), cyanines (Fig. 1.15b), 
phenothiazinium compounds (Fig, 1.15c) and rhodamines (Fig 1.15d). Many of 
these compounds are commercial dyes and stains.
MegN NMeo
NH,
d
Figure 1.15 - Non-porphyrin based photosensitisers. a - psoralen, b - merocyanine 
MC540, c - methylene blue, a phenothiazinium and d - rhodamine Rhl23
It has even been proposed that, as Ceo and C?o can be converted to their triplet 
states during UY-irradiation, Buckminster FuUerene derivatives may be able to
2 2
cause photodynamic damage. The two fiiUerenes shown (Fig. 1.16) are cytotoxic 
to cell lines only after irradiation with light.
Figure 1.16 - Potential fullerine photosensitisers. R = C0(CH2)2C02H or C0(CH2)2C02H.NEt3
Combinations of sensitisers for PDT are being investigated to try to enhance their 
effects*^ ® but, as yet, there is no ideal pbotosensitiser.
1.6.3 ‘The Ideal Photosensitiser’ and Problems Associated With Existing 
Drugs
There are seven requirements that a good pbotosensitiser should possess. Ideally
• it should be a pure compound with a reproducible synthesis.
• it should be activated at high wavelengths of light (greater than 600 nm) to 
enhance tissue penetration.
• in the absence of light the compound should not be toxic
• it must show some specificity for localisation in tumours over normal tissue.
• its triplet excited state must be fairly long-lived to allow time for the generation 
of singlet oxygen.
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• Solubility in the body’s tissues, or formulation to enable the drug to be
delivered to the active site, is essential.
• It must be removed from the body quickly, because, if the drug is not
eliminated shortly after treatment, the patient would remain photosensitive to
sunlight."^
Unfortunately, there are drawbacks in the use of many of the commercially 
available photosensitisers. Skin photosensitivity is a major side effect in the use of 
HpD and PII for PDT. The drugs can be retained by the patient for eight to ten 
weeks after treatment and, during this time, they have to stay away from all bright 
lights, particularly sunlight, to avoid formation of a severe sunburn. Chlorins are 
cleared from the body within three to ten days.^^  ^ Patients treated using Foscan 
are told to avoid direct sunlight for two weeks after treatment. After this time 
they must try test exposures on the backs of their hands for five to ten minutes to 
check for photosensitisation. If none occurs they can gradually increase the time 
they are exposed to the sun.*^  ^ Benzoporphyrin, phthalocyanines and purpurins 
require lipid based delivery systems to get to the tumour site.^^  ^PII and HpD aie 
mixtures of compounds. Some of them are inactive, hence, dosage is 
inaccurate.
One of the biggest problems to overcome is the synthesis of a compound which is 
activated by a long enough wavelength. This is normally achieved by expanding 
the macrocycle to give compounds such as phthalocyanines, or by reducing one, 
or more, of the pyrrole rings of the porphyrin to give a c h l o r i n . T h e  longest 
wavelength at which PII can be activated is less than ideal for PDT.^^^
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Over the last seven years, a new approach to PDT has been investigated using 5- 
aminolevulinic acid (ALA). ALA itself is not a pbotosensitiser but is metabolised 
within the body to give protoporphyrin IX (PpIX) which is known to be a very 
effective photosensitising a g e n t .U s i n g  ALA as a pro-drug overcomes the 
delivery problems of PpIX, a highly insoluble molecule and, as PpIX is one of the 
body’s natural compounds (the precursor to haem), it is metabolised quickly 
leaving the patient light sensitive for just a few hours. ALA induced PpIX is 
becoming an important area in PDT research.
1.7 5-Aininolevuliiiic Acid Induced Protoporphyrin IX as a 
Pbotosensitiser
ALA itself is not a pbotosensitiser. It acts as a pro-drug, i.e. a molecule which is 
metabolised within the body to give the active compound. ALA is an intermediate 
in the synthesis of tetrapyrollic structures such as vitamin B12 and corrins’"*^ but its 
use in PDT is because it is a precursor in the haem biosynthetic pathway in 
mammals, plants and photosynthetic bacteria. It is the immediate precursor to 
haem, PpIX which is the photosensitising agent.
In the body, ALA is formed from glycine and succinyl CoA using ALA synthase, 
a pyridoxal phosphate (PLP) activated enzyme. Two molecules of ALA can then 
combine, in the presence of porphobilinogen synthase (PEG synthase), to give 
porphobilinogen (PEG). Two molecules of water are eliminated at this stage. 
PEG deaminase and uroporphyrinogen III cosynthetase cause four molecules of
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PBG to react in a head-to4ail fashion and cyclise, yielding uroporphyrinogen III. 
Decarboxylation with uroporphyrinogen decarboxylase followed by oxidation 
catalysed by coproporphyrinogen oxidase and protoporphyrinogen oxidase form 
PpIX (Fig. 1.17), the active molecule in PDT. The formation of haem from PpIX 
involves insertion of iron into the porphyrin ring in the presence of the enzyme 
ferrochelatase (Fig. 1.18).^ ®^ ’
NH
HN-
Figure 1,17 - PpIX, the active compound in ALA-PDT.
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Figure 1.18 - The biosynthetic pathway to haem. A = CH2CO2H, P -  CH2CH2CO2H
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The rate of production of PpIX is determined by the rate of synthesis of ALA 
which, under normal conditions, in healthy tissue, is regulated by a feedback 
mechanism dependant on the concentration of free haem. By adding extra ALA to 
the system the feedback control is by-passed and concentrations of PpIX in some 
cells and tissue build up. This tissue selective mechanism allows the use of ALA 
induced PpIX in PDT.^^^
PpIX tends to accumulate to a greater extent in abnormal tissue, i.e. preferentially 
in tumours rather than in healthy cells, which is advantageous. Two possible 
explanations for this are that cancerous cells grow more rapidly, hence high levels 
of PpIX are generated faster, or that different enzymes are present in cancerous 
growths. PpIX may accumulate due to limited capacity of ferrochelatase. PBG 
deaminase levels are higher in some tissues whereas ferrochelatase is lower.’ 
Tumour tissues have a reduced blood flow, hence a lower oxygen content and, as 
oxygen is a vital reagent in the photodynamic process, this can have an effect in 
PDT.
1.8 Other Uses of 5-Aminolevulinic Acid
1.8.1 5-Aminolevulinic Acid as a Photodynamic Herbicide and Insecticide
ALA induced PpIX can also be used as a selective herbicide or insecticide. When 
sprayed with a solution of ALA certain types of plants can be destroyed after 
exposure to sunlight.Photodynamic herbicides induce accumulation of 
chlorophyll precursors as well as PpIX in an analogous reaction to the 
biosynthesis of haem in humans. Light then causes photodamage to the plants by
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formation of singlet oxygen.’'’^  Much of the work on the mechanisms of 
photodamage by porphyrins has been carried out using plants rather than 
animals.’'*^ PpIX is the immediate precursor to protohaem in both plant and 
animal cells and, as plants and animals share the same tetrapyrrole biosynthetic 
pathway from ALA to PpIX, the mechanisms for photodamage are the same.’"’'* 
These compounds have become known as “photodynamic herbicides” or "laser 
herbicides” and cause bleaching of the plants leaves, loss of turgidity and, 
eventually, death of plants.’'’^
1.8.2 5-Aminolevulmic Acid as a Plant Growth Regulator
In some plants, e.g. barley and tobacco, ALA does not act as a herbicide. Instead 
it can be used to inhibit growth. This suppression does not involve 
photodestruction by porphyrins, but an entirely different biosynthetic pathway. 
Exogenous ALA acts as a good source of carbon for formation of amino acids, 
proteins, sugars, lipids and organic acids as well as porphyrin synthesis. It is 
thought that plant growth is controlled by cytokinms which are derivatives of 6- 
aminopurine. ALA not involved in porphyrin synthesis is converted initially to 
dioxovaleric acid, which then utilises the aldehyde group carbon to form a purine 
ring (Fig. 1.19).
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HOCHOCm i
ALA 4,5-dio?flOvaleric acid
Puriiie Ring
Figure L19 - Formation of a purine ring using ALA as a carbon source.
ALA esters and N-acylated derivatives have been patented in Japan as potential 
plant growth regulators. '^^^’ Interest is also growing in these types of 
compounds as potential pro-drugs for PDT.
1.8.3 Early Detection of Lead Poisoning
Lead poisoning has been implicated as a cause of brain damage, behavioural 
problems, anaemia, mental impairment, kidney failure and coma. Early detection, 
therefore, is advantageous.’^ ’ Excess lead in the body is known to inhibit several 
of the enzymes involved in the biosynthetic pathway to haem, particularly 
ferrochelatase, which is involved in the production of haem from PpIX and PBG 
synthase, the enzyme that converts two molecules of ALA into PBG.’^  ^Inhibition 
of PBG synthase prevents photosensitisation from occurring as the biosynthetic 
pathway is blocked, therefore, lead poisoning causes ALA levels to build up in the 
body. High concentrations of ALA measured in blood or urine can give an early 
indication of lead poisoning’^  ^ which can then be treated easily using chelation 
therapy.’^ '’
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1.8.4 5-Ammolevulinic Acid and the Porphyrias
The porphyrias are a group of diseases which result from a deficiency in one of 
the enzymes involved in the biosynthesis of haem.’^  ^ They can lead to 
accumulation of porphyrin precursors resulting in photosensitisation of the skin.’^^  
Other symptoms of an acute attack of porphyria include abdominal pain and 
constipation.’^ ’* More serious cases result in hypertension or psychiatric 
problems.This  was one of the ailments of King George IV.
Diagnosis of the porphyrias depend on detection of increased levels of porphyrin 
precursors in urine, particularly ALA and PBG.’^  ^ It has been demonstrated, 
however, that ALA given orally, even in large doses, does not cause neurotoxic 
effects or any of the other symptoms associated with the acute porphyrias.
1.9 5~Ammolevulinic Acid Based Photodynamic Therapy for the 
Treatment of Cancer
1.9.1 Lung Cancer
The majority of cancer deaths in the western world are caused by lung cancer. 
Tumours can block the airways and conventional radiotherapy and chemotherapy 
are not very successfiil. ALA-PDT has been used both to detect and treat early 
stage lung cancers.’”^  ALA can be inhaled by the patient, who is then examined 
using fluorescent light. PpIX fluorescence is much stronger in the tumour than in 
surrounding tissue. After PDT in one study, seven out of eight tumours showed a 
complete response and no skin photosensitivity was reported.””
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1.9.2 Oral Cancer
Two thousand four hundred new cases of oral cancer are detected every year in 
the UK. A study of eighteen patients with a variety of malignant lesions in the 
mouth was carried out using ALA-PDT and showed promising results particularly 
in patients with dysplasia.Another study involving four patients, who were 
given ALA orally, showed tumour necrosis in three cases. PpIX levels had 
returned to normal within twenty four hours.
1.9.3 Bladder Cancer
A bladder carcinoma was the first human tumour treated using PDT in 1975.’”' 
The first health agency approval for PDT using PII was granted in Canada for use 
in cancer of the bladder. PpIX accumulation in tumours of the human bladder is 
ten times greater than in normal t i s s u e . I n  one study ten patients were treated 
intravenously with ALA. After just one exposure to light four showed a complete 
remission and two a partial remission. No side effects were observed, hence, 
multiple treatment sessions were a possibility.’^ ^
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1.9.4 Skin Cancer
Non-melanoma primary skin cancer is the most common disease to affect man/^° 
Topically applied ALA-PDT is particularly suited to the treatment of skin cancer 
as the drug is concentrated in the affected area enhancing the PpIX accumulation 
within the diseased tissue. The first clinical results of ALA-PDT were published in 
1980 and reported a 90% complete response rate in the treatment of eighty basal 
cell carcinomas. Numerous papers showing similar, or better results have been 
published since then. ‘ ’ *
1.9.5 Other Cancers
ALA-PDT is being examined, with some success, as a treatment for several other 
areas of cancer therapy including cancers of the gastrointestinal tract and 
rectum*^ ,^ the endometrium^and the colon.
1.9.6 Enhancing 5-Aminolevulinic Acid Based Photodynamic Therapy
ALA-PDT can be used in conjunction with surgery. The bulk of the tumoui' is 
removed by surgery then the residual tissue can be necrosed using PDT.’ "^^
Topical delivery can be enhanced using DMSG, which assists penetration through 
the skin.^ ®^
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A new approach to enhancing ALA-PDT is to add iron chelators. This is an 
attempt to block the final step in haem metabolism. Conversion of the active 
compound, PpIX, to haem using the enzyme ferrochelatase involves insertion of 
iron into the porphyrin ring. This should cause a build up of PpIX. Iron chelators 
include l,2-diethyl-3-hydroxypyridin-4-one (CP94) (Fig. 1.20a)*^  ^ and 
desferrioxamine mesylate (Fig. 1.20b).‘^ '^  EDTA (Fig. 1.20c), a non-specific metal 
chelator, is also used.^ '*^
OH H2OC2HÇ 
HOjCHjC—K 'N—OI^ OQjH
ct^œ^H
OHOH
OH
b
Figure 1.20 - Iron chelating agents, a - CP94, b* desferrioxamine mesylate and c - EDTA
1,10 phenanthroline (Fig. 1.21), a tetrapyrrole biosynthesis modulator has also 
been shown to enhance the PDT effect.^ '^ '^ ’
-N
Figure 1.21 - Structure of 1,10-phenanthroline.
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PDT using esters of ALA is also proving to be a promising concept. This will be 
discussed in greater detail later, in Section 6.2.* '^
1,10 5-Aminolevulinic Acid Based Photodynamic Therapy for Other
Conditions
PDT is also undergoing trials for many non-cancerous conditions ranging from the 
supression of superfluous hair growth or very heavy periods to the destruction of 
bacteria and viruses in transfusion blood.
Psoriasis is a very common ailment caused by a large number of proliferating cells 
in the epidermis resulting in the formation of plaques on the surface of the skin.’^  ^
It was one of the first diseases treated using PDT with Psoralens and UV light 
(PUYA). Trials have shown that a single dosage of topical ALA can be successfiil 
in treating psoriasis. A clinical improvement of greater than fifty percent can be 
observed and multiple treatments can be even more successfiil.
PDT can be used to purge bone marrow in patients with leukamia as porphyrins 
accumulate in leukemic cells.Atheroschlerotic plaques and rheumatoid arthritis 
are also well suited to photodynamic damage. As haemoglobin binds to nitric 
oxide (NO), it blocks the action of NO on cyclic-GMP levels affecting smooth 
muscle relaxation. Initial results suggest that ALA could be used as a modulator 
of smooth muscle tone.^ ^®
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Perhaps the most important non-tumour application of PDT, however, is the 
photodynamic destruction of viruses (PDV). Many viruses, including herpes 
simplex virus (HSV), some of the hepatitis viruses and retroviruses like human T 
cell leukemic virus (HTLV) and human immunodeficiency virus (HIV) can be 
transmitted in blood fi*om a transfusion.’®^ Research has shown that these can be 
destroyed using a suitable photosensitiser and visible light. Singlet oxygen kills the 
virus, leaving the surrounding essential blood cells intact.’^ ’
1.11 Photodynamic Detection of Tumours using Fluorescence (PDD)
Early detection of cancer is very important. Many tumours are not discovered 
until it is too late. An area related to PDT is that of photodynamic detection 
(PDD). As photosensitisers possess the ability to fluoresce and they can 
accumulate preferentially in cancerous growths, there is great potential for their 
use in tumour detection.
In order to avoid photodynamic damage being caused to the cells, lower light 
levels are used to excite the sensitiser. The resulting fluorescence is, therefore, too 
low to be detected using just eyesight, so intensified video cameras are used. A 
disadvantage in the use of some photosensitisers for detection of tumours is long­
term skin photosensitisation” ^  but, by using ALA induced PpIX, maximum 
fluorescence levels occur approximately two hours after administration of ALA. 
After four hours, levels are returned to normal, resulting in skin photosensitisation 
being short lived. If PDD is to be used for routine clinical diagnosis, the short
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incubation time is an additional advantage, as treatment can be on an out-patient 
basis.
PDD using ALA has been studied mainly for bladder and lung cancer, where a 
twenty fold difference in PpIX levels between tumour and normal surrounding 
tissue has been observed.”  ^ ALA esters may also be suitable for fluorescence 
detection, as they exhibit even more selectivity between tumour and normal 
tissue.’®' Work is being carried out in the Physics department, St. Andrews 
University using ALA induced PpIX fluorescence for tumour detection (Fig 
1.22a, b and c).
Figure 1.22a - Photograph of apparatus used for FDD in St. Andrews.
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Figure 1.22b - Photograph of ALA induced fluorescence in the human oesophagus
Figure 1.22c - Photograph of endoscope used for PDD.
1.12 Problems With the Use of 5-Aminolevulinic Acid in Photodynamic 
Therapy and Outline of Thesis
ALA is a fairly expensive compound to purchase. One gram of ALA.HC1 costs 
around £50 from Sigma/ Aldrich, therefore, Chapter 2 deals with the chemical 
synthesis of the molecule.
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In the body, two molecules of ALA dimerise enzymatically using PBG synthase to 
form PBG in a Knorr type of reaction (Fig. 1.23).
CO2H cOjH
CO,H
PBG
synthase
Figure 1.23 - The enzymatic dimérisation of ALA forming PBG
An alternative pyrrole synthesis, known as the Fisher-Fink synthesis, would result 
in the formation of pseudoporphobilinogen (Fig. 1
HO.C
NH.
CO,H
Figure 1.24 - The structure of pseudoporphobilinogen.
Chapter 3 discusses reaction of ALA.HCI with a variety of diketones to 
investigate whether a Knorr, Fisher-Fink, both reactions or no reaction would 
occur.
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A major problem in PDT using ALA is its stability. ALA is stable as the HCl salt 
but can not be administered unbuffered, as this causes both pain and hypotension 
to the patient. Removal of the HCl salt causes a different dimérisation reaction 
to occur (Fig. 1.25).
HO.
2 X
CO2H
HO.
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CO2H OO2H
Figure 1.25 - The non-enzymatic dimérisation of ALA.
Two molecules of ALA, in the absence of the enzyme PBG synthase react to form 
a dihydropyrazine, which is oxidised in air forming a pyrazine. This reaction is 
irreversible and occurs in solutions prepared in PDT clinics. It is associated with 
formation of a brown colour (demonstrated in Section 6.5), presumably due to 
polymerisation reactions. It is not known whether or not tins pyrazine is toxic.
Its formation also lowers the dosage of the drug being administered to the patient. 
Chapter 4 investigates this non-enzymatic reaction.
The compound prepared initially in the non-enzymatic reaction is a 
dihydropyrazine. It is fairly short lived due to aerial oxidation which gives the 
more stable aromatic compound. Chapter 5 concerns the chemistry of 
dihydropyrazines, particularly their form in solution.
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In order to prevent a brown colouration and pyrazine formation during PDT, 
derivatives of ALA were prepared with different groups blocking either, or both 
ends of the molecule. These could have the added advantage of enhancing tissue 
penetration and selectivity in the body. Chapter 6  deals with their chemical 
synthesis, and Chapter 7, their biological testing.
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Chapter 2 
Synthesis of 5-Aminolevulinic Acid
2.1 Introduction
Many syntheses of ALA.HCI have been published. They fall into three distinct 
groups. There are routes where the nitrogen atom is introduced into the molecule 
using cyanide, azide or phthalamide, routes where the nitrogen is already attached 
to the basic carbon skeleton and routes involving manipulation of functional 
groups on five or six membered rings followed by ring opening. Several routes to 
labelled ALA.HCI, both ^^ C and ‘^ N, have been published but these, in general, 
involve longer synthetic routes.^®’ ' The aim of this work was to produce 
reasonably large quantities of ALA.HC1 as quickly, cheaply and safely as possible.
2.1.1 Routes Involving Introduction of a Nitrogen Atom
Syntheses of this type are the most numerous. Several routes involve the 
introduction of nitrogen into the molecule using cyanide.^ *^ *"’ Others involve 
sodium azide,^ ®* but the majority of published syntheses of ALA.HC1 involve 
reacting a brominated or chlorinated compound with potassium phthalimide.^®^
2.1.2 Nitrogen Already Attached to the Basic Carbon Skeleton
Syntheses have been attempted using succinamide,^^  ^ g l y c i n e , ^ h i p p u r i c  
acid^^’’ and diethylacetamidomalonate^^^ as starting materials.
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2.1.3 Synthesis by Ring Opening
ALA.HC1 has also been prepared from N-methoxycarbonylated cyclic amines 
2 ,5 -piperidinedione,^^^ ■ ftirans^^*'^^  ^ and oxazolinones.^^^
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2.2 Experimental Discussion
Initially, the route of Ha, Lee, Ha and Park^ ®^  was followed (Fig. 2.1).
OOgH
o = = /rGOgMe
(1)
NaNg 
DMF
HCI.H2N
MeOH
c-HCl ^ 0 =
H2
30% Pd/C
OOgMe OOgH
(2) (3)
Figure 2.1 - Ha, Lee, Ha and Park synthesis of ALA.HCI.
Levulinic acid was brominated using bromine in methanol (Reaction 8.1) yielding 
a three to one ratio of methyl 5-bromolevulinate (1) to methyl 3-bromolevulinate. 
Small quantities of the dibrominated compound and free acid were also detected
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by gc. The mixture was separated by column chromatography or distillation. The 
resulting methyl 5-bromolevulinate was then reacted with sodium azide (Reaction 
8.2) giving methyl 5-azidolevulinate (2), a clear oil which appeared to be 
reasonably stable. Hydrogenation (Reaction 8.3) yielded ALA.HCI (3) as a white 
solid. Overall yield for this reaction was approximately 25%.
To avoid formation of the potentially dangerous azide, the Gabriel synthesis of 
Benedikt and Kost^ *'^  was adapted (Fig. 2.2).
(1)
O 6MHC1 O
OOgMe
(4)
Figure 2.2 - Gabriel synthesis of ALA.HCI.
Methyl 5-bromolevulinate (1) was reacted with potassium phthalimide in DMF 
giving a fairly low yield of methyl 5-phthalimidolevulinate (4) (approximately 40- 
50%) (Reaction 8.4). Heating under reflux conditions in 6M HCl (Reaction 8.5) 
yielded ALA.HC1 (3) in an overall yield of only 10%.
Brominated levulinic acid proved to be a severe skin irritant. In order to decrease 
contact time with the molecule, the brominated mixture was reacted with
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potassium phthalimide without purification (Reaction 8 .6 ). Phthalimide reacted 
with only the bromine on the terminal carbon yielding the desired product (4) in 
an adequate yield (approximately 25%).
To try to increase the overall yield, methyl 5-chlorolevulinate (7) was prepared as 
a pure compound (Fig. 2.3).
MeOHTT —" HO^ C
CO2CH3
(6)
SOCI2 o
C02CH
6MHC1
COgH
CO2Œ 3
1. CH2N2
2. c-HCl
HCI.H2N
CO2CH3
Figure 2.3 - Synthesis of ALA.HCI via methyl 5-chlorolevulinate
Methyl hydrogen succinate (5) was prepared from succinic anhydride and 
methanol (Reaction 8.7) using the method of Cason.^^  ^ Reaction with thionyl 
chloride yielded methyl 3 -chloroformylpropanoate (6 ) (Reaction 8 .8), An Arndt- 
Eislert Synthesis (Fig. 2.4) using diazomethane followed by c-HCl gave methyl 5-
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chlorolevulinate (7) via the method of Neuberger and Sco t t /Overa l l  yield for 
the three steps was reasonable (approximately 30%).
R  ^  H2C N = N   ► R----^
Qci CH2-N^N
+ CH2N2 
-Me.N2®
R-
O
Cl
c-HCl .0
CHN^N
0
Figure 2.4 - The Arndt-Eislert Synthesis.
Methyl 5-chlorolevulinate was reacted with potassium phthalimide (Reaction 
8.10) giving a 45% yield of methyl 5-phthalimidolevulinate (4) which was 
converted to ALA.HCI (3) as before (Reaction 8.5).
The low yielding step in all reaction schemes proved to be addition of phthalimide. 
Soai, Ookawa and Kato^ "^^  found that catalytic amounts of crown ethers, 
particularly 18-crown-6, increase both reaction rate and yield in the preparation of 
N-substituted phthalimides from alkyl halides and potassium phthalimide (Fig. 
2.5).
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o o
18-crown-6
NK + RX ----------►10 mol % N R  + KX
O O
Figure 2.5 - Adapted Gabriel synthesis of N-substituted phthalimides.
18-crown-6 as a phase transfer catalyst in the reaction of methyl 5- 
chlorolevulinate (7), or methyl 5 -bromolevulinate (1) with potassium phthalimide 
increased the yield from 50 to 75%, hence optimising the lowest yielding step 
(Reaction 8.11 and 8.12).
The highest overall yielding route for the preparation of ALA.HC1, however, was 
obtained using an adaptation of the method of lida, Takao, Ogai and Kajiwara 
(Fig. 2.6).'"'
O Cl
NK
O
COzH
DMF
O
N O.
O (8)
RuClg, NaT04 
CH3CN, arklone, H2O
OHCLHjN
6M HCl
*
(3) (9)
Figure 2.6 - lida, Takao, Ogai and Kajiwara synthesis of ALA.HCI.
CO2H
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This synthesis was designed for the preparation of ' "N-labelled-ALA.HC1 but is 
also a feasible route to ALA.HC1 itself. N-Tetrahydrofurfuryl chloride is 
commercially available and was used in place of N-tetrahydrofurfuryl bromide in 
the reaction with potassium phthalimide to give N-tetrahydrofurfuryl phthalimide 
(8 ) (Reaction 8.13) Increasing the reaction time to three hours gave yields 
comparable to those of lida et al. (approximately 95%). Oxidation using sodium 
metaperiodate and ruthenium (III) chloride (Reaction 8.14) opened up the furan 
ring to give phthalimidolevulinic acid (9) in very good yield. Heating under reflux 
conditions in 6 M HCl (Reaction 8.15) gave ALA.HC1 (3) in a yield of greater 
than 80% over three steps.
2.3 Conclusions
ALA.HCI can be prepared in a matter of days, in good overall yield using an 
adaptation of a published route shown in Figure 2.6. This route, however, is less 
cost effective than the longer route shown in Figure 2.3. The first two stages 
(Reactions 8.7 and 8 .8 ) can be used on a large scale (greater than 100 g) making 
it, effectively, a three step procedure. Addition of crown ether in the Gabriel 
synthesis optimises the lowest yielding step. None of the procedures would be 
suitable for the large scale production of ALA.HC1, due to the high irritant 
properties of both brominated and chlorinated ketones, the toxicity of ruthenium 
based compounds, and the explosive nature of diazomethane. As regular 
laboratory procedures, however, any of the above routes are suitable for the 
preparation of ALA.HC1.
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Chapter 3
Reactions of 5-Aminolevulinic Acid with Linear and
Cyclic Diketones
3.1 Introduction
When two molecules of ALA combine in the presence of the enzyme 
porphobilinogen synthase (PBG synthase), porphobilinogen (PBG) is formed in a 
Knorr type of reaction (Fig 3.1).
HOgC
2  X
porphobilinogen
Figure 3.1 - Formation of PBG from ALA via the Knorr Pyrrole Synthesis.
Knorr first reported the synthesis of 2,4-diethoxy-3,5-dimethylpyrrole m 1886.^ ®^  
The condensation of ethyl a-aminoacetoacetate with ethyl acetoacetate produced 
the molecule now known as Knorr's Pyrrole (Fig. 3.2).
The Knorr Synthesis involves reaction of an a-aminoketone with a carbonyl 
containing compound which has a reactive methylene group alpha to the carbonyl 
group.^”^  The reaction has been used extensively to prepare building blocks for 
haem precursors.
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aOgC
Y 
/
o
aq, NaNC>2 2 Zn V o
CH3CO2H y L  4 CH3CO2H I
EtO^ C NOH EtOgC NH2
ethyl acetoacetate ethyl a-oîdmino-acetoacetate ethyl a-animo-acetoacetate
Vo
o
ethyl acetoacetate
aOgC NH2 
ethyl a-amino-acetoacetate
Figure 3.2 - Synthesis of Knorr’s Pyrrole.
The two molecules of ALA could potentially cyclise via the 5-methylene group of 
one of the compounds yielding another product, pseudoporphobilinogen 
(Fig.3.3). This synthesis is known as the Fischer-Fink Reaction.^^^
NB
Figure 3.3 - The structure of pseudoporphobilinogen.
Fischer and Fink^ *^  ^ isolated a minor product in the reaction of ethyl a-oximino- 
acetoacetate with 2,4-pentanedione (Fig. 3.4),
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o2,4-pentanedione
V
/ \  EtOgC NOH
ethyl a-oîdmino-acetoacetate 
Zn/CHgœ^H
O
EtO,C O
O
-N
Knorr Cyclisation
O
COjEt
Fischer-Fink Cyclisation
HO FIO
= o
3-acetyl-2,4-dimethyl-5-
etho)ycarbonylpynole
EtCLC N ^ H
2,4-dimethyl-5-
etho>ycarbonylpyrrole
Figure 3.4 - Knorr and Fischer-Fink Pyrrole Syntheses.
The major product found, 3-acetyl-2,4-dimethyl-5-ethoxycarbonylpyrrole, was a 
result of the Knorr Pyrrole Synthesis. A small quantity of 2,4-dimethyl-5-
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ethoxycarbonylpyrrole, however, was due to a different cyclisation mechanism 
now known as the Fischer-Fink Synthesis.
The general Knorr (Fig. 3.5a) and Fischer-Fink (Fig.3.5b) syntheses are shown 
below.
C0 R2 C0 R2
\
Figure 3.5a - The Knorr Pyrrole Synthesis.
H
.COR2 R2. \
RiQC" N 'r3
Figure 3.5b - The Fischet-Fink Pyrrole Synthesis.
In order to explore the mechanism for these reactions, a related reaction, that of 
ALA.HCl and 2,4-pentanedipne (acetylacetone), was used. This reaction has also 
been used as an assay for ALA in biological fluids, particularly for the detection 
of lead poisoning which inhibits the conversion of ALA into PBG (See Section
1.8.3).
In most cyclisation reactions of this type the Knorr product is the dominant one. 
The mechanism of cyclisation may depend on the form of ALA in solution. This
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has been studied using a number of isotopic probes including NMR 
spectroscopy of [4-^^C] ALA, NMR spectroscopy and ^H/ %  and 
exchange. The study demonstrated that enols are formed at both C5 and C3 but 
more so at C5 . At pH 6 .8 , énolisation at C5 is five times faster than at C3 . In more 
acidic conditions, relevant to these reactions, the rate is slower but the ratio 
similar.^ "^^  In aqueous solutions, ALA can exist as a hydrate and in two enolic 
forms as well as the keto-compound. (See Fig. 4.1).
ALA.HC1 has been reacted with a variety of different diketones related to 2,4- 
pentanedione in order to determine whether the Knorr, Fischer-Fink or both 
products are produced.^®  ^ As a continuation of that work, ALA.HC1 has been 
reacted with other diketones, particularly cyclic diketones to produce pyrroles 
and indol-4-ones.
3.2 Experimental Discussion
3.2.1 Reaction of 5-AminolevuIinic Acid with Linear Diketones
Pyrroles are highly insoluble in water, therefore, all pyrrolic products precipitate 
out of the reaction mixtures and can be analysed. Reaction of ALA.HCl with 2,4- 
pentanedione (Reaction 8.16) in acetate buffer yielded both 3-acetyl-4-(2- 
carboxyethyl)-2-methylpyrrole, the Knorr product (10) and 2-(3- 
carboxypropionyl)-3-5-dimethylpyrrole, the Fischer-Fink product (11) (Fig. 3.6). 
The Knorr product was obtained as greater than 90% of the total yield.
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CO^ H HO2C
acetate
HOnCHC1.H2N
(10) (11)
Figure 3.6 - Reaction of ALA.HC1 with 2,4-pentanedione.
Reaction of ALA.HC1 with 4,6-dioxoheptanoic acid (succinyl acetone. Reaction 
8.17), could potentially yield four products, two from the Knorr type reaction 
(Fig. 3.7a) and two from the Fischer-Fink (Fig. 3.7b). Only the two Knorr 
products were isolated in approximately a 4:1 ratio of 3-(4-carboxybutionyl)-4- 
(2-carboxyethyl)-2-methylpyrrole (12) to 2-(4-carboxybutionyl)-4-(2- 
carboxyethyl)-3-methylpyrrole (13), presumably due to steric effects caused by 
interaction between the bulky CH2CH2CO2H groups.
HO2Q
OOoH HO2C
i-ia.i-hN
HO.C
O acetate buffer
CO2Hacetate buffer I-IO2C
CO2H
CO2H
Figure 3.7a and b - Reaction of ALA.HCl with succinyl acetone.
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3.2.2 Reaction of 5-Aminolevulinic Acid with Cyclic Diketones
In the reaction of ALA.HC1 with cyclic diketones, only the Knorr product is 
possible and an indol-4-one is formed. Reaction of ALA.HC1 with 5-methyl-1,3- 
cyclohexanedione (Reaction 8.18) under acidic conditions gave, on standing for 
some days, a small quantity o f a white crystalline solid and the analytical data are 
consistent with the formation of an indol-4-one (14) (Fig. 3.8).
CO,H
OH
(14)
Figure 3.8 - Reaction of ALA.HCl with 5-methyl-1,3-cyclohexanedione.
The mechanism proposed previously^^  ^ for reaction with a non-cyclic diketone 
and shown in Fig. 3.8 accounts for the formation of this product. The mechanism 
demands that one hydrogen at the 2 position of the cyclohexane moiety is
6 1
sufficiently acidic for tautomerism of the imine to occur. Cyclisation indicates that 
steric constraints imposed by the cyclic nature of the diketone do not prevent the 
formation of the transition state of the heterocyclic ring. The presence of the 5- 
methyl group, however, appears to slow the reaction, for reasons which will be 
discussed later in Section 3.3.2.
Reaction of ALA.HC1 with 1,3-cyclohexanedione (Reaction 8.19) gave some 
crystalline product immediately after reflux. The spectral data are consistent with 
the formation of the indol-4-one (15) but it was not possible, from simple NMR 
spectra, to assign chemical shifts for the five methylene groups labelled a-e (Fig. 
3.9).
CO2H
0=
HC1.H2N
c
b
Ha
(15)
Figure 3.9 - Reaction of ALA.HC1 with 1,3-cyclohexanedione.
Their unambiguous assignments were determined using COSY and 
correlation two dimensional NMR spectroscopy. In the NMR spectrum all 
signals, apart from the aromatic proton at ô 6.6 and two signals at ô 11.1 and
11.8, corresponding to NH and OH, are due to methylenes. Four signals are 
triplets and one, at Ô 2.1, is a quintet which must be due to CHa-b. The signal at
6 2
ô 2.4 shows a symmetrical distortion with the quintet suggesting that they are 
neighbours (i.e. CHz-a'or CHz-c). In the COSY spectrum (Fig. 3.10) the signal at 
Ô 2.1 has cross peaks with the signals at ô 2.4 and 2.8 and so the last two must be 
due to CHz-c and CHz-a. In the correlation spectrum (Fig. 3.11) the signal
in the NMR spectrum for the methylene with the highest chemical shift, 
corresponding to CH2-C because of the proximity to the carbonyl group, is at 6 
38.24. This correlates with a signal in the spectrum at 5 2.4, thus the shifts of 
CH:-a and CH2-C are assigned. The signals at ô 2.6 and 2.9 have cross-peaks 
with one another but with no other signals and must, therefore, correspond to 
CH2-e and CH2-d. The one at 5 2.6 correlates with a signal in the spectrum at 
the high value of ô 34.52 so must be the methylene group next to the carbonyl of 
the carboxylic acid, i.e. CH2-e. The signal at ô 2.9, therefore, is due to CH2-d.
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Figures 3.10 and 3.11 - COSY and correlation two dimensional NMR spectra.
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3.3 Conclusions and Mechanism
3.3.1. Reaction of 5-Aminolevulinic Acid with Linear Diketones
With the exception of the acetylacetone reaction, all products obtained were 
Knorr rather than Fischer-Fink. Previously, when the same experiment was 
carried out with ethyl acetoacetate only the Knorr product was formed. With 3- 
methyl-2,4-pentanedione and 3-isopropyl-2,4-pentanedione, however, only the 
Fischer-Fink product was formed and with 2,4-hexanedione, four products were 
formed, two from each mechanism.^®^
From an observation that l,l,l,5,5,5-hexafluoro-2,4-pentanedione, which exists 
almost entirely in the keto form or its hydrate, does not react with ALA.HC1 it 
can be concluded that the reactive form of the dione is most likely to be an enol. 
It can be assumed that the intermediate formed as the first product of the reaction 
is the enaminoketone.
If this enaminoketone can exist in as many forms as ALA then two enolic forms 
are possible intermediates in the subsequent cyclisation step (Fig. 3.12).
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HO
H
O
CO.H
OH"
H— G
H
Knorr Product Fischer-Fink Product
Figure 3.12 - Two possible intermediates formed during the Knorr and Fischer-Fink Pyrrole
Syntheses.
Protonation of the 4-keto group of ALA leads readily to cyclisation and 
elimination of water giving the Knorr product. Enolisation of this keto-group and 
protonation of the other keto group gives the Fischer-Fink product.
It is known that ALA can enolise at the 5-position, and this should occur in a 
similar way in the enaminoketone, but there are other factors involved in 
determining whether the Knorr or Fischer-Fink products are formed.
If you consider the relative ease of protonation of the two keto groups it is not 
surprising that both products are obtained in some cases. If is an electron 
withdrawing group, protonation of the neighbouring keto-group is disfavoured 
and only the Knorr product is obtained.
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If two molecules of ALA.HC1 were reacted to form the equivalent enaminoketone 
this could then, theoretically, be cyclised to give PBG in a non-enzymatic 
reaction. This, however, does not work as the ketone would be formed only from 
the C3 enol of ALA and this is disfavoured with respect to the C5 enol. This 
could possibly explain why two molecules of ALA combine to form a pyrazine 
(Fig. 1.25) and do not spontaneously cyclise to give PBG.
3.3.2 Reaction of 5-Aminolevulinic Acid with Cyclic Diketones
Reaction of ALA.HC1 with cyclic diketones yield indol-4-one products. There is, 
however, a surprising feature in the NMR spectra of these. The simplicity of the 
NMR signals, with no geminal coupling for the methylene groups at positions 
a, b and c indicates that ring inversion of the half-chair form of the six-membered 
ring must be fast on the NMR timescale. Since the solvent used was % -DM SO it 
was not possible to freeze out this inversion by lowering the temperature.
Another interesting observation is that the methyl group at the 5 position 
substantially lowers the rate of cyclisation. In the transition state for cyclisation, 
which approximates to a half-chair structure, the methyl group could be in either 
the pseudo-axial or pseudo-equatorial position. From an examination of models it 
is clear that there is enough steric interference when in the pseudo-axial position 
to reduce the rate of reaction. This view was confirmed by our observation that 
no readily isolable product resulted from the reaction, under the same conditions, 
of ALA.HC1 with 5,5-dimethyl-1.3-cyclohexanedione (dimedone) (Reaction
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8.20). This could also be due to the lack of solubility of the compound, and the 
fact that dimedone is quite acidic. Enols can be formed at both C5 and C3. The 
protonation step can occur before or after resonance between the carbonyl group 
and a negatively charged oxygen species. At pH 6.8, énolisation at C5 is five 
times faster than at C3. In more acidic conditions the ratio is similar but the rate is 
slower and this may have affected the formation of any products during the 
reaction (Fig. 3.13).
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oOH
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H
CO2H
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Henaminoketone
OH
H(15)
Figure 3.13 - Mechanism for the formation of an indol-4-one.
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Chapter 4 
Dimérisation Reactions
4.1 Introduction
ALA, a 4-keto-5"amino acid, is a highly reactive molecule which can exist in a 
number of forms in aqueous solution (Fig. 4.1).
O2C
NH,
O2C
OH
O2C
OH
NH,
OH
OH
NH3+
Figure 4.1 - Forms of ALA in solution.
In the body, PBG synthase'^ ®^  is the only enzyme involved in the usage of ALA, 
converting two molecules to PBG (Fig. 4.2).
2x
PBGsynthase
NH2
\  +  2 H2 0
Figure 4 .2  - T he enzym atic conversion o f  A L A  to PBG.
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In the absence of the enzyme, two molecules of ALA react in a different manner 
forming, firstly, a dihydropyrazine which is oxidised to a pyrazine in air making 
the reaction irreversible (Fig, 4.3).
2  X
COgH HO.
[01
N"
\ \COjH COgH
Figure 4.3 - The non-enzymatic dimérisation of ALA.
It has been shown that, under physiological conditions, 2,5-di-(p-carboxyethyl) 
pyrazine can be formed"^ ®^  and that alternative forms of ALA, or its non-enzymatic 
condensation products, may be involved as neurotoxins in lead poisoning or in 
some of the diseases known as the porphyrias (See Section 1.8.4).'^ ®^  A pyrazine, 
probably resulting fi^ om the non-enzymatic dimérisation of ALA has been detected 
in the urme of patients with acute intermittent porphyria.'^ '^^
Clinical solutions of ALA for PDT are generally prepared at the beginning of the 
session. As time wears on, these solutions go a dark brown colour (this is 
illustrated in Section 6.5) and pyrazine is formed. We believe that two different 
reactions are taking place, polymerisation of ALA resulting in colour formation 
and dimérisation giving the pyrazine. These lower the dosage of the drug being 
given to patients to an unknown amount and the toxicological properties of 2,5- 
di-(p-carboxyethyl) pyrazine are not known.
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We have attempted to prepare a pure sample of the non-enzymatic dimérisation 
product of ALA for toxicological testing (Section 4.2), and have developed an 
equation to calculate the percentage of ALA dimérisation in clinically useful 
solutions (Section 4.3). We have also investigated the kinetics of dimérisation of 
ALA at various pHs using solution state NMR (Section 4.4). Finally we have 
investigated the dimérisation reactions of other molecules (Section 4.5).
4.2 Experimental Discussion - The Synthesis of 2,5-Di-(P-Carboxyethyl) 
Pyrazine
Initially, an attempt was made to prepare 2,5-di-(p-carboxyethyl) pyrazine directly 
from ALA.HC1 (Reaction 8.21) by heating under reflux conditions in acetate 
buffer, then freeze drying (Fig. 4.4).
acetate
buffer2 X pH 4.4
HO2C.\
\ CDoH
HO:
[O]
N
\ CDoH
Figure 4.4 - Attempted synthesis of 2,5-di-(3-carboxyethyl) pyrazine.
This gave a brown hygroscopic oil. Attempts to purify the mixture using 
decolourising charcoal and column chromatography failed and NMR and mass
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spectrometry confirmed that the product had polymerised (peaks above the 
molecular weight of the pyrazine were detected).
An alternative approach was devised, beginning with the pyrazine ring intact (Fig.
4.5).
Br
NBS
K
N' dibenzoylperoxide N-
Br
2xCH2(C02%NaOH
HO2C\ HO2C GOgEt\ y
H+,H20,
-COo
\ C02H Et02C œ2Et
Figure 4.5 - Alternative attempted pyrazine synthesis.
Dibromination of 2,5-dimethylpyrazine (Reaction 8.22) followed by reaction with 
diethyl malonate and treatment with aqueous acid should yield 2,5-di-(p- 
carboxyethyl) pyrazine. As the brominated product is known to be highly 
lachrymatory, extremely irritating to the skin, highly unstable and liable to 
polymerisation,'*^  ^ it was reacted immediately, without purification, with diethyl 
malonate. Unfortunately, tic showed there to be at least seven products so this 
approach was abandoned.
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The pyrazine was, therefore, prepared using the route shown in Fig. 4.6,
1.SOCI2
2. BnOH <J== MeOH
(3)
BnO^C CO^ Bn " \
NaOMe
HO^ C
10%Pd/C
MeOI-I
W
(16) (17)
OOgBn OO2II
Figure 4.6 - Synthesis of 2,5-di-(P-carboxyethyl) pyrazine.
The HCl salt was removed from the benzyl ester of ALA.HC1 using sodium 
methoxide (Reaction 8.23), causing the benzyl ester of the pyrazine (16) to form. 
Hydrogenation over 10% Pd/C catalyst (Reaction 8.24) yielded the pyrazine (17) 
in good yield. This compound can now be used for toxicological testing.
4.3 Kinetics of the Dimérisation of 5-Aminolevulinic Acid
The convenient use of ALA in a clinic for PDT has not yet been realised. In the 
concentrated solutions of ALA at the pH required for use, there are two 
unwanted side reactions, i.e. dimérisation of ALA to give 2,5-di-(p- 
carboxyethyl)-3,6-dihydropyrazine, which then undergoes immediate oxidation to 
give 2,5-di-(P-carboxyethyl) pyrazine (17) (Fig. 4.3) and a reaction of unknown 
nature which results in the solution going dark brown. After storage for a few 
hours a solution of ALA looks rather like Coca-Cola (See Section 6.5). These 
two reactions, which we think are not necessarily related, make it very difBcult to 
know how the dose of ALA given to patients decreases during the lifetime of the
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solution. It should be possible to ascertain the progress of dimérisation by 
spectrophotometric means as the pyrazine (17) has a distinctive spectrum. The 
gradual deterioration (i.e. the browning) of the solution after a short time, 
however, prevents this. The absorbance after the completion of the reaction, 
which could be used to measure the extinction coeflBlcient for the pyrazine, cannot 
be measured due to this darkening reaction.
For a first order reaction it is possible to deduce the extinction coefiBcient of the 
product fi'om spectral changes occurring during early stages of the reaction using 
the method of Swinboume'’^  ^ and Kedzy.'***^  Most second order reactions can be 
converted into pseudo-first order reactions by appropriate adjustment of the 
concentration of one of the reactants and the Swinboume-Kedzy treatment can 
then be applied. This is not possible for a dimérisation reaction, however, as 
pseudo-first order conditions can never be realised. We have attempted a 
treatment of the kinetics of dimérisation reactions which parallels the Swinboume- 
Kedzy treatment of a first order reaction and applied it to solutions of ALA to 
ascertain the extent of dimérisation at timed intervals.
4.3.1 Derivation of the Equation
Consider a general dimérisation reaction:-
k2 A --------► P A = ALA; P = pyrazine
If X is [A] at time t, p is [P] also at time t and Xo is the initial [A] then:-
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= W  = k(xo - 2p)2
Separation of the variables gives:-
dp
(xo - 2p )2
Jf ^  = f  Mt
J  (xo-2p)2
kdt
'  kt + C2(xo - 2p)
where C is the constant of integration. The reaction is monitored by observing 
spectral change associated with the formation of P.
If At is the absorbance at a fixed wavelength at time t and s is the extinction 
coefficient of P, then
At = ep
 ----- = kt + C2(xo - 2Atq)
where q is the reciprocal of 8. If Ai is the absorbance at time ti and At = ta - ti, 
then
1 1
2(xo - 2A2q) 2 (xq - ZA^q) 
For times ts and U, where U - h  is the same At, then
= kAt
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1 1
1
2(xo - 2A^q) 2(xo - lA ^q )
1 1
= kAt
1
2(xo - 2A2q) 2(xo - 2Aiq)
(xQ-2Aiq)>(xQ-2A2q)
(xo-2A2q)(xo-2Aiq)
Azq - Aiq 
(xo - 2A2q)(xo - 2Aiq)
2(xo - 2A^q) 2(xo - 2Agq)
( xq - 2A]q) - (xq - 2A^q) 
(xo-2A4q)(xo-2A3q)
A4q - Agq
(xo"2A4q)(xo-2A3q)
This gives a cubic equation which can be solved giving 3 solutions. One solution 
is q = 0, there is a false one and one real one. A range of values of q were 
obtained by taking a number of combinations of Ai, A2, A3 and A4, keeping At 
constant.
4.3.2 Kinetic Measurements
The spectral changes accompanying the conversion of a 3 mM solution of ALA 
into 2,5-di-(P-carboxyethyl) pyrazine at 37 °C are shown in Fig. 4.7.
1
Figure 4 .7  -  Spectral ch anges associated w ith the conversion o f  A LA  into 2,5-di-(P*
carboxyethyl) pyrazine.
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The absorbance at 280 nm was measured at timed intervals and those values were 
used to monitor the progress of the reaction in terms of concentration. It is certain 
that the dimérisation of ALA reaction does not stop at the dihydropyrazine but 
there is rapid aerial oxidation to the pyrazine (17). This was shown to be a 
product of reaction by Jaffe and Rajagopalan'^®  ^ and the dihydropyrazine has only 
been observed by NMR under the most stringent anaerobic conditions.'*®® Various 
combinations of absorbance values at 280 nm were used to generate the derived 
cubic equation and this, on solution, gave a range of values for the extinction 
coefficient of 2,5-di-(p-carboxyethyl) pyrazine of 1361 ± 260 dm^mol'*cm'\
4.3.3 Conclusions
The derived value of s was applied to absorbance data for the dimérisation of 
ALA at both 3.0 mM and 0.3 mM and the results are displayed in Fig. 4.8.
Initial [ALA]/ mM Time/ mins. % dimérisation.
3 30 2
3 60 5
3 90 7
3 120 12
0.3 30 3
0.3 60 4
0.3 90 6
0.3 120 8
Figure 4 .8  - Table show ing dim érisation o f  a 3 .0  or 0.3 m M  solution o f  A L A  at a given  time.
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The significant conclusion is that, in a solution containing concentrations of ALA 
necessary for PDT, substantial amounts of dimérisation will occur during the 
lifetime of a clinic and so the dose of ALA being given depends upon the age of 
the solution. This is unsatisfactory and we have also been working on modifying 
ALA in ways which will still allow it to be incorporated into the biosynthetic 
pathway for haem production but which prevent dimérisation and browning in 
solution during storage (See Chapters 6 and 7).
4.4 Studies on the Dimérisation of Labelled 5-Aminolevulinic Acid by 
Solution State NMR
labelled ALA.HCl was prepared using the method of lida, Takao, Ogai and 
Kajiwara.'**® (Scheme 2.6), (Reactions 8.13, 8.14 and 8.15) using labelled 
potassium phthalimide. This was used to investigate the kinetics of dimérisation of 
ALA. Kinetic studies using NMR spectroscopy have the distinct advantage that 
starting materials, intermediates and products can be identified and characterised. 
The reaction can be followed closely. The spectra of *^ N ALA (50 mg) dissolved 
in phosphate buffer (pH 7, 8 and 11,2 cm^) with a few drops of ^HaO to provide 
a lock signal was recorded each hour for 15 hours at room temperature (20 °C). 
In all three cases no dimérisation was observed. The *^ N spectra of ALA with one 
sharp peak at ô 25.75 was identical 15 hours after preparation of the solution to 
its initial spectra. The solutions remained colourless. Dimérisation reactions are 
highly concentration dependent. By multiplying the concentration by two, the 
amount of dimer will increase four fold. These ALA solutions were 0.15 M which 
is much less concentrated than a clinically useful solution. The result is, however,
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surprising and appears to contradict the results found using the derived equation 
and UV/visible spectroscopy (Section 4.3). Temperature is an important factor. 
UV/visible measurements were recorded at 37 °C. An NMR study at higher 
temperatures would be an interesting exercise. When the samples were heated 
using a heat gun they became a darker brown colour. NMR spectra showed 
only one sharp peak, this time at ô 274.88, a value consistent with pyrazine 
formation.'^^ This study indicates that if clinically useful solutions could be kept 
cold and were less concentrated, they may not dimerise as readily. Further work, 
however, is required to optimise conditions for the storage of solutions of ALA.
4,5 Investigation of Other Dimérisation Reactions
As part of this study to modify ALA chemically to make it more acceptable for 
clinical use we thought it would be of value to investigate further the mechanism 
of a dimérisation reaction.'*®^ '
4.5.1 Kinetics of the Dimérisation of 2 * - Am ino-2-Hyd roxy acetoph en one
The UV/visible spectral changes accompanying the conversion of ALA to 2,5-di- 
(p-carboxyethyl) pyrazine are very small and the reaction is complicated by the 
formation of a brown colour, thus we are denied one of the most useful tools in 
the study of reaction mechanism. To counteract this problem we have also 
investigated the spectral changes accompanying a similar dimérisation reaction 
involving a compound incorporating a chromophore. Such a reaction is the
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conversion of 2’-amino-2-hydroxyacetophenone into 2,5-dihydro-2,5-di-(2’> 
hydroxyphenyl) pyrazine (Fig. 4.9).
H2K\
2 X
(a)
1 ^ 0  k HO 
\  K0H,H20Ar
:v Ar(b)
‘NH2 A r
O -H2O
(20)
'NH2 Ar
(c)
Ar =
Ar^ Ar^
(d)
(21) H Ar
.OH
Figure 4.9 - The dimérisation of 2’-amino-2-hydroxyacetophenone.
4.5.1.1 Synthetic Discussion
Initially, the route of Huebner and Link for the preparation of 2’-amino-2- 
hydroxyacetophenone was followed. 4-Hydroxycouniarin was nitrated using nitric 
acid in acetic acid in good yield to give 3-nitro-4-hydroxycoumarin (18) (Reaction 
8.25). Considerable difficulty was found, however, in reproducing the next stage 
of the reaction. Huebner and Link prepared 2'-amino-2-hydroxyacetophenone 
hydrochloride by the reaction of 3-nitro-4-hydroxycoumarin (18) with hydriodic 
acid in acetic acid, using hypophosphorous acid to reduce the resulting iodine 
(Reaction 8.26). After many different attempts, an alternative method was 
found.'*3-Nitro-4-hydroxycoumarm was reacted with aqueous NaOH, then c- 
HCl, to form 2-hydroxy-2' -nitroacetophenone (19) (Reaction 8.27). The NMR 
spectra of this compound proved to be interesting. Two sets of signals were
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visible in the aromatic region and two carbonyl signals were detected in the 
spectrum. Addition of ^ He-DMSO to the pale yellow solid caused the formation of 
a bright yellow solution. We think that the nitronic acid form of the molecule is 
being produced in solution in approximately a 1:1 ratio with the expected product. 
The CH=N+ is not visible in the spectrum (Fig. 4.10).
.NQ
OH
(19)
CH=N— OH
Figure 4.10 - Formation of nitronic acid from 2-hydroxy-2’-nitroacetophenone.
The 2-hydroxy-2’-nitro-acetophenone (19) was then converted to 2’-amino-2- 
hydroxyacetophenone (20) using tin chloride in HCl (Reaction 8.28). A sample of 
2,5-dihydro-2,5-di-(2'-hydroxyphenyl) pyrazine (21) was prepared (Reaction 
8.29) by dissolving 2'-amino-2-hydroxyacetophenone (20) in KOH solution 
giving the product (21) as a highly insoluble, therefore, uncharacterised pink solid 
(Fig. 4.11).
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OH OH
NO2 NO2
OH(19)(18)
OH
OH
(21)
OH
(20)
Figure 4.11 - Scheme for the preparation of 2,5-dihydro-2,5-di-(2’-hydroxyphenyI) pyrazine.
4.5.1.2 Kinetic Investigation
The reaction must occur in a number of steps; a possible sequence is shown in 
Fig. 4.9. More than one of the steps labelled (a-d) could be slow but a single slow 
step should be indicated by a tight isosbestic point as the spectrum of the reaction 
mixture changes with time. This was found to be the case (Fig. 4.12).
1.5
1.0
0.5
Figure 4.12 - UV/visible spectrum of the dimerisatimi reaction of 2’-amino-2-hydroxy- 
acetophenmie showing the tight isosbestic point.
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The most likely situation, and one that has been observed in other reactions of this 
type*^ *^  is that (a) is the slow, rate-determining step and this should give rise to 
simple, second order kinetics. Simplification of the situation to generate pseudo- 
first order conditions is, again, not possible. As both reactant and product absorb 
at wavelengths suitable for monitoring the reaction, there is no direct way of 
converting observed absorbance into concentration of reactant for substitution 
into an integrated rate equation. However, the extinction coefficients for the 
starting material and product (ei and 82) were readily determined and some trivial 
algebra indicates how [SM]t (the concentration of the starting material at time t) 
may be deduced from At (the absorbance at time t)
At = [SM]t 8] + [P]t82
[SM]t8i + 0.5 ([SM]o - [SM]t) 82
[SM]t (81 - 0.5 82) + 0.5 [SM]o 82
[SM] =
2 8 i - 82
The term [SM]o is the initial concentration of the starting material and 2 appears 
in this equation because two moles of starting material give only one mole of 
product, P. From the observed values of At it was possible to calculate [SM] as a 
fiinction of time. For a second order reaction with one reactant, a plot of l/[SM]t 
against time should be linear with a slope of k. This plot is shown in Fig. 4.13.
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Figure 4.13 - Second order plot of l/[SM]t against time.
The linearity indicates the second order nature of the reaction and the value of k, 
taken from the slope, is 0.26 Imof^s'^ Thus the observed kinetics are consistent 
with the mechanism shown in Fig. 4.9 It is not unreasonable to assume that the 
mechanism does not involve, for example, the slow énolisation of one molecule of 
the starting material and rapid reaction with a second molecule.
4.5.2 The Dimérisation of Acetoacetamide
One of the driving forces in the dimérisation of ALA is the nucleophiHcity of the 
amine group so the reaction is prevented by storing the material as the HCl salt. 
We wondered if compounds containing an amide rather than an amine would 
show the same readiness to dimerise and selected acetoacetamide for study (Fig. 
4.14).
85
o OH
acetate buffer 
pH 4.4 ^
o
HO
(22)
Figure 4.14 - The dimérisation of acetoacetamide.
This material was heated under reflux conditions in acetate buffer and the reaction 
mixture allowed to stand for some days to give a small quantity of a white 
crystalline product (Reaction 8.30). All the analytical data points to dimérisation 
with elimination of water and the NMR spectrum suggests formation of 2- 
(acetylmethyl)-6-methylpyrimidin-4-one (22) with the particular tautomeric form 
shown in Fig. 4.14. The absence of signals corresponding to methylene groups 
and the presence of a signal most readily assigned to an olefinic proton are the 
main pieces of evidence to support this identification. We have been unable to find 
any references in the chemical hterature to a previous observation of this reaction, 
although the low yield obtained hardly makes it an acceptable synthetic route in 
the unlikely event of the product ever being required. The mechanism of 
formation must involve reaction of an amide NH2 group with both the carbonyl of 
another amide and an isolated carbonyl and the driving force must be the creation 
of an aromatic ring. The existence of the exocyclic olefinic double bond is to 
allow conjugation with theheteroaromatic ring (Fig. 4.15).
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O N.
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OH(22)
Figure 4.15 - Mechanism for the formation of 2-(acetylmethyl)-6-methylpyrimidin-4-one.
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Chapter 5 
The Chemistry of Dihydropyrazines
5.1 Introduction
The initial product formed in the non-enzymatic dimérisation of ALA is a 
dihydropyrazine (Fig. 5.1). 2,5“Di-(p-carboxyethyl) dihydropyrazine is oxidised 
immediately in air forming the more stable aromatic pyrazine. The 
dihydropyrazine has been detected only during anaerobic NMR studies.^ ®'* To 
try to understand the chemistry of dihydropyrazines we have attempted to prepare 
a series of more stable derivatives. This chapter deals with the synthesis, use and 
structure of dihydropyrazines.
2x
OOgH HO,
+  2 H 2 O
OOgH
Figure 5.1 - Dimérisation of ALA yielding 2,5-di-(p-carboxyethyl) dihydropyrazine.
5.2 Literature Review of the Synthesis of Dihydropyrazines
All reactions involving preparation of dihydropyrazines must be done under 
anaerobic conditions to prevent aerial oxidation to the corresponding pyrazine.
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5.2.1 Synthesis of 2,5-Dihydropyrazines by the Self-Condensation of a- 
(Primary Amino) Carbonyl Compounds
The first reported synthesis of a 2,5-dihydropyrazine was in 1902 when 
aminoacetone, in the presence of potassium, was found to dimerise giving 2,5- 
dihydro-2,5-dimethyl pyrazine (Fig. 5.2).^^^
2x o  K
NH,
Figure 5.2 - The first reported synthesis of a dihydropyrazine.
In a reaction analogous to the self-condensation of two molecules qf ALA, 2,5- 
dihydropyrazines can be prepared fi-om a-(primary amino) carbonyl compounds. 
A more recent example is the reaction of alkyl ketones with warm aqueous 
alkaline potassium ferricyanide to give a-aminoketones. Depending on the 
reaction conditions used during work-up, either the hydrochloride salt of the a- 
aminoketone, or a 2,5-dihydropyrazine can be formed (Fig. 5.3).^ "^^
H ^
K,Fe(CN)6
HCLHjN Rj
Ri HgO, base
HCFHoOR NaOH/HjOO:
R,
R,
Figure 5.3 - Synthesis of 2,5-düiydropyrazines from alkyl ketones.
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Phase transfer catalysis can be used to assist the condensation reaction/^^ Heating 
the ortho esters of some amino acids also results in dihydropyrazine formation 
(Fig. 5.4).'""
2 X
aoEt>3 A
R NH.,
Figure 5.4 - Synthesis of a 2,5-dihydropyrazine from the ortho ester of an amino acid.
5.2.2 Synthesis of 2,5-Dihydropyrazines from 3-Membered Heterocyclic 
Rings
Azirines dimerise, on standing or heating, to give 2,5-dihydropyrazines (Fig.
5.5).'"^
2 X
a .
H-
Et
7N a- .a
a
Figure 5.5 - Dimérisation of an azirine to give 2,5-dihydro-3,3,6,6-tetraethylpyrazine.
2-Chlorooxirane can also be converted into a 6 membered heterocycle by forming 
an a-aminoketone followed by dimérisation (Fig. 5.6).'"*
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/
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:o + NH3
-H .0
K
N — H 
1
'N
Figure 5.6 - Synthesis of dihydropyrazines from 2-chIorooxiranes.
5.2.3 Preparation of 2,5-Dihydropyrazines via Diketopiperazines
By far the most commonly used route for the preparation of 2,5-dihydropyrazines 
uses SchôUkopf type chemistry.'"^ A diketopiperazine (piperazine-2,5-dione, 
cyclic dipeptide) can be prepared by coupling a tertiary butoxycarbonyl (t-Boc) 
protected amino acid to an amino acid protected at the acid functionality as an 
ester. Formic acid can then be used to generate a dipeptide ester formate which, 
after reflux in toluene and butanol yields a diketopiperazine (Fig. 5.7).'^"
OOgH COoMe DCC Q
R NHtBoc R
derivative
HR O. K1. formic acid ,R
R' COnMe 2. BuOH, toluen^ ‘NHtBoc R H
Figure 5.7 - Formation of a diketopiperazine.
Exposure of the dipeptide methyl ester to methanol-ammonia for up to 5 days also 
yields a diketopiperazine but these conditions can lead to racémisation.'^^ 
Diketopiperazines are converted into 2,5-dihydropyrazines using Meerwein’s 
Salts (triethyloxonium or trimethyloxonium tetrafluoroborate) (Fig. 5.8).
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a
Me,0+BF.-' ' or
Etc,0+BF/R ' N " ^O  “ 3^ ^^4 
H
Figure 5.8 - Reaction of a diketopiperazine with Meerweins Salts.
We have used a-aminoketones and SchôUkopf chemistry to generate a series of
2,5-dihydropyrazines. Azirine chemistry was avoided due to the instability and 
toxic nature of the molecules.
5.3 Applications of Dihydropyrazine Chemistry
Most of the work published concerning dihydropyrazine chemistry is applicable to 
three main areas of research. These are the browning of foods during the Maillard 
reaction,'studies on antiaromaticity and the synthesis of chiral amino acids.
5.3.1 The Maillard Reaction519
The MaiUard, or non-enzymatic browning reactions are some of the major 
pathways causing the flavourings and aromas of cooked foods. The Strecker 
degradation is one of the most important reaction schemes leading to compounds 
with an aroma (Fig. 5.9).
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V NHo
COoH
R O
2x
NHoY
A oh
o% /
HoN'A
-2H.0  *—-► [03
K
'N' N"
Figure 5.9 - The Strecker Degradation.
It involves a Schiff base formation between an a-dicarbonyl compound and an 
amino acid. Rearrangement, decarboxylation and hydrolysis yield an a- 
aminocarbonyl compound, a precursor of dihydropyrazines.'^"
5.3.2 Antiaromaticity
A range of dihydropyrazines have been prepared to assist in the study of 
antiaromaticity. Cyclic systems containing 4n + 2 7t electrons, such as benzene, 
are defined as aromatic and are very stable. Cyclic conjugated systems with 4n n 
electrons, on the other hand, are strongly destabilised and are classed as 
‘antiaromatic’.'^" The dihydropyrazine ring system has been studied as it contains 
8 7C electrons, resulting in a potential antiaromatic nature.'^'
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5.3.3 Chiral Amino Acid Synthesis
Many dihydropyrazines have been prepared as intermediates in the asymmetric 
syntheses of amino acids. Functional groups can be added to dihydropyrazines via 
the alkylation of lithiated bis-lactim ethers. Hydrolysis then yields the optically 
active amino acids (Fig. 5.10).'^'
.OMe 
......H'
MeO
O'
CO2CH3
H30+■<— -----
-LrLeu-OCHo MeO^
R-X
R
Figure 5.10 - Chiral amino acid synthesis using a dihydropyrazine.
5.4 Experimental Discussion
5.4.1 Dihydropyrazines from the Reaction of an Alkyl Ketone with 
Potassium Ferricyanide
Initially, the route of Farnum and Carlson'""  ^ (Fig. 5.3) using an alkyl ketone and 
potassium ferricyanide was used to try to prepare a series of dihydropyrazines. 
Various ketones were reacted with potassium ferricyanide in water in the presence 
of ammonia to form the «-(primary amino) carbonyl compound which can lose
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two molecules of water to form a dihydropyrazine. The reaction was attempted 
with 3-methyl-2-butanone (Reaction 8.31), ethyl methyl ketone (Reaction 8.32) 
and acetone (Reaction 8.33). The results of these reactions are summarised in Fig. 
5.11.
Ketone Expected Product Actual Product
3-methyl-2-butanone
(23)
As expected
ethyl methyl ketone CX Pyrazine
acetone None
Figure 5.11 - Summary table of reactions of alkyl ketones with potassium ferricyanide.
Unfortunately, if an exchangeable proton was present, it was possible to isolate 
only the pyrazine or nothing at all. The yields for the reactions were very low and, 
as a ten times excess of potassium ferricyanide was required, very wasteful. This 
approach was abandoned.
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5.4.2 Dihydropyrazines from Diketopiperazines
A range of dihydropyrazines was prepared using SchôUkopf chemistry (Fig, 5.7 
and 5.8). The amino acids glycine, L-alanine, L-phenylalanine and L-valine were t- 
Boc protected (Reactions 8.34 (24), 8.35 (25), 8.36 (26), and 8.37 (27)) using di- 
t-butyl pyrocarbonate, then coupled to the methyl ester of the same amino acid 
(Reactions 8.38 (28), 8.39 (29), 8.40 (30) and 8.41 (31)) using a derivative of 
dicyclohexyl carbodiimide (DCC), l-cyclohexyl-3,2-morpholinoethyl-p-toluene 
sulphonate (CHME).'^^ Treatment with formic acid removed the t-Boc group 
causing the molecule to cyclise giving a series of diketopiperazines (Reactions 
8.42 (32), 8.43 (33), 8.44 (34) and 8.45 (35)).'^° The diketopiperazines were 
reacted in the presence of Meerwein’s Salts, trimethyloxonium 
tetrafluoroborate'^^ (Reactions 8.46 (36), 8.47 (37), 8.48 (38) and 8.49 (39)) and 
triethyloxonium tetrafluoroborate'(Reactions 8.50 (40) and 8.51 (41)) to give a 
range of dihydropyrazines (Fig. 5.12). The NMR spectra and structures of these 
compounds are discussed in Section 5.6.
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H .N. .ORi 
R2 Q> OR?
H
Amino Acid Compound Number Rl R2
gfycine (36) CH3 H
L-alanine (37) CH3 CH3
L-phenylalanine (38) CH3 CH2Ph
L-valine (39) CH3 CH(CH3)2
glycine (40) CH2CH3 H
L-alanine (41) Œ 2CH3 CH3
Figure 5.12 - Table of dihydropyrazines.
5,5 Literature Review of the Structures of Dihydropyrazines
The simplest, unconjugated known dihydropyrazine which does not incorporate 
stabilising groups e.g. phenyl or hydroxyphenyl is 2,5-dihydro-2,5- 
dimethylpyrazine. Three structures for this molecule are possible (Fig. 5.13).'^'
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(a)
Ar
(b)
H
(c)
Figure 5.13 - The three possible structures for 2,5-dihydro-2,5-dimethylpyrazine.
The compound was first synthesised by Gabriel and Colman in 1902,'"^ Structure 
(a) is generally assumed to be correctX"^ although structure (b) has also been 
suggested.'^' Using IR spectroscopy, in 1958, it was suggested that either a 
mixture of (a) and (b) was present or (c) alone. These conclusions were based 
upon the presence of a strong band in the IR spectrum at 3260 cm'% which was 
interpreted as an NH stretch. This band was later found to be due to the 
compound being wet.'^* NMR spectroscopy in 1970 concluded that the structure 
of 2,5-dihydro-2,5-dimethylpyrazine was (a). SmaU peaks were observed which 
were assumed to be due to the presence of (b) or (c). As most of the work 
concerning the structures of dihydropyrazines was done in the 1960s before NMR 
was a readily available tool, a series of dihydropyrazines were prepared and their 
NMR and IR spectra used to try to probe their structures in solution (See Section 
5.6).
The conformation of the dihydropyrazine ring was investigated by Blake et al in 
1972.'^" They found that reaction of phenylalanine anhydride with the Meerwein’s 
Salt, triethyloxonium tetrafluoroborate, yielded a cis/trans mixture of 
dihydropyrazines. They found that extensive isomérisation occurred during the 
reaction. (Fig. 5.14).
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N OB.
EtO
EtO. N
R=CH2Ph
^  EtO. N
M OEt
H R
Figure 5.14 - Conformation of a dihydropyrazine which had isomerised during synthesis.
Using variable temperature NMR they concluded that the major isomer is the 
trans form (Fig. 5.14b). They concluded also that, if there were rapid equilibrium 
between the two boat conformers, the trans isomer would be equilibrating with an 
identical conformer (Fig. 5.14b) and temperature change would not affect the 
ratio. The cis isomer (Fig. 5.14a), however, would equilibrate with a different 
conformer hence change in temperature would alter the r a t i o . W e  have 
compared the NMR spectra of compounds containing methyl and ethyl groups 
where R is either H or CH3 to try to investigate this fiirther (see Section 5.6).
5.6 NMR Studies on the Structures of Dihydropyrazines
The proton and carbon NMR spectra of 2,5-dihydro-2,5-dimethoxypyrazine (36) 
are very simple. The molecule is symmetrical giving only two singlet peaks in the 
proton NMR corresponding to OCH3 and CH2 and three peaks in the carbon
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NMR corresponding to OCH3 CH2 and COCH3. Regardless of the solvent, 
solution strength or time only these peaks were visible. On occasion, after some 
time, additional peaks corresponding to the oxidised pyrazine were detected. No 
NH stetch was observed in the IR, hence, we conclude that the structure of the 
molecule is as shown in Fig. 5.15.
CH3O N
(36)
OCH.
Figure 5.15 - Structure of 2,5-dihydro-2,5-dimethoxypyrazine.
The proton and carbon NMR spectra of 2,5-dihydro-2,5-dimethoxy-3,6- 
dimethylpyrazine (37) were much more complex. The proton peaks were split and 
carbon peaks were all doublets indicating cis trans isomérisation. There was still 
no evidence for any formation of structures similar to those shown in Fig. 5.13b 
and c. We conclude that the structure of the molecule is as shown in Fig. 5,16.
H
'CH,
CH3O. .N H
a
ca
‘c a
W  ^OCH,H
(37) (37)
Figure 5.16 - Cis and trans isomers of 2,5-dihydro-2,5-dimethoxy-3,6-dimethylpyrazine.
The compounds prepared from L-phenylalanine, 3,6-dibenzyl-2,5-dihydro-2,5- 
dimethoxypyrazine (38), and ftom L-valine, 2,5-dihydro-2,5-dimethoxy-3,6-
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dipropylpyrazine (39), were less susceptible to aerial oxidation than the less 
hindered compounds but their NMR spectra were even more complicated. There 
was no evidence for the formation of any compound containing an NH group.
We conclude that dihydropyrazines of this type are in the form shown in Fig. 
5.17a and not as in Fig. 5.17b or c.
H
a
H
'R a
a  ocH,
R
.R
oca
Figure 5.17 - Potential structures of a dihydropyrazine in solution.
The use of triethyloxonium tetrafluoroborate added another degree of 
complication to the NMR spectra of these compounds. 2,5-diethoxy-2,5- 
dihydropyrazine (40) and 2,5-diethoxy-2,5-dihydro-3,6-dimethylpyrazine (41) 
were prepared. These compounds were both found to be in the same 
conformation as the molecules synthesised from trimethyloxonium 
tetrafluoroborate but had even more complex spectra, presumably due to 
additional couplings between the various groups around the molecule. Their NMR 
spectra have not been fully assigned as this would be beyond the scope of the 
study.
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5.7 Conclusions
Dihydropyrazines are extremely difficult molecules to work with. In the absence 
of stabilising groups they are readily oxidised to give the corresponding aromatic 
pyrazine compound. They must, therefore, be handled under nitrogen at all times. 
All the dihydropyrazines that we prepared were in the same conformation, 
although the Meerwein’s Salts caused isomérisation, complicating the study. 
There are two feasible reasons why dihydropyrazines are in this form. Firstly, a 
C=N bond is, energetically, stronger than a C=C bond making the molecule more 
stable. The other reason is due to a ‘push-pull’ mechanism.^^^ This concept 
provides some stability to otherwise unstable systems. An example can be seen in 
the cyclobutadiene ring system which is stabilised by a push-pull effect between 
the electron-donating amino groups and the electron-withdrawing ester groups 
(Fig. 5.18).
HoN.
OR
RO2C NR2 O'---- <
\ O'
NiEto
OR
Figure 5.18 - Stabilisation of a cyclobutadiene ring system by a push-pull mechanism.
A similar argument can be used for the dihydropyrazine ring system (Fig. 5.19).
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r 6 \ ^ n
+
'TQ N ^OR
Figure 5.19 - Stabilisation of a dihydrcpyrazine ring system by a push-pull mechanism.
As 2,5-di-(P-carboxyethyl) dihydropyrazme contains no stabilising groups it is 
very unlikely that it would be present for any length of time. It would be 
immediately oxidised to give 2,5-di-(p-carboxyethyl) pyrazine making the reaction 
irreversible. It would, potentially, be possible for ALA to be in equilibrium with its 
dihydropyrazine but oxidation to the pyrazine is an irreversible step, causing the 
percentage of ALA in solution to gradually decrease vWth time.
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Chapter 6
Synthesis of Derivatives of 5-AminoIevulinic Acid
6.1 Introduction
Although ALA induced PpIX is proving to be one of the more promising 
techniques in PDT, there are still problems associated with its use. Solutions of 
ALA go dark brown over time, probably due to a polymerisation reaction (See 
Chapter 4 and Section 6.5). ALA may also dimerise, in the absence of the enzyme 
PBG synthase, to give a pyrazine (See Chapter 4). A third problem is the low 
bioavailability of ALA. Consequently, very high doses are required to produce 
clinically useful PpIX levels.^^^
ALA exists as a zwitterion at physiological pH (Fig. 4.1), so has very low lipid 
solubility. This means that it is inefficient at passing through biological barriers, 
e.g. walls of the stomach or intestine, the stratum corneum (the outer layer of the 
skin) and cellular membranes.^”^  ALA has limited penetration ability through the 
skin and, as porphyrins are produced in the deepest layers of lesions, there is a 
need to enhance both ALA absorption and porphyrin production in tumours.^®^
Fortunately, penetration of ALA into normal, healthy skin is poorer than in 
malignant lesions or in skin which has had chronic sun damage. Also, chemicals 
such as DMSO can be used to enhance its penetration capacity.^ '^  ^However, there 
is still a need for pro-drugs which have an enhanced lipophilicity. The esters of 
ALA have proved useful in this respect. By forming an ester, ALA no longer has a 
negative charge under physiological condi t ions . I t  is known that increasing the 
number of carbon atoms m a chain attached to an existing drug results in an 
increased lipophilicity of that drug^°  ^but it is not known how ALA is taken up
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into cells. Various non-specific routes such as diffiision, or transport by a specific 
membrane protein, have been suggested. It is possible, therefore, that the uptake 
of ALA into cells could be modified by chemically changing groups on the 
molecule. It is known that transport proteins recognise their substrates by the 
charged groups and so, by altering these, ALA uptake may be enhanced (or 
inhibited), or the molecule may be recognised by another transporter. If  there is a 
transport protein which is responsible for regulating levels of ALA, export of the 
molecule from the cell may be inhibited allowing levels of ALA to increase. This 
would be advantageous for PDT.^^^
From a chemical perspective, addition of groups to the acid end of ALA such as 
esters, or amino acids might stop polymerisation and the associated browning 
from occurring. A better solution, however, would be to attach groups to the 
amino end stopping dimérisation. The ideal compound would be stable and non­
toxic until the appropriate enzymes in the body cleaved the inactive group from 
ALA leaving the active compound and some other non-toxic group, e.g. an amino 
acid, sugar or alcohol. Biologically, addition of esters, amino acids, sugars and 
long chain alkyl groups could enhance the bioavailability of the molecule.
A series of twelve derivatives, with a mixture of functional groups, have been 
prepared and tested biologically for activity as pro-drugs in PDT.
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6.2 Literature Review of 5-Aminolevulinic Acid Pro-Drugs
Only recently has an interest in derivatives of ALA as pro-drugs for PDT 
developed. The first paper on the subject was published in 1996.^ *^  ^ Work has 
centred on alkyl esters of ALA (ALA-methyl ester to ALA-octyl ester)/°^ ' 
with varied success. In general, shorter chained alcohols (ALA-methyl and ethyl 
esters) are less effective than ALA itself.^ ®'^ ’^ ^^  The longer chained esters, 
however, particularly the hexyl ester, have been found to be efficient. Prodrugs 
with long chains are hydrolysed more slowly than ones with a shorter chain but 
have been shown to penetrate deeper into the cell.^ ®^
Some success has been found with the tetrahydrofurfiiryl and tetrahydropyran 
esters. N-Acetyl-ALA, however, has been ffiund to be a poor pro-drug for PDT 
sensitisation.^^^ AU the aUcyl esters and N-alkanoyl protected derivatives of ALA 
have been patented in Japan for use as potential plant growth regulators,^®^’ but 
not, as yet, for use as pro-drugs in PDT.
6.3 Experimental Rationale
Firstly, it was necessary to be able to synthesise alkyl esters of ALA.HC1, for use 
in both biological testing and as synthetic precursors for NH2 protected 
derivatives of ALA.
Initial attempts to prepare ALA-methyl (ALA-OMe) and ALA-ethyl (ALA-OEt) 
esters foUowed on from experience gained during the synthesis of ALA.HC1 itself
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(See Chapter 2). Methyl 5-phthalimidolevulmate was prepared as before 
(Reactions 8.1 (1) and 8.4 (4)). Likewise, ethyl 5-phthalimidolevulinate (43) was 
synthesised by substituting ethanol for methanol in the initial bromination reaction 
(Reactions 8.52 and 8.53). Phthalimide was then removed, leaving the ester intact, 
using N,N-dimethyl-1,3-propanediamine (Reactions 8.54 and 8.55) giving a very 
poor yield of both the esters (44) and (46). The majority of the product in each 
case was found to be a pyrazine (45) and (47) (Fig. 6.1).
Br, ROH Q.
COjH
O N o
COjR 
R=CH3 (1) 
R^ CH^ CHg (42)
DMF
R=CHg (4) 
R=CH2CH3 (43)
/
RO2C.
CO^ R
MeOH, EtgN
R=Œ3 (45) 
R=C%CH3 (47)
HCI.H2N
R= CH3 (44)
O R-CH2CH3 (46)
CO2R GOgR
Figure 6.1 - Synthesis of ALA-OMe and ALA-OEt from methyl 5-phthalimidolevulinate,
A route to prepare both ALA-OEt and carbobenzyloxy-ALA (Z-ALA) was 
attempted.^^^ Carbobenzyloxyglycine (Z-Gly) and valine methyl ester (Val-OMe)
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were coupled using the mixed anhydride approach (Reaction 8.56, (48)). The 
methyl ester was then removed by saponification (Reaction 8.57 (49)). The next 
stage involved the synthesis of an oxazoline ring. Z-Gly-Val-OH (49) was reacted 
initially with acetic anhydride for 50 minute, then fi'eshly distilled ethyl acrylate 
and triethylamine for 5 days at 50 °C (Reaction 8.58). Purification of the resulting 
orange oil was carried out using a polyamide column. Polyamide, a stationary 
phase, is not acidic, hence, does not break up the oxazoline ring. AJfter passing the 
same solvent through the column for 1 day, the orange colour remained on the 
column leaving an almost white solid product (50). This was reacted with sodium 
bicarbonate in aqueous ethanol to produce Z-ALA-OEt (Reaction 8.59, (51)). At 
this stage only a small amount of product was obtained so only the preparation of 
ALA-OEt was attempted. Hydrogenation, however, yielded 2,5-di-((3- 
carboxyethyl) pyrazine diethyl ester (Reaction 8.60, (47)) rather than the required 
product (Fig. 6.2).
I l l
ZHN.. .CO2H CO^Me
COgMe ------
HoN
1.NaOH
2. HCl _ HN
O
co^n
o
EtOgC\
NHZ 
(48)
COgEt
NHZ
(49)
N"
(47)
H2,Pd/C
ZHN
'COgEt (51)
Eton, H2O 
NaHCO^M--------
1. AC2O
2. ethyl aciylate, Et^ N
H
COgEt
NHZ (50)
Figure 6.2 - Attempted synthesis of ALA-OEt and Z-ALA.
The use of Z-protecting groups for ALA was abandoned as removal, by 
hydrogenation, leaves a free NH2 group which can either cyclise internally, 
forming piperidine-2,5-dione (55) (Fig. 6.3a) or dimerise giving a pyrazine (Fig. 
6.3b),
COgEt
H
(55)
Figure 6.3a - Internal cyclisation of ALA-OEt to form piperidine-2,5-dione.
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2 X
EtO.C
[O]
N
(47)
Figure 6.3b - Dimérisation of ALA-OEt to form a 2,5-di-((3-carboxyethyl) pyrazine diethyl ester.
The ester has a much better leaving group than the free acid making ALA esters 
more reactive and more susceptible to side reactions than ALA itself (See Section
6.5). This approach to the synthesis of protected ALA was, therefore, abandoned.
Instead, ALA esters were prepared directly from ALA.HCl (3) using the 
appropriate alcohol and thionyl ch lor ide .A LA -O Et  (Reaction 8.61 (46)), 
ALAOhexyl ester (Reaction 8.62, ALA-OHex, (52)) and ALA-benzyl ester 
(Reaction 8.63, ALA-OBn, (53)) were prepared in this way (Fig. 6.4).
COgH
0=
HCI.H2N
CO2R
R=CH3CH2 (46) 
R=CH3(CH2)5 (52) 
R=PhCH2 (53)
(3)
Figure 6.4 - Direct preparation of ALA esters.
ALA esters could then be reacted with various NH2-protected amino acids and 
deprotected to form ‘dipeptides’. Initial strategy involved reaction of Z-protected
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amino acids with ALA-OBn as both protecting groups could be removed together 
using hydrogenation. Z-Gly was coupled to ALA-OBn using CHME as the 
coupling reagent (Reaction 8.64, (54)) as the mixed anhydride approach resulted 
in a much lower yield (Reaction 8.65). Deprotection by hydrogenation (Reaction 
8.66), however, yielded a diketopiperazine derivative and not the expected fully 
deprotected product (Fig. 6.5).
ZHN"^  ^CO^H
+
O
o
CHME ,N, ^  ZHN CO^ Bn
HCI.H2N,
O (54)
CO^ Bn
H2,Pd/C
CO2H
H.N COgH
Figure 6.5 - Formation of a diketopiperazine during an ALA derivative deprotection.
Z-Groups can also be removed using HBr/ acetic acid^ ^® but this would yield an 
HBr salt which is not ideal for biological testing.
Another method had to be developed where a free NH2 group was never allowed 
to form. t-Boc groups can be removed veiy cleanly using HCl gas, therefore, to 
prepare deprotected derivatives, this strategy was adopted. t-Boc-Gly was 
coupled to ALA-OEt using CHME (Reaction 8.67, (56)). The product was found 
to contain a small quantity of piperidine-2,5-dione (Fig. 6.3a (55)).The t-Boc
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group was then removed using HCl gas to give Gly-ALA-OEt (Reaction 8.68, 
(57)) which was, unfortunately, not prepared early enough to be biologically 
tested. Preparation of t-Boc-Gly-ALA-OBn followed by hydrogenation to remove 
the benzyl ester, then treatment with HCl gas to remove the t-Boc group may be a 
good strategy for the synthesis of dipeptide derivatives (Fig. 6.6).
HCI.H2N. COzBn a^ME. tBocIDSl
O
O
% P d/C
COjBn
O HCl gas 
HO Ac
O
COjH tBocHN
O O
CO,H
Figure 6.6 - Suggested strategy for the synthesis of deprotected ALA derivatives.
Initially, however, protected derivatives of ALA coupled to amino acids were 
prepared using Z-protected amino acids with either ALA-OEt or ALA-OHex. Z- 
Protected amino acids coupled to ALA esters with better yields than t-Boc- 
protected amino acids and there is some precedent for leaving Z-groups intact on 
biologically active molecules. Z-Protected amino acids were prepared using 
standard peptide synthesis techniques (Reactions 8.69 (58), 8.70 (59) and 8.71 
(60)).^" Z-Gly-ALA-OEt (Reaction 8.72, (61), ALAI), Z-L-Phe-ALA-OEt 
(Reaction 8.73, (62), ALA2), Z-D-Phe-ALA-OEt (Reaction 8.74, (63), ALAll) 
and Z-Gly-ALA-OHex (Reaction 8.75, (64), ALAIO) were all prepared using
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CHME couplings. Yields for these reactions were fairly low (approximately 45 - 
55%) due to the fact the HCl salt could not be removed from ALA.HC1 without 
causing pyrazine formation (Fig. 6,3b). Addition of base to the reaction mixture 
led to formation of two by-products, piperidine-2,5-dione (55) and pyrazine 
derivative (Fig. 6.3a and 6.3b).
Phthalimidolevulinic acid (Phthal-ALA (9)), prepared as an intermediate in the 
synthesis of ALA.HC1 (Reactions 8.13 and 8.14) (Fig. 6.7a) or by removing the 
methyl ester from methyl 5-phthalimidolevulinate (Reaction 8.76, Fig. 6.7b) was 
also tested (ALA4).
NK
Figure 6.7a - Synthesis of phthalimidolevulinic acid from tetrahydrofurfuryl chloride.
6MHC1 
1 hour ^
(9)
Figure 6.7b - Synthesis of phthalimidolevulinic acid from methyl 5-phthalimidolevulinate.
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ALA was attached to a sugar in an attempt to make it more bioavailable. 1,3,4,6- 
tetra-o-acetyl-2-amino-2-deoxy-p-D-glucopyranose (glucosamine acetate) was 
prepared in a four step reaction from glucosamine hydrochloride.^^^ using the 
scheme shown in Fig. 6.8 (Reactions 8.77 (65), 8.78 (66), 8.79 (67) and 8.80 
(68)).
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ÇHO OH
HO-
HO-
■O
NH2.HCI OH NaOH, H2O
.N OH
f
(65)
OMe
pyridine, 
acetic anhydride
OAc
OAc AcO
AcO
AcO
AcO
acetone, H2O
NH2.HCI c-HCl
HgO
NaOAc
OAc
OAc
OMe OAc
(68) NH.
CHME, AcO
OAc OAc
O (69)
N-
=0
(9) O O -C02H
\  ,0Where OAc = O2CCH3 N-
Scheme 6.8 - Scheme for the preparation of Phthal-ALA-Gluc-OAc.
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Coupling of Phthal-ALA (9) to the protected sugar (68) was achieved using 
CHME (Reaction 8.81 (69)) in a fairly high yield (approximately 75%). Various 
attempts were made to remove the phthalimide group. Reaction with N,N- 
dimethyl-1,3 -propanediamine yielded a mixture of products, including piperidine-
2,5-dione (Fig. 6.3a, (55), Reaction 8.82), the leaving group this time being a 
sugar. Reaction with hydrazine, followed by purification using an ion-exchange 
column yielded a very small quantity of the required product contaminated with a 
large amount of NaCl (Reaction 8.83). The sugar derivative was, therefore, tested 
in its protected form (ALA3).
?It is possible that piperidine-2,5-dione (55), detected as a by-product in many of «
the reactions, could be a pro-drug of ALA. It is known to open up to give 
ALA.HC1 in c-HCl^^  ^but, potentially, it may be capable of this reaction under less 
severe conditions. Attempts were made to prepare the molecule directly fi*om 
ALA-OEt by removing the HCl salt. Sodium methoxide was chosen as the base, 
as the resulting sodium chloride could be removed by filtration leaving only 
methanol, hence, a very clean reaction. Initially a small amount of solvent was 
used, due to the partial solubility of NaCl in methanol (Reaction 8.84), but, as 
small quantities of solvent encourage intermolecular reactions the only product 
isolated was a pyrazine (47) (Fig. 6.3b). A large excess of solvent (1000 fold) was 
used to try to encourage an intramolecular reaction (Reaction 8.85) but this 
simply lengthened the reaction time and resulted, again, in the formation of 
pyrazine (47) (Fig. 6.3b). A different approach was, therefore, attempted (Fig.
6.9).^^ '^  2-Hydroxypyridine was oxidised using an Elbs peroxydisulfate reaction 
(Reaction 8.86) to give 2,5-dihydroxypyridine (70) as a black sohd. Repeated
■ j
recrystallisations from ethanol removed most of the colour and the 2,3- 
dihydroxypyridine by-product, but, upon contact with air it darkened. Column 
chromatography produced a white solid but it also darkened upon standing.
NaOKH^O HO.
ferrous sulfate >-potassium
N OH peroîQ'disulfate
Hn, Pd/ C
N
(70)
'OH ^ N ^ OH
(55)
Figure 6.9 - The Elbs Peroxydisulfate oxidation of 2-hydroxypyridine.
A later paper^^  ^suggested that ferrous sulfate did not improve the reaction (it was 
thought that a radical process would benefit from its addition). It, in fact, 
encouraged side reactions and lowered the yield. Repetition of the reaction 
without ferrous sulfate increased the yield from 20 to 50% (Reaction 8.87 (70)). 
The resulting brown coloured 2,5-dihydroxypyridine was hydrogenated over 10% 
Pd/C catalyst and purified by column chromatography then recrystallisation^^^ 
(Reaction 8.88) to give a small quantity of piperidine-2,5-dione (55) as a slightly 
brown coloured solid. This was, unfortimately, not prepared in time to be 
biologically tested.
An attempt was made to couple N-acetyl glycine to ALA-OHex (Reaction 8.89) 
but this failed, probably due to the poor solubility of N-acetyl glycine in DCM. 
The product isolated was 2,5-di-((3-carboxyethyl) pyrazine dihexyl ester (71).
N-Acetyl-ALA has been tested biologically^^  ^ and found to be a fairly poor ALA 
pro-drug but, to the best of our knowledge, longer chain alkanoyl derivatives have
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%not been studied for PDT. A series of N-alkanoyl derivatives were prepared^°^ by 
coupling ALA-OBn to an appropriate acid chloride, then removing the benzyl 
ester by hydrogenation (Fig. 6.10).
\cH2)n NH..HC1 /o 0 = (
/  NHO /  H2,Pd/C
O
n = 0 (72) /  n = 0 (73)
\ n  = 2 (7 4 )  \  n = 2 (75)
n = 3 (7 6 )  / n  = 3 (7 7 )
n = 4 (7 8 )  CO2H n = 4 (79)
n = 5 (80) n = 5 (81)
Figure 6.10 - Scheme for the preparation of N-alkanoyl derivatives of ALA.
Derivatives where n = 0 (N-acetyl-ALA, N-Ac-ALA (73), Reactions 8.90 and 
8.91), n = 2 (N-butanoyl-ALA, N-But-ALA (75), Reactions 8.92 and 8.93, 
ALAI2), n = 3 (N-pentanoyl-ALA, N-Pent-ALA (77), Reactions 8.94 and 8.95, 
ALA6), n = 4 (N-hexanoyl-ALA, N-Hex-ALA (79), Reactions 8.96 and 8.97, 
ALA7) and n = 5 (N-heptanoyl-ALA, N-Hept-ALA (81), Reactions 8.98 and 
8.99, ALA8) were prepared in this way. N-Ac-ALA (73) was also prepared 
directly (Reaction 8.100) from ALA.HC1 by reaction with acetic anhydride. 
Sonication assisted the formation of the product which NMR data suggested was 
the enol form of the molecule (Fig. 6.11).
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COjH
acetic anhydride, ^  ^
EtgN, CH3CN ___ g
----------- ^  HU . ^ ------► W /; ^----CO2H
N' "
HHCI.H2N
(73)
Figure 6.11- Direct preparation of N-Ac-ALA resulting in enol formation.
Formation of the enol could result in stabilisation by formation of a 7-membered 
ring. This compound was tested biologically (ALA9).
An attempt was made to couple N-Ac-ALA to the Gly-OMe (Reaction 8.101) but 
this, like Reaction 8.89, failed due to solubiHty problems.
Finally N,N-dhnethyl-ALA (82) was prepared by reacting ALA.HC1 with 
formaldehyde under an atmosphere of hydrogen (Reaction 8,102, ALA5) (Fig. 
6.12).
pOgH CO2H
Foimaldehyde  )►
H 2,Pd/C 0=
HCI.H2N N (82)
/  \
Figure 6.12 - Formation ofN,N-dimethyl-ALA.
i
]
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6.4 Table of 5-Aminolevulinic Acid Derivatives ALAI - ALA12
ALA 1,2, 10 and 11
(CH2)n
R = H 11 = 1
ZrL-Phe-ALA-OEt 
ALA2 
(62)
n= 1R =
Z-Gly-ALA-OHex 
ALAIO 
(64)
R = H
Z-D-Phe-ALA-OEt 
ALAll 
(63)
n= 1R  =
ALA 6, 7, 8, 9, and 12 
.  ^OH
ALA6 (77) x = 3 N-Pent-ALAALA8 (81) x = 5 N-Hep-ALA
ALA7 (79) x = 4  N-Hex-ALAALA9 (73) x = 0  N-Ac-ALA
ALAI 2 (75) X = 2 N-But-ALA OAc
N-PMial-ALA AcO-
AcO
OAcNH
ALA4 (69)
ALA3
N-N-Dimethyl-ALA
.HClHO,
Where OAc = O2 CCH3
ALA5 (82) - Phthal-ALA- Glue-OAc
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Derivatives ALAI to ALAI2 were tested biologically at the National Medical 
Laser Centre, UCL and the results are discussed in Chapter 7.
6.5 Photographs of the Browning of 5-Aminolevulinic Acid and 
Derivatives.
One problem encountered in the non-enzymatic dimérisation of ALA to 2,5-di-(|3- 
carboxyethyl) pyrazine is the formation of a brown colour. To demonstrate this, 
ALA.HCl, ALA-OHex, N-Ac-ALA and Z-L-Phe-ALA-OEt (40 mg) were 
dissolved in phosphate buffer (1 cm ,^ pH 7.4) and DMSO (1 cm^) and 
photographed at various time intervals for 24 hours. Fig. 6.13a shows the samples 
before the solvents were added. Fig, 6.13b was taken 1 hour after sample 
preparation and Fig. 6.13c shows the solutions 24 hours after their preparation.
The photographs clearly show that the solution of ALA.HC1 itself turned yellow 
but the ALA-OHex solution went brown. This demonstrates that ALA-esters are 
less stable than ALA itself. The two derivatives of ALA appear to be stable in 
solution, as they did not change colour with time, hence, if they prove to be 
effective in the biological testing, they could be efficient pro-drugs for PDT.
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iFigure 6 .13a - Photograph o f  ALA.HCl and derivatives before the addition o f  solvent.
Figure 6.13b - Photograph o f  ALA.HCl and derivatives 1 hour after addition o f  solvent.
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m ?Z-L-Phe-5-ALA"OEt
^2g23SS2sail
ALA
A cetyl OHè*
Figure 6.13c - Photograph of ALA.HCl and derivatives 24 hours after addition of solvent. 
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Chapter 7
Biological Testing of Derivatives of 5-Aminolevulinic
Acid
7.1 Introduction
ALA derivatives 1-12 and AL A-O Hex were tested on samples of normal, healthy 
human and rat skin (explants) at the National Medical Laser Centre, UCL. 
Exposure of cells to an external source of ALA results in enhanced porphyrin 
synthesis and the accumulation of PpIX. The efficiency of the pro-drugs, 
therefore, was determined by the ability of the skin to produce PpIX, the active 
compound for PDT, from the derivative. ALA induced PpIX formation has been 
shown to be greater in tumour cells than normal cells so any effect observed in 
healthy tissues should be enhanced in tumour cells.
The skin is made up of several layers known as the epidermis, the dermis and the 
subcutis (Fig. 7.1)
dermo eqiOermai 
[unctjonut>pap]iiar>
sebaceous
gland
reticular
dermis
isubcutis
cutaneous
plexus
epidermis
dermis
subcutis
thick skin (e.g. sole) thin skin (e.g. arm)
sutxulanecus
plexus
Figure 7.1 - Diagram show ing the structure o f  the skin. Adapted from Ref. 701
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The epidermis is the outer protective layer of the skin and is in contact with the 
external environment. It consists of stratified epithelium (i.e. layers of tightly 
packed cells). The outermost layer is composed of very closely packed flat keratin 
protein cells which form a tough water repellant layer known as the stratum 
corneum. Growths into the epidermis produce sweat glands and hair follicles. The 
dermis is the middle, supporting layer and contains blood vessels and nerves. The 
deepest layer, the subcutis, contains the main network of arteries and veins and is 
the site of PpIX production in skin.
The four main requirements of the compounds were that they had to
• be taken up by the cells
• difluse at a reasonable rate through the dermis
• be able to liberate ALA
• be non-toxic to the cells
Normal skin varies in its ability to resist ALA penetration. Thin skin, e.g. the arm, 
is less of a barrier than thick skin, e.g. soles of the feet, so there is even a variation 
fi-om site to site on the same patient. Heavily fi-eckled skin, a characteristic of the 
Celtic race, is penetrated in a very irregular p a tte rn ,h en ce  explants containing 
marks, freckles or bruises are avoided.
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7.2 Testing Protocols
7.2.1 Animal and Human Skin Samples
Animal skin samples were obtained from normal female Wistar rats who were 
sacrificed by CO asphyxia. Their skin was shaved and the stratum corneum 
removed with a razor. The skin of the rat was removed with scissors and kept on 
ice until it was used. Fresh samples of human skin were obtained from the plastic 
surgery department after surgical excisions.
7.2.2 Skin Expiant Cultures
Sections of skin (explants) of 70 - 100 mg were floated on plastic meshes in 2.5 
cm  ^of serum free Dulbecco’s D-MEM / F12 medium without Phenol Red which 
contained 50 lUral'^ penicillin and 50 pg.ml-1 streptomycin. To the serum was 
added ALA, ALA-OHex or one of the derivatives ALAI-12 dissolved in DMSO. 
The samples were then incubated at 37 °C in an atmosphere of humidified air with 
5% CO2 in the dark (Fig. 7.2)
expiant (section of rat or human skin tissue)
epidermis 
Face Down dermis 
subcutis
subcutis
plastic mesh to keep the ejqjlant afloat
Figure 7.2 - Diagram of skin explant culture
dermis Face Up 
epidermis
2.5 cm^  of medium containing 
ALA, ALA derivative, DMSO etc.
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Control experiments were incubated without ALA or a derivative and with 
DMSO only to ensure the pro-drug itself was causing the effect. Skin samples 
were placed either face up or face down onto the medium (Fig. 7.2). If the explant 
was face up the drug had to diffuse through the epidermis and dermis and this 
mimicks topical application (Le. application of the drug in a cream or ointment 
onto the surface of the skin). If  the explant was face down the drug was delivered 
directly to the subcutis and this mimicks intravenous application (injection of the 
drug).
7.2.3 Measurement of Protoporphyrin IX Content
As PpIX fluoresces, levels can be measured directly and this was done using a 
plate fluorescence reader (Perkin Elmer) connected to a Perkin Elmer LS 5 OB 
fluorescence spectrophotometer using 410 nm excitation and 635 nm emission 
with slit widths set to 10 nm both on the excitation and emission 
monochromators. An internal 530 nm highpass filter was used on the emission 
side and intensity calibrations were performed using a standard of Rhodamine B 
embedded on a Perspex disc. Measurement of the fluorescence emission spectra 
firom chemically extracted porphyrins showed that fluorescence values were 
proportional to porphyrin concentration. Chemical extraction was done by 
homogenizing the tissue samples in a 4:1 solution of ethyl acetate and glacial 
acetic acid. The homogenates were centrifuged for 30 minutes at 3000 g and the 
supernatents were extracted with 5% HCl until the aliquots showed no 
fluorescence. Porphyrins in the media were also extracted with ethyl acetate/ 
acetic acid and HCl. The direct fluorescence emission spectra of explants exposed
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to ALA were characteristic of PpIX with peak emission at 635 and 710 nm (Fig. 
7.3).
10 -I
Î
I
500 550 600 650 700 750 800
Wavelength / nm
Figure 7.3 - Direct fluorescence emission spectra of PpDC.
Coproporphyrin and uroporphyrin, the precursors to PpIX are water soluble and 
direct fluorescence spectra o f the medium showed peaks which probably 
correspond to these.^”^  The percentage of porphyrins released into the medium 
was found to be 20% of the total porphyrins synthesised during the 2 to 19 hours 
of incubation. Medium which was incubated with ALA and no tissue, or tissue 
only was found to contain no porphyrin peaks.
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7.3 Results
7.3.1 ALA and ALA-OHex
In rat tissue exposed to 0.6 mM ALA the PpIX levels increased linearly with time 
over the 19 hour incubation period. Exposure to the ALA-OHex lead to a 
maximum of PpIX synthesis after 5 hours of incubation (Fig. 7.4)
Time/hours
ALA ALA-OHex
Figure 7.4 - Graph showing PpIX fluorescence after exposure of rat skin explants to 0.6 mM 
ALA and ALA-OHex for 2, 3, 5 and 19 hours. Direct skin fluorescence was measured at 410 nm 
excitation and 635 nm emission and autofluorescence of explants incubated without ALA was 
subtracted. Fluorescence values are in arbitrary units.
As human skin exhibits low fluorescence levels at short incubation times, 19 hours 
was the time selected for the analysis of PpIX concentration.
In rat skin both ALA and ALA-OHex showed maximum PpIX accumulation 
between 0.6 and 1.2 mM (Fig. 7.5).
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0.8 1.2 
Concentration/mM
ALA ALA-OHex
Figure 7.5 - Graph showing PpIX fluorescence after 19 hours exposure of rat skin to different 
concentrations of ALA and ALA-OHex. Fluorescence values are in arbitrary units.
In human cells, however, ALA-OHex gave significantly lower values than ALA at 
these concentrations (Fig. 7.6).
25,
20
15
10
1.2
Concentration/mM 
ALA ■  ALA-OHex
Figure 7.6 - PpIX fluorescence after 19 hours exposure of human skin to different concentrations 
of ALA and ALA-OHex. Fluorescence values are in arbitrary units.
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7.3.2 ALA Derivatives 1-12
For a summary of the chemical structures of the derivatives and the abbreviations 
used, see Section 6.4.
N-But-ALA, N-Hep-ALA, N-Phthal-ALA-Gluc-OAc, Z-L-Phe-ALA-OEt and N- 
Phthal-ALA failed totally to induce PpIX fluorescence in human and rat skin. N- 
But-ALA, N-Hep-ALA and Z-L-Phe-ALA-OEt appeared to have a toxic effect 
on the cells as lower values of PpIX were recorded than in the control. The results 
of the other derivatives are illustrated by graphs (Fig. 7.7a, b, and c) and are 
summarised in the table (Fig. 7.8).
F~1 N,N-Dimethyl-ALA
1.2
Concentration/mM
H i  N-Pent-ALA 
■ I  N-Ac-ALA
N-Hex-ALA
Figure 7.7a - Graph of ALA and derivatives showing PpIX production in rat skin
135
U 6
c 1
1.2
Concentration/mM
ALA
Z-D-Phe-ALA-OEt
Z-Gly-ALA-OHex
Z-Gly-ALA-OEt
Figure 7.7b - Graph of ALA and derivatives showing PpIX production in rat skin
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1.2
Concentration/mM
ALA
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Figure 7.7c - Graph of ALA and derivatives showing PpIX production in human skin.
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ALA
N-Pent-ALA
N-Hex-ALA
0.6 mM 
1.2 mM 
2.0 mM
0.6 mM 
1.2 mM 
2.0 mM
0.6 mM 
1.2 mM 
2.0 mM
Rat
5.67 ±0.43 
6.80 ±1.31 
3.25 + 0.48
0.35 ± 0.52 
1.09 ±0.09 
1.00 + 0.60
2.25 ±1.31 
1.40 ±0.90 
4.38 + 0.01
Human
5.83 ±0.98 
16.87 ±3.45 
21.25 + 5.40
0.09 ±0.11 
0.15 ±0.11 
0.41 + 0.24
0.03 ± 0.08 
0.01 ± 0.20 
0.39 + 0.16
Z-Gly-ALA-OHex
0.6 mM 
1.2 mM 
2.0 mM
1.18 ±0.78 
2.40 ± 0.82 
3.23 + 1.53
0.22 ± 0.04 
0.24 ± 0.09 
0.41 + 0.22
Z-D-Phe-ALA-OEt
Z-Gly-ALA-OEt
0.6 mM 
1.2 mM 
2 .0 mM
0.6 mM 
1.2 mM 
2.0 mM
0.6 mM
N,N-Dimethyl-ALA 1.2 mM
2.0 mM
N-Acetyl-ALA
0.6 mM 
1.2 mM 
2.0 mM
7.81 ± 0.95 
7.33 ± 0.95 
6.57 + 3.12
1.75 ±0.86 
4.81 ±0.76 
5.56+1.25
0.51 ±0.09 
1.92 ±0.65 
2.91 + 0.78
0.96 ±0.12 
2.87 ±2.19 
1.43 + 0.58
2.87 ± 0.83
8.60 ±1.59
29.60 + 5.26
0.67 ± 0.25 
2.83 ± 0.93 
10.36 + 2.28
0.08 ± 0.22 
0.06 ± 0.26 
0.24 + 0.07
0.02 ± 0.09 
0.16 ±0.09 
0.21 + 0.39
Fig, 7.8 - Table of results of biological testing of ALA derivatives.
In general, the degree of PpIX induction was less than the corresponding effect of 
ALA. Z-Gly-ALA-OEt showed an increase in PpIX production in rat skin at 2
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mM. Z-D-Phe-ALA-OEt, however, showed promising results. It gave an increase 
in PpIX production in rat skin and similar levels in human skin to ALA itself at all 
concentrations.
7.4 Fluorescence Microscopy
Fluorescence microscopy was used to monitor the distribution of PpIX in the skin
i.e. where it is produced. Sections of expiants of human skin, treated with ALA- 
OHex at 1.2 mM for 19 hours, were taken and mounted onto microscope slides. 
The image seen under a microscope (Scale 880 x 550 p) using ordinary white 
light was photographed and can be seen in Fig. 7.9. The slide was stained with 
haematoxylin and eosin. The adjacent section was not stained and was viewed 
under laser light. The fluorescence of the slide was measured using a fluorescence 
detector and this image can be seem in Fig. 7.10. The white and blue colours 
indicate a large quantity of fluorescence, the red colours an intermediate amount 
and black indicates little or no fluorescence. PpIX is seen to accumulate in areas 
such as where there are hair follicles and in the epidermis. Production of PpIX 
from ALA-OHex is much more localised than from ALA itself. The epidermis can 
be seen on the right hand side of the photographs and has a higher fluorescence 
intensity than the dermis.
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Figure 7.9 - White light microscopy image of a section of human skin stained with haematoxylin 
and eosin after treatment with 1.2 mM ALA-OHex for 19 hours.
Figure 7.10 - Fluorescence microscopy image of a section, adjacent to that in Fig. 7.9, of human 
skin treated with 1.2 mM ALA-OHex for 19 hours.
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7.5 Conclusions
In this study, the ALA-OHex was found to be very effective in rat skin at 
producing PpIX, but not as effective in human skin. The hexyl ester has already 
been found to be the most effective of the esters at producing high levels of PpIX 
for PDT.^^  ^ It is not known whether the ester is cleaved from ALA before it is 
incorporated into PpIX. Fluorescence microscopy showed that PpIX formed from 
the esters of ALA is much more localised than from ALA itself.
Although most of the derivatives were not as effective at producing PpIX in 
healthy skin samples as ALA itself, most produced some PpIX. This implies that 
the enzymes required to release ALA from the derivatives must be present in the 
cells. Presumably proteases or non-specific esterases are required. It would be an 
interesting exercise to study the enzyme kinetics of the breakdown of some of the 
derivatives to give ALA itself. The derivatives containing phenylalanine contain a 
chromophore which would be useftil for UV/visible studies. ALA-OBn and N,N- 
Dimethyl-ALA-OBn would be ideal for the study of ester hydrolysis. It may be 
possible to monitor the formation of ALA by recording the formation of 2,5-di- 
(P-carboxyethyl) pyrazine, the non-enzymatic dimer of ALA (See Chapter 4)
All the derivatives of ALA are much more chemically stable than ALA itself (See 
Section 6.5) so have the advantage that the dosage being given is known. If they 
are as effective as ALA itself, they may be of use in PDT
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N-Acylated derivatives of ALA do not seem to be effective pro-drugs. The 
shorter alkyl chained derivatives, with the exception of N-Ac-ALA, were 
cytotoxic. N-Ac-ALA was found to be in its enol form (Fig. 6.11) and produced 
low levels of PpIX. N-Hex-ALA was more effective than ALA itself at 2 mM in 
rat skin but no significant results were obtained with these compounds. A 
potential candidate could be N-phenylacetyl-ALA as this group is known to be 
cleaved by the enzyme chymotrypsin.
It is not really surprising that the cells were not able to remove the N-phthalimide 
group fi*om the molecules. An alternative N-protecting group strategy is required. 
As t-Boc-groups can be put on iu non-aqueous conditions and can be removed 
leaving an HCl salt, this may be a possibility for the preparation of other 
derivatives. Less heavily protected sugar derivatives may prove to be interesting.
Given the heavy protection of N,N-Dimethyl-ALA, the results are remarkably 
good. At the highest concentration the PpIX levels in rat skin are comparable to 
ALA itself.
The most interesting results, however, are fi-om the dipeptide derivatives. It was 
expected that Z-Gly-ALA-OHex would be more effective than Z-Gly-ALA-OEt. 
This was not the case. At all three concentrations, the ethyl ester was more 
effective. Interestingly, Z-L-Phe-ALA-OEt was found to be cytotoxic. It is 
possible that releasing L-Phe into the cells is disturbing another biochemical 
pathway as L-Phe is naturally occurring so is bioavailable. Z-D-Phe-ALA-OEt, 
the other isomer, was the most effective of all the derivatives producing higher
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levels of PpIX than ALA itself at aU concentrations in rat skin and at 2 mM in 
human skin. Releasing D-Phe into the cells does not disturb other pathways as it is 
simply excreted.
There is certainly a great deal of scope for future work. Many of the other 
naturally occurring amino acids, both L and D, and possibly some of the unnatural 
ones could be attached to either end of the molecule. Another possibility would be 
to prepare a dipeptide consisting of two molecules of ALA. This could be more 
stable than ALA itself and would break down to give only the active compound. 
The use of solid state chemical techniques could be useful in preparing a large 
variety of derivatives for further biological testing.
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Chapter 8 
Experimental
Reagents. AU reagents were purchased from Sigma-Aldrich and were reagent 
grade (unless otherwise stated).
Instrumentation. Melting points were determined with open glass capiUaries using 
a GaUenkamp machine. Elemental analysis were performed on a Carlo-Erba 
Instrumentazione model 1106 CHN analyser. Mass spectrometry was performed 
using a Finnigan MAT INCOS 50 mass spectrometer. NMR spectra were 
obtained either at 200 MHz using a Varian Gemini 200 spectrometer or at 300 
MHz using a Varian 300 MHz spectrometer. NMR spectra were recorded at 
either 50 or 75 MHz using the same instruments. Chemical shifts (ô) for ^H and 
*^ C are recorded in ppm downfield of TMS (ô = 0). NMR spectra were 
obtained at 30.412 MHz on a Bruker AM 300 spectrometer. AU ^^ N spectra were 
^H decoupled and were referenced to external nitromethane (with 20% C^HaO^H 
to provide the lock signal) set at ô 380.23. UV-Visible spectroscopy used a 
PhiUips PU 8730 scanning spectrophotometer.
Purification o f Solvents. Dry DMF*®^  was prepared by storing the commerciaUy 
avaUable solvent over molecular sieves (type 4A) for 48 hours then distUling the 
resulting liquid under reduced pressure, keeping the temperature below 50 °C.
Diethyl ether and THF were dried over sodium wire. Dry ethanol and methanof 
were prepared using a Grignard reaction. Magnesium turnings (2.5 g) and iodine 
(0.25 g) were added to a smaU amount of the ethanol (or methanol). This mixture 
was warmed gently untU hydrogen gas was given off and aU the iodine
disappeared. Once the magnesium had been converted into magnesium ethoxide i
'(or methoxide), ethanol (or methanol) (500 cm ) was added and the mixture j
Iheated under reflux conditions for 30 minutes. The dry solvent was distUled and |
istored in a flask containing Type 4A molecular sieves. Thionyl chloride^^  ^ was |
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purified to remove the impurities of sulfiir chlorides and sulfuryl chlorides. 
Technical grade thionyl chloride (250 cm^) and dipentene (23 cm^) were distilled 
until the temperature of the distillation mixture reached 85 °C. The colourless 
liquid obtained was redistilled and stored in a dark bottle. Hexane used in column 
chromatography was redistilled prior to use to remove non-volatile impurities. 
Dry pyridine^ ®^  was prepared by heating pyridine under reflux conditions over 
potassium hydroxide pellets for 1 hour then distilling the resulting mixture. Dry 
pyridine has a boiling point of 115.3 °C and this fi-action was stored over calcium 
hydride.
8 .1 Synthesis of methyl 5-bromolevulinate.*®'‘
O Brj 0
COjH 'C O 2CH3
(1)
Bromine (2.6 cm ,^ 50 mmol) was added to a solution of levulinic acid (5.1 cm \ 
50 mmol) m methanol (1 0 0  cm^) at room temperature over 15 minutes under an 
atmosphere of N2. The reaction mixture was stirred for 1 hour at room 
temperature then heated under reflux conditions for 3.5 hours. The methanol was 
removed under reduced pressure and the residue partitioned between diethyl ether 
and water. The pH of the solution was adjusted to 8 by addition ofNaHCOs The 
diethyl ether layer was washed with aqueous NaHCOg and brine and then dried 
(MgSO#), filtered and concentrated to give a 3 to 1 mixture of methyl 5- 
bromolevulinate and methyl 3-bromolevulinate. These were separated by 
distillation (yield of methyl 5-bromolevuhnate 2.01 g, 19%), or by silica gel flash 
column chromatography using 40-60 petroleum ether : DCM 1:5, with 0.5%
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acetic acid as the eluant yielding methyl 5-bromolevulinate (1) as a pale yellow oil 
(3.46 g, 33%), b.p. 90 - 95 °C at 0.75 mm/Hg (Lit.*“  55-64 “C at 0.1 mm/Hg). 
Sh (200 MHz, C'HCb) 2.6 (2H, m, C%), 2.9 (2H, t, J = 6.7 Hz, CH;), 3.6 (3H, s, 
CHs) and 3.9 (2H, m, BrCH,); 8 c (50 MHz, C^HCb) 27.15 (CH2COO), 34.82 
(COCH2CH2), 48.21 (BrCHz), 51.35 (CHj), 174.12 (COO) and 203.69 (CO).
8.2 Synthesis of methyl 5-azidolevulinate.*''''
0  NaN3 9
---------- GO2CH3
(1) (2)
Methyl 5-bromolevulinate (Reaction 8.1, 1.0 g, 4.8 mmol) was added to a 
solution of sodium azide (0.96 g, 14.4 mmol) in dry DMF (40 cm^) under an 
atmosphere of N2 at -10 °C. The resultant reaction mixture was stirred for 1 hour 
at this temperature. Diethyl ether was added and the DMF was washed out with 
brine (3 x 400 cm^). The organic layer was washed with 5% NaHCOs solution and 
water (2 0 0  cm  ^of each), dried (MgSÛ4), filtered and concentrated under reduced 
pressure giving methyl 5-azidolevulinate (2) as a clear oil (0.8 g, 91%), the boiling 
point was not recorded due to the potentially explosive nature of the compound. 
ÔH (300 MHz, % -DM SO) 2.5 (2H, t, J = 6.7 Hz, CH2COO), 2.7 (2H, t, J = 6.7 
Hz, COC//2CH2), 3.5 (3H, s, CH3) and 4.17 (2H, s, N3CH2); 8c (75 MHz, % -  
DMSO) 28.12 (CH2COO), 32.34 (COC^CHg), 52.00 (CH3), 58.31 (N3CH2), 
174.25 (COO) and 203.42 (CO).
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8.3 Synthesis of 5-aminolevulinic acid
O
804
CO2CH3 n
c-HCl,MeOH 
30% Pd/(^ HCI.H2N
O
CO2 H(2) (3)
Methyl 5-azidolevulinate (Reaction 8.2, 0.5 g, 2.9 mmol) in methanol (10 cm^) 
was stirred with c-HCl (2 cm^) and 30% Pd/C catalyst (100 mg) under an 
atmosphere of H2 at room temperature and atmospheric pressure for 2 0  hours. 
The reaction mixture was filtered through Celite and the filtrate concentrated 
under reduced pressure. Recrystallisation fi"om acetic acid/butanol yielded 
ALA.HC1 (3) as white crystals (0.41 g, 84%), m.p. 148 - 150 °C (Lit.®*^  ^ 147 °C). 
m/z (E f) 132 (M" - HCl salt). Found: C, 35.8; H, 6.0; N, 8.2; Calculated for 
C5H10NO3CI: C, 35.8; H, 6.0; N, 8.4%. Ôh (200 MHz, % 0 )  2.6 (2H, t, J = 6.2 
Hz, CH2COO), 2.8 (2H, t, J =  6.2 Hz, COCH2CR2) and 4.0 (2H, s, NH2CÆ); 8 c 
(50 MHz, % 0 )  28.71 (C76C00), 35.81 (COCT^CHz), 48.00 (NH2CH2), 
176.15 (COO) and 204.21 (CO).
8.4 Synthesis of methyl 5-phthalimidolevulinate.807
CO.CH
Potassium phthalimide (1.0 g, 5 mmol) was suspended in dry DMF (5 cm^). To 
this was added methyl 5-bromolevulinate (Reaction 8.1, 1.0 g, 5 mmol) and the 
mixture was stirred for 30 minutes at room temperature and 1 hour at 60 °C. The 
cooled reaction mixture was filtered to remove KCl and unreacted phthalimide
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before DCM (20 cm^) and water (60 cm^) were added. The aqueous phase was 
washed with DCM ( 2 x 1 0  cm^). The DCM extracts were washed with 0.2 M 
NaOH (10 cm^) and then with water until the washings were colourless (5 x 20 
cm^). Combined DCM extracts were dried (MgS0 4 ), filtered and the solvent 
removed under reduced pressure. The residue was recrystaUised fi-om water 
yielding methyl 5-phthalimidolevulinate (4) as white crystals (0.68 g, 50%), m.p. 
96 - 98 °C (Lit.*®^  96- 97 °C). Ôh (200 MHz, C^UCh) 2.7 (2H, t, J = 7.6 Hz, 
CH2COO), 2.9 (2H, t, J = 7.6 Hz, COC^CHg), 3.7 (3H, s, CH3), 4.6 (2H, s, 
NCH2), 7 .8  (2H, m, aromatics) and 7.9 (2H, m, aromatics); 8 c (50 MHz, C^HCb)
28.07 (C /6C00), 34.98 (COC/6 CH2), 47.02 (NCH2), 52.45 (CH3), 123.91, 
124.04, 134.55 (3 x aromatics), 168.06 (2 x phthalimide-CO), 173.03 (COO) and 
203.10 (ALA-CO).
8.5 Synthesis of 5-aminolevulinic acid 807
6MHC1
(3)
Methyl 5-phthalimidolevulinate (Reaction 8.4, 0.5 g, 1.8 mmol) was heated under 
reflux conditions in 6  M HCl (6  cm^) for 8 hours. The solution was cooled, 
filtered to remove phthalic acid and concentrated under reduced pressure to give 
ALA.HC1 (3) as white crystals (0.2 g, 65%). Data as for Reaction 8.3.
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8.6 Synthesis of methyl 5-phthalimidolevulinate.
4-o
DMF
Potassium phthalimide (1 g, 5 mmol) was suspended in dry DMF (5 cm^). To this 
was added a mixture of methyl 5-bromolevulinate and methyl 3-bromolevulinate 
(Reaction 8.1, 1.0 g) and the reaction was stirred for 30 minutes at room 
temperature and 1 hour at 60 °C. The cooled mixture was filtered to remove KCl 
and any unreacted phthalimide before DCM (20 cm^) and water (60 cm^) were 
added. The aqueous phase was washed with DCM (2 x 10 cm^). The DCM 
extracts were washed with 0.2 M NaOH (10 cm^) and then with water until the 
washings were colourless (5 x 20 cm^). Combined DCM extracts were dried 
(MgS0 4 ), filtered and the solvent removed under reduced pressure. The residue 
was recrystallised fi-om water. Unreacted methyl 3-bromolevulinate, an oil, was 
removed by filtration yielding only methyl 5-phthalimidolevulinate (4) as white 
crystals (0.34 g, 23%, yield calculated firom quantity of crude strating material). 
Data as for Reaction 8.4.
8.7 Synthesis of methyl hydrogen succinate
O
MeOH O ----------► HOo
808
(5)
OO2CH3
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A mixture of succinic anhydride (50 g, 0.5 mol) and dry methanol (25 cm^) was 
stirred vigorously under reflux conditions for 1 hour. Excess methanol was 
removed under reduced pressure and the crude product was recrystallised from 
toluene/cyclohexane to give methyl hydrogen succinate (5) as large white crystals 
(54 g, 82%), m.p. 57 - 59 °C (Lit.*°* 57 - 58 °C). 6h (200 MHz, ^HzO) 2.6 (4H, s, 
2 X  CHz) and 3.6 (3H, s, CH3); 6c (50 MHz, % 0 )  31.61, 31.81 (2 x CH2), 55.24 
(CH3), 178.51 and 179.89 (2 x COO).
8 .8  Synthesis of methyl 3-chloroformylpropanoate.*®^
O5002^ I
CO2CH3 C 1^''"^-‘^ ^^C 02C H 3(6)
A mixture of methyl hydrogen succinate (Reaction 8.7, 48.3 g, 0.37 mol) and 
thionyl chloride (53 cm \ 0.73 mol) was warmed to 30 °C for 4 hours. Excess 
thionyl chloride was removed under reduced pressure at the water pump. The 
crude product was purified by distillation at the oil pump to give methyl 3- 
chloroformylpropanoate (6 ) as a clear oÜ (40 g, 73%), b.p. 50 - 60 °C at 2 
mm/Hg (Lit.'®  ^ 92- 94 °C at 18 mm/Hg). 6h (200 MHz, C^HCb) 2.7 (2H, t, J =
6 .6  Hz, CH2COO), 3.2 (2H, t, J = 6 .6  Hz, COCH2CH2) and 3.7 (3H, s, CH3); 6c 
(50 MHz, C^HCh) 29.62 (CET^COO), 42.21 (COŒ6 CH2), 52.74 (CH3), 171.85 
and 173.52 (2  x CO).
HOoC
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8.9 Synthesis of methyl 5-chlorolevulinate.
8.9.1 Synthesis of diazomethane 809
CgHgOCHgCH^ OCH^ CH^ OH
KOH
SÔ2 ^2®
N-
+ H2O + CH2N2
SO2OCH2CH2OCH2CH2OC2H5 
NO
Potassium hydroxide (6.0 g) was dissolved in water (10 cm^) and carbitol 
(di(ethyleneglycol) ethyl ether, 35 cm^) and diethyl ether (10 cm^) were added. 
The solution was heated and maintained at 50 °C using a water bath. Diazald 
(21.4 g), dissolved in diethyl ether (130 cm^) was added dropwise to the solution 
over approximately 45 minutes. The bright yellow distillate was collected in a 
flask immersed in an ice bath and the whole system was fitted with a drying tube. 
An additional amount of diethyl ether (100 cm^) was added until the diethyl ether 
distilling over was colourless. The bright yellow coloured ethereal solution 
contained approximately 3 g of diazomethane (71 mmol).
8078.9.2 Synthesis of methyl 5-chlorolevulinate.
1  ^  »
2-c-H a ®  'CüjCH,(6) (7) ' '
To a solution of diazomethane (Reaction 8.9.1, 3 g, 71 mmol in 200 cm  ^of diethyl 
ether) cooled to -5 °C was added, with stirring, a solution of methyl 3- 
chloroformylpropanoate (4.44 g, 0.029 mol. Reaction 8 .8 ) in dry diethyl ether (14 
cm^), dropwise over 2 hours. The mixture was allowed to warm to room
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temperature overnight. An equivalent molar amount of c-HCl (2.45 c m , 0.029 
mol, 3 7 %) was added gradually with stirring to the diazoketone, resulting in a 
rapid evolution of N2 after which the solution became a very light yellow colour. 
The solution was concentrated to 100 cm  ^by leaving the flask unstoppered for 48 
hours. It was then washed with water (3 x 30 cm^) to remove HCl and the 
combined water washings were extracted with diethyl ether (6  x 2 0  cm^) due to 
the solubility of the ketic ester in water. The combined diethyl ether extracts were 
dried (MgS0 4 ), filtered and the solvent was removed under reduced pressure 
giving methyl 5-chlorolevulinate (7) as a clear oh (2.3 g, 47%), b.p. 80 - 85 °C at
1.5 mm/Hg (Lit.^^  ^92 - 94 °C at 2 - 3 mm/Hg). Ôh (200 MHz, C^HCb) 2.6 (2H, t, 
J = 6.2 Hz. CH2COO), 2.9 (2H, t, J = 6.2 Hz, COŒ6 CH2), 3.7 (3H, s, CH3) and
4.2 (2H, s, CICH2); ÔC (50 MHz, C^HCb) 28.24 (C76C00), 34.80 (COG^CHg), 
48.83 (CICH2), 52.30 (CH3), 173.23 (COO) and 201.74 (CO).
8.10 Synthesis of methyl 5-phthalimidolevulinate.807
IK
CO.CH.
Methyl 5 -phthaHmidolevulmate (4) was prepared using the same method as for 
methyl 5-bromolevulinate (Reaction 8.4) but using methyl 5-chlorolevulinate 
(Reaction 8.9.2, 2.3g, 0.014 mol), yielding the product (4) as a white crystalline 
solid (1.74 g, 45%). Data as for Reaction 8.4.
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8.11 Synthesis of methyl 5-phthalimidolevulinate. 810
To a mixture of potassium phthalimide (0.22 g, 1.2 mmol) and methyl 5- 
bromolevulinate (Reaction 8.1, 0.21 g, 1 mmol) in toluene (5 cm^) was added a 
catalytic amount of 18-crown-6 (10 mg). The solution was heated to 100 °C for 6  
hours under N2 before water (5 cm^) was added. The organic layer was separated 
and the aqueous layer was extracted with DCM ( 3 x 5  cm^). The organic fractions 
were combined, dried (MgS0 4 ), concentrated under reduced pressure and purified 
by recrystallisation from water, yielding methyl 5-phthahmidolevulinate (4) as 
white crystals (0.21 g, 77%). Data as for Reaction 8.4.
8.12 Synthesis of methyl 5-phthalimidolevulinate.810
-►
CO .C H conca
18-crown-6
Methyl 5-phthalimidolevulinate was prepared using the same method as for 
methyl 5-bromolevulinate (Reaction 8.11) but using methyl 5-chlorolevulinate 
(Reaction 8.9.2, 0.16 g, 1 mmol), yieldiug the product (4) as white crystals (0.2 g, 
74%). Data as for Reaction 8.4.
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8.13 Synthesis of tetrahydrofurfliryl phthalimide 811
Cl
DMF
Tetrahydrofiirfiiryl chloride (2.54 g, 21,1 mmol) was added to a suspension of 
potassium phthalimide (3 g, 16.15 mmol) in dry DMF (7.5 cm^) over 12 minutes 
at 0 °C under N2. The mixture was heated to reflux for 3 hours then quenched 
with water (5 cm^). The reaction was extracted with DCM (3 x 30 cm^) and the 
combined extracts were washed with water (2 x 25 cm^) and brine (25 cm^). The 
DCM solution was dried (MgS0 4 ), filtered and concentrated under reduced 
pressure. Purification by silica gel flash column chromatography using ethyl 
acetate : hexane 1:5, and then 1:3, as the eluant yielded tetrahydrofurfliryl 
phthalimide (8) as white crystals (3.01 g, 96%), m.p. 84 - 86 °C (Lit.*’  ^ 82.6 - 
86.3 °C). ÔH (200 MHz, C^HCb) 1.7 (IE , m, CT^CHzO), 1.8 - 2.1 (3H, m, 
C%C%CH20), 3.7 - 3.8 (2H, m, NCH2), 3.9 (2H, m, CH2O), 4.3 (IE, m, 
NCE2C77) and 7.7 - 7.9 (4E, m, aromatics); ôc (50 MHz, C^ECb) 25.78 
(O^CHzO), 29.65 (C^CEzCEzO), 42.25 (NCH2), 68.38 (CE2O), 76.10 
(NCE2Œ ), 123.65, 132.56, 134,40 (3 x aromatics) and 168.89 (CO); Ôn (30 
MHz, CfECb) 157.21.
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8.14 Synthesis of phthalimidolevulinic acid (ALA4).*  ^^ 
O O
N  ^ o
CHoCN, Aridone
(8) \  /  H^ O ^  (9)
N.
CO2 H
O O
Sodium metaperiodate (6.0 g, 28.2 mmol) and hydrated ruthenium (III) chloride 
(34 mg) were added to a solution of N-tetrahydrofurfurylphthalimide (Reaction 
8.13, 1.63 g, 7 mmol) in 1,1,2-trichloro-1,2,2-trifluoroethane (arklone, 5 cm^), 
acetonitrile (25 cm^) and water (7.5 cm^) and the mixture was heated at 80 °C for 
2 hours, then evaporated under reduced pressure. The residue was taken up in 3M 
HCl (75 cm^) and extracted with DCM (6 x 50 cm^). The combined extracts were 
dried (MgS0 4 ), filtered, and concentrated under reduced pressure. Purification by 
silica gel flash column chromatography using ethyl acetate : hexane 1:2 and then 
ethyl acetate as the eluant yielded phthalimidolevulinic acid (9) as a white solid 
(1.69 g, 92%), m.p. 158 - 160 °C (Lit.*'^ 158.9 - 161.7 °C). Ôh (200 MHz, 
CfHCh : ^Hô-DMSO 9:1) 2.6 (2H, t, J = 6.5 Hz, CH2COO), 2.8 (2H, t, J = 6.6 
Hz, COC^CHz), 4.6 (2H, s, NCH2) and 7.8 - 7.9 (4H, m, aromatics); ôc (50 
MHz, C^HCh : % -DM SO 9:1) 28.12 {CH2COO), 34.91 (COCH2CH2), 46.96 
(NCH2), 123.95, 132.35, 134.41 (3 x aromatics), 168.04 (NCO), 173.10 (CO2H) 
and 203.15 (ALA-CO); Ôn (30 MHz, C^HCh : % -DM SO 9:1) 151.30.
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8.15 Synthesis of 5-aminolevulmic acid.811
6MHC1
CO.H
Phthalimidolevulinic acid (Reaction 8.14, 1 g, 3.8 mmol) in 6 M HCl (10 cm^) was 
heated to reflux for 12 hours then cooled to 0 °C. The resulting phthalic acid was 
filtered off and the mixture was concentrated under reduced pressure, keeping the 
temperature below 30 °C to give ALA.HC1 (3) as a white solid (0.57 g, 89%). 
Data as for Reaction 8.3. Ôn (30 MHz, ^HaO) 25.75.
8.16 Synthesis of 3-acetyl-4 -(2 -carhoxyethyl)-2 -methylpyrrole and 2-(3-
carboxypropionyl)-3,5-dimethylpyrrole. 812
HOgC
HOX
acetate buffer
pH 4.57
\H,HC1 (10)
(3)
A solution of ALA.HC1 (Reaction 8.15, 0.17 g, 1.0 mmol) and pentane-2,4-dione 
(0.10 g, 0.10 cm^, 1.0 mmol) in acetate buffer (4 cm^, pH 4.57) was heated 
under reflux conditions for 30 minutes then allowed to cool to room temperature 
overnight. The resulting brown solid was filtered off, washed thoroughly with 
cold water and dried to constant weight (0.04 g, 19%), m.p. 192 - 194 °C (Lit.^ ^^
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191 °C). m/z (EI"*^  195 (M*). NMR spectroscopy identifies the two products in 
approximately a 9:1 ratio: 3 acetyl-4-(2-carboxyethyl)-2-methylpyrrole (10); 8j^
(300 MHz, C2H302H) 2.4 (3H, s, COCft), 2.5 (3H. s, O iC H j) ,  2.6 (2H, t, J =
7.5 Hz, CHjCiïjCOjH), 2.9 (2H, t, J = 7.5 Hz, CH2CH2CO2H) and 6.4 (IH, s, 
CHNH); 6c (75 MHz, C^HjO^H) 15.41 (CHC%), 24.22 (CH2CH2CO2H), 30.71
(COCft), 35.92 (CHîCFjCOjH), 116.14 (CHNH), 121.26 (C=C-CO), 125.87 
(C=C-CH2), 138.12 (C=C-CH3>, 177.97 (COO) and 197.19 (CO) 2-(3- 
earboxypropionyl)-3,5-dimethylpyrrole (11); 6g (C^^O^H) 2.2 (3H, s,
CHsC=CCO), 2.3 (3H, s, CftCNH), 2.6 (2H, t, J = 6.5 Hz, CH2CH2CO2H), 3.0 
(2H, t, J = 6.5 Hz, C%CH2C02H) and 5.8 (IH, s, CHCCH3); 6g (75 MHz,
CZHjO^H) 12.85 (CffiC=CCO), 14.62 (C&CNH), 27.14 (CH2CH2CO2H), 
35.29 (CÆCH2CO2H), 113.72 (CÆCCH3), 129.14 (CCO), 131.96 
(CH3OCCO), 136.47 (CCHsNH), 177.00 (COO) and 189.12 (C=0).
8.17 Synthesis of 3-(4-carboxybutionyl)-4-(2-carboxyethyl)-2-methylpyrrole 
and 2-(4-carboxyhutionyl)-4-(2-carboxyethyl)-3-methylpyrrole.
HQjC
Ml; .HCl
HO2C,
acetate buffer
HO2Q
(x . 0 1 '
H H
(1 2 ) S (13)CO2 H
156
A solution of ALA.HC1 (Reaction 8.15, 0.09 g, 5.3 mmol) and 4,6-
dioxoheptanoic acid (succinyl acetone) (0.05 g, 5.3 mmol) was heated under
reflux conditions in acetate buffer (5 cm^, pH 4.57) for 30 minutes. The solution 
was allowed to eool and the resulting white precipitate was filtered off and dried
to constant weight (0.06 g, 43%), m.p. 224 - 226 °C. m/z (ET'^ 253 (M*). Fotmd 
C, 56.5; H, 6.3; N, 5.5. C12H 15O5N requires C, 56.9; H, 6.0; N, 5.5%. NMR 
spectroseopy identifies the two products in approximately a 4:1 ratio: 3-(4- 
carboxybutionyl)-4-(2-carboxyethyl)-2-methylpyrrole (12); 5jj (200 MHz,
C^HgO^H) 2.7 (3H, s, CH3), 2 .8  (3H, m, CH2), 2.9 (2 H, m, CHj), 3.1 (2 H, m, 
CH2), 3.2 (2H, m, CH2) and 6 .6  (IH, s, CHNH); 5c (75 MHz, C^HjO^H) 12.25 
(CH3), 20.03 (CH3CH2CO2H), 25.31 (CH2CH2CO2H), 31.75 (CH2CH2CO2H), 
33.63 (COCH2), 111.71 (CH-aromatic), 116.53 (CCH;), 120.91 (CCO), 131.80 
(CNH), 171.35 (COO), 171.52 (COO) and 191.36 (CO). 2-(4-carboxybutionyl)- 
4-(2-carboxyethyl)-3-methylpyrrole (13); 5jj (300 MHz, C^HgO^H) 2.6 (3H, s, 
CH3), 2.7 (2H, m, CH2), 2.9 (2H, m, CH2) 3.2 (2H, m, CH2), 3.4 (2H, m, CH2 ) 
and 6.7 (IH, s, CHNH); 5c (75 M H z,C% 0'H ) 15.25 (CH3), 21.24 
(CH2CH2CO2H), 28.04 (CH2CH2CO2H), 29.06 (CH2CH2CO2H), 34.02
(COCH2), 116.02 (CH-aromatie), 118.05 (CCH2), 123.04 (CCO), 135.21 (CNH),
173.06 (COO), 173.57(000) and 193.01 (CO).
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8.18 Synthesis of 3,2-(carboxyethyl)-6-methyl-4,5,6,7-tetrahydroindol-4-one.
CO2H
HO2C
ONH2.HCI
(3)
acetate buffer
ethanol pH 4.48
(14)
ALA.HC1 (Reaction 8.15, 0.17 g, 1 mmol), 5-methyl-l,3-cyclohexanedione (0.13 
g, 1 mmol in a saturated solution of ethanol) and acetate buffer (5 cm^, pH 4.48) 
were heated under reflux conditions for 30 minutes. The solution was cooled to 0 
°C and after a few days the white crystalline product (14) that formed was filtered 
and dried over P2O5 to constant weight (0.01 g, 6 %), m.p. 198 °C (dec.), m/z 
(E f) 221 Çs/t). Found 221.1052. C12H15NO3 requires 221.1052. %  (200 MHz,
^He-DMSO) 1.1 (3H, d, J = 6.1 Hz, CH3), 2.0 - 2.3 (5H, m, 1 x CH and 2 x 
CH2), 2.8 (2H, m, CH2), 6.5 (IH, s, aromatic) and 11.0 (IH, bs, NH or OH); Ôc 
(50 MHz, ^Hg-DMSO) 20.92 (CH3), 21.98 (CH2CH2CO2H), 28.65 (CH), 30.83, 
31.72 (CH2CCH3 and CH2CO), 34.65 (CH2CO2H), 116.24 (CH-aromatic), 
117.13, 121.14 (CCH2 and CCO), 143.77 (CNH), 174.62 (COO) and 193.54 
(CO).
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8.19 Synthesis of 3-(2-carboxyethyl)-4, 5, 6, 7-tetrahydroindol-4-one.
HOgC
acetate buffer 
pH 4.57^
c
b
Ha
GO^ H
NH2.HCI
(3)
(15)
A solution of ALA.HC1 (Reaction 8.15, 1 g, 5.97 mmol) and 1,3-cyclohexandione 
(0.67 g, 5.97 mmol) in acetate buffer (20 cm^, pH 4.57) was heated under reflux 
conditions for 30 minutes then allowed to cool to room temperature overnight. 
The resulting yellow coloured solid was filtered, washed thoroughly with water 
and recrystallised from ethanol to give 3 -(2-carboxyethyl)-4,5,6,7- 
tetrahydroindol-4-one (15) as a white solid (0.14 g, 12%), m.p. 194-196 °C. m/z 
(E f) 207 (hf). Found C, 63.5; H, 6.5; N, 6.7. C11H13NO2 requires C, 63.8; H, 
6.3; N, 6 .8%. ôy (300 MHz, %-DM SO) 2,1 (2H, quin, J = 6 .6  Hz, CHz-b), 2.4 
(2H, t, J = 6 .6  Hz, CH2-C), 2.6 (2H, t, J = 7.4 Hz, CH2-e), 2.8 (2H, t, J = 8.2 Hz, 
CH2-a ), 2.9 (2H, t, J = 6 .6  Hz, CH2-d), 6 .6  (IH, s, aromatic CH), 11.1 (IH, s, 
NH) and 11.8 (IH, bs, OH); ôc (75 MHz, ^Hg-DMSO) 22.01 (CH2-a), 23.04 
(CH2-d), 24.06 (CH2 -b), 34.52 (CH2-e), 38.24 (CH2-C), 116.01 (aromatic CH), 
118.24, 122.43 (CCH2 and CCO), 144.06 (CNH), 174.98 (COO) and 195.05 
(CO). These interpretations were made using ^H - ^^ C and COSY two 
dimensional NMR spectroscopy (See Section 3.2.2),
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8.20 Attempted synthesis of 3-(2“Carboxyethyl)-6,6-dimethyl-4,5,6,7- 
tetrahydroindol-4-one.
HOjC
acetate buffer
ethanol 
pH 4.48
CO2 H
NH2.HCI
(3)
ALA.HC1 (Reaction 8.15, 0.17 g, 1 mmol), 5,5-dimethyl-1,3-cyclohexanedione 
(dimedone, 0.14 g, 1 mmol in a saturated solution of ethanol) and acetate buffer 
(5 cm^, pH 4.48) were heated under reflux conditions for 30 minutes. The 
solution was allowed to cool to room temperature then refrigerated for several
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weeks but no product appeared. The ethanol was removed under reduced 
pressure and, on cooling, a yellow solid formed which was filtered off and dried to 
constant weight (0.015 g). From mixed melting point determination, the product 
was unreacted 5,5-dimethyl-l,3-cyclohexanedione, the starting material.
8.21 Attempted synthesis of 2,5-di-(p-carboxyethyl) pyrazine.
CO2H
acetate buffer
pH 4.4
HCLH2N
(3)
ALA.HC1 (Reaction 8.15, 0.5 g, 2.98 mmol) in acetate buffer (10 cm ,^ pH 4.4) 
was heated under reflux conditions for 6 hours causing the solution to go a dark 
brown colour. The mixture was freeze dried giving brown hygroscopic crystals. 
Decolourising charcoal failed to remove the colour as did recrystallisation from 
ethanol or acetone. The product was, therefore, purified by column 
chromatography using ethyl acetate : DCM 9:1 with 0.5% acetic acid as the 
eluant. This yielded a brown hygroscopic off. Mass spectrometry suggested 
polymerisation had occurred.
1 6 1
8.22 Attempted synthesis of 2,5-di-(p-dicarboxyethyl) pyrazine tetraethyl
813ester.
MBS
dibenzoylperojdde
Br
N..
Bi
NaOEt
diethyl
malonate ACF^CHzOzC OO2CH2CH3
A solution of 2,5-dimethylpyrazine (1.09 cm ,^ 1.08 g, 0.01 mol), N- 
bromosuccinamide (3.56 g, 0.02 mol) and dibenzoyl peroxide (50 mg, 0.20 mmol) 
in THF (50 cm^) was heated under reflux conditions for 6 hours then stirred at 
room temperature for 48 hours. After cooling to 0 °C the mixture was filtered, 
and the filtrate concentrated under reduced pressure. The resulting residue was 
reacted immediately to avoid polymerisation. Sodium ethoxide was generated by 
the addition of sodium metal (3.45 g) to ethanol (100 cm^). The crude residue was 
then added (1.98 cm^) along with diethyl malonate (3.20 g, 0.02 mol, 
approximately 2 equivalents) and the mixture was heated under reflux comditions 
for 2 hours. The resulting solution was concentrated under reduced pressure and 
extracted with diethyl ether (50 cm  ^x 2). The diethyl ether extracts were washed 
with HCl solution, then brine (50 cm  ^ of each), dried (MgSO#), filtered and 
concentrated under reduced pressure to give a pale orange coloured oil. Tic 
showed this to contain at least seven products, therefore the approach was 
abandoned.
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8.23 Synthesis of 2,5-di-(p-carboxyethyl) pyrazine dibenzyl ester.
CO^ Bn BnO.
NaOMe  »
MeOH
HCI.H2N (53)
N'
(16)
‘CO2B11
5“Aminolevulinic acid benzyl ester (Reaction 8.63, 0.5 g, 1.9 mmol) was 
dissolved in methanol (5 cm^). Sodium metal (0.044 g, 1.9 mmol) was added 
causing NaCl to precipitate from the solution. The mixture was stirred at room 
temperature for 3 hours then filtered to remove the NaCl. The solvent was 
removed under reduced pressure giving 2,5“di-(p“Carboxyethyl) pyrazine dibenzyl 
ester (16) as a slightly yellow coloured oil (0.35 g, 90%). m/z. (EI^) 404 (IS/T). A 
correct elemental analysis was not obtained as the product was contaminated with 
a small quantity of NaCl. Ôh (200 MHz, C^HCb) 2.8 (4H, t, J = 9.1 Hz, 2 x CH2), 
3.1 (4H, t, J = 9.1 Hz, 2 X  CH2), 5.1 (4H, s, 2 x CH2?h), 7.3 - 7.4 (lOH, m, 2 x 
aromatics) and 8.4 (2H, s, 2 x aromatic CH); ôc (50 MHz, C^HCb) 29.97 (2 x 
CH2CH2COO), 33.22 (2 X  CH2COO), 66.95 (2 x CHgPh), 127.48, 128.10, 
128.52, 128.74, 129.03, 136.29 (2 x aromatics), 143.99 (2 x NCCCH2), 153.33 
(2 X  NCCCH2) and 172.98 (2 x CO).
4
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8.24 Synthesis of 2,5-di-(p-carboxyethyl) pyrazine.
BnOr HO.
N"
(16)
Hj, 10% Pd/C 
MeOH
TO^Bn
N"
(17)
COjH
2,5-Di“(p-carboxyethyl) pyrazine dibenzyl ester (Reaction 8.23, 0.3 g, 0.7 mmol) 
was dissolved in methanol (10 cm^). 10% Pd/C catalyst (50 mg) was added and 
the mixture was stirred under an atmosphere of Hz at room temperature and 
atmospheric pressure for 24 hours. The resulting mixture was filtered through 
Celite to remove the catalyst and the solvent was removed under reduced pressure 
to give 2,5-di-(p-carboxyethyl) pyrazine (17) as a light brown coloured oil (0.15 
g, 88%). Sh (200 MHz, '%-DMSO) 2.8 (4H, t, J = 9.1 Hz, 2 x CHj), 3.0 (4H, t, J 
= 9.1 Hz, 2 X CHz) and 8.4 (2H, s, 2 x aromatic CH); 8 c  (50 MHz, ^Hs-DMSO)
29.76 (2 X CftCHîCOO), 32.83 (2 x CffiCOO), 143.81 (2 xNCCCHj), 153.64 
(2 X NCCCHj) and 179.29 (2 x CO).
814
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8.25 Synthesis of 3-nitro-4-hydroxycoumarin
nitric acid  »,
acetic acid
A suspension of nitric acid (4.6 cm ,^ 0.11 mol) in glacial acetic acid (5 cm^) was 
added to a suspension of 4-hydroxycoumarin (10.12 g, 0.062 mol) in glacial acetic 
acid (25 cm^). The mixture was heated to 70 to initiate the reaction then
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allowed to cool to room temperature for 2 hours. The product was filtered, 
washed with ice cold water and dried over P2O5 giving 3-nitro-4- 
hydroxycoumarin (18) as a pale orange solid (9.62 g, 75%), m.p. 178 °C (dec.) 
(Lit 815 0Ç (jggj) (200 MHz, % -DM SO) 7.3 (2H, t, J = 8 .8  Hz, 
aromatics), 7.6 (IH, t, J = 6.9 Hz, aromatics) and 7.9 (IH, d, J = 8.2 Hz, 
aromatics); ôc (50 MHz, % -DM SO)l 16.54, 120.04, 123.89, 125.76, 128.95, 
133.39 (5 X  Aromatics and CNO2), 152.55 (CHCO), 157.00 (CO) and 165.65 
(COH).
8.26 Attempted synthesis of 2’-amino-2-hydroxyacetophenone 
hydrochloride.^^^
macetic acid NH2.HCI
hypophosphorous 
(18)
3-Nitro-4-hydroxycoumarin (Reaction 8.25, 2 g, 9.7 mmol) was heated under 
reflux conditions in a mixture of hydriodic acid (5 cm ,^ 58%) and glacial acetic 
acid (10 cm^) for 15 minutes. Hypophosphorous acid (5 cm^) was added to 
reduce the resulting iodine. The mixture was cooled to 0 °C and the crystals that 
formed were filtered ofif and recystallised fi'om c-HCl. After numerous different 
attempts, NMR data shows the resulting solid to be 3-nitro-4-hydroxycoumarin, 
the starting material.
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8.27 Synthesis of 2-hydroxy-2’-nitroacetophenone 814
OH
.NQ ,NQl.Aq.NaOH
2. HCl
OH(19)(18)
CH— NOH
o-OH
3-Nitro-4-hydroxycoumarin (Reaction 8.25, 4.0 g, 19.3 mmol) was dissolved in 
aqueous sodium hydroxide solution (5 g in 100 cm ,^ 12.5 mM, 5%). The solution 
was stirred at 50 - 60 °C for 1.5 hours during which time it turned a bright orange 
colour. The mixture was allowed to cool to room temperature for 2 hours. An 
excess of c-HCl (15 cm^) was added causing the immediate precipitation of pale 
yellow coloured crystals. After standing overnight, the crystals of 2-hydroxy-2’- 
nitroacetophenone (19) were filtered off and washed with water (2.1 g, 60%), 
m.p. 102 -104 °C (Lit."'' 106 °C). m/z (EO  181 (IVf). Found C, 52.9; H, 4.2; N, 
7.7; Calculated for CgH^NO#: C, 53.0; H, 3.9; N, 7.7%. Sh (200 MHz, ^He- 
DMSO) 6.2 (2H, s, CHa), 7.0 (2H, m, ar.), 7.6 (IH, m, ar.), 7.8 (IH, m, ar.) and
11.2 (IH, s, OH); Sc (50 MHz, ^He-DMSO) 91.05 (CH;), 122.79, 123.25, 
124.88, 125.23 and 135.74, 135.97, 144.37, 142.08 (2 sets of aromatics), 164.97 
and 166.83 (2 x 0=0). From '^C data, the product seems to isomerise in solution 
giving a 1:1 ratio of 2-hydroxy-2’-nitro-acetophenone and its nitronic acid.
8.28 Synthesis of 2’-amino-2-hydroxyacetophenone hydrochloride.
c-HCl
^OH
(20)
OH(19)
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2-Hydroxy“2’~nitroacetophenone (Reaction 8.27, 0.88 g, 5,34 mmol), tin (II) 
chloride dihydrate (4 g, 0.02 mol) and c-HCl (6.66 cm^) were stirred together 
causing an exothermic reaction. The temperature rose to 60 °C and after 5 
minutes the mixture was heated to 90 °C and left for 30 minutes. Water (6.6 cm^) 
was added and the mixture was heated under reflux conditions until a clear yellow 
solution formed (approximately 30 minutes was required). The solution was 
cooled to 0 °C and stirred during the dropwise addition of NaOH solution (lOM) 
to pH 5. The resulting light brown precipitate of 2’-amino-2- 
hydroxyacetophenone hydrochloride (20) was filtered off and dried (0.52 g, 
70%), m.p. 230 °C (Lit."" 229 - 230 °C). m/z (E f) 151 (M"). 8 h  (200 MHz, 
DMSO) 4.4 (2H, s, C%), 7.0 (IH, t, J = 7.3 Hz, aromatic), 7.2 (IH, d, J = 8.0 
Hz, aromatic), 7.6 (IH, t, J = 8.0 Hz, aromatic), 7.8 (IH, d, J = 8.0 Hz, 
aromatic), 8.3 (2H, bs, NH;) and 11.3 (IH, bs, OH); 6c (50 MHz, %-DM SO)
53.76 (CH;), 123.37, 125.16, 126.18, 135.59, 141.82 (aromatics) and 165.21 
(C=0).
8.29 Synthesis of 2,5-dihydro-2,5-di-(2’-hydroxyphenyl) pyrazine 815
OHNaOH,
OH
OH(20)
2’-Amino-2-hydroxyacetophenone hydrochloride (Reaction 8.28, 0.32 g, 1.8 
mmol) was dissolved in water (10 cm^). One equivalent of KOH (0.6 M, 3 cm ,^ 
0.1 g, 1.8 mmol) was added resulting in the formation of a gelatinous pink
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precipitate, which was filtered off and recrystallised fi'om dioxane to give 2,5- 
dihydro-2,5-di-(2’-hydroxyphenyl) pyrazine (21) as highly insoluble, therefore 
uncharacterised, pink crystals (0.10 g, 45%).
8.30 Synthesis of 2-(acetylmethyl)-6-methylpyrimidin-4-one.
O Q OH
acetate buffer ^J r ^
HO (22)
A solution of acetoacetamide (1 g, 10 mmol) in ethanol (5 cm^) and acetate buffer 
(20 cm ,^ pH 7.4) was heated under reflux conditions for 30 minutes then allowed 
to stand at room temperature for 4 days. The resulting white solid was filtered off 
and recrystallised fi'om ethanol to give 2-(acetylmethyl)-6-methylpyrimidin-4-one 
(22) as white crystals (0.16 g, 10%), m.p. 222 °C (dec.) m/z (EI^) 166 (M^). 
Found C, 57.2; H, 6.1; N, 16.6; Calculated for CgHioNgOz: C, 57.8; H, 6.1; N, 
16.8%. ÔH (200 MHz, ^Hô-DMSO) 2.1 (6H, s, 2 x CHs), 6.0 (IH, s, CH), 7.5 
(IH, s, aromatic), 7.7 (IH, s, OH) and 11.5 (IH, s, OH); ôc (50 MHz, % -  
DMSO) 22.59 (C%CN), 25.15 (CiTjCOH), 121.52, 121.68 (2 x CHCOR)
147.32 (NCCHs), 154.82 (NCHN), 167.75 (NCOH) and 174.08 (CH3CBOH).
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8.31 Synthesis of 2,5-dihydro-hexamethylpyrazine. 816
K3Fe(CN)6
H2O, ammonia.
O
NHo
O
-2H2O
(23)
Water ( 6 6  cm^), in a three necked flask fitted with a reflux condenser, a 
thermometer and a fi'itted glass nitrogen inlet tube was heated to 80 °C and 
degassed with a slow stream of nitrogen before potassium ferricyanate (7.82 g, 24 
mmol) was added. After 2 minutes of additional degassing the nitrogen bubbler 
was replaced with a dropping fimnel. While a static nitrogen atmosphere was 
maintained 3-methyl-2-butanone (0,45 g, 5.3 mmol) was added aU at once 
followed by degassed ammonia solution (4 cm^) dropwise over 30 minutes during 
which time the temperature remained between 80 and 85 °C. This caused the 
solution to turn a green colour. The reaction mixture was stirred at 85 °C for 8 
hours resulting in formation of a brown coloured solution. It was then cooled and 
extracted with DCM (5 x 25 cm^). The combined DCM extracts were washed 
with brine then 6 % HCl solution (50 cm  ^ of each). The acid layer was basified 
using NaOH then re-extracted with DCM (2 x 50 cm^). DCM layers were dried 
(MgS0 4 ), filtered and concentrated under reduced pressure to give impure 
product. Sublimation yielded 2,5-dihydro-hexamethylpyrazine (23) as a white 
solid (0.11 g, 26%), m.p. 8 8  - 90 °C (Lit.®‘" 8 8  - 89 °C). Ôh (200 MHz, ^He- 
DMSG) 1.2 (12H, s, 4 X CH3) and 1.9 (6 H, s, 2 x CH3); ô c  (50 MHz, % -  
DMSO) 22.62, 28.41, 55.86 (C(CH3)2) and 111.14 (CCH3).
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8.32 Attempted synthesis of 2,5-dihydro-2,3,5,6-tetramethylpyrazine.
O
KgFeCŒ)^   ►
HgO, ammonia.
NH2 r1 -2H20
. Ï  . 'N'
The reaction was carried out using the same method as for 2,5-dihydro- 
hexamethylpyrazine (Reaction 8.31), but using ethyl methyl ketone (0.38 g, 5.3 
mmol). The dihydropyrazine was not isolated. The product of reaction was 
2,3,5,6-tetramethylpyrazine (0.08 g, 22%), m.p. 88 - 90 °C (Lit.^^  ^85 - 86 °C). Ôh 
(200 MHz, "Hô-DMSO) 1.4 (12H, s, 4 x CH3); ôc (50 MHz, ^Hé-DMSO) 19.03 
(CH3) and 153.84 (aromatics).
8.33 Attempted synthesis of 2,5-dihydro-2,5-dimethylpyrazine.
KgFe(Œ)6
O HgO, ammonia.
NHo
O -2HgO ^N-
The reaction was carried out using the same method as for 2,5-dihydro- 
hexamethylpyrazine (Reaction 8.31) but using acetone (0.31 g, 5.3 mmol). No 
product was isolated.
8.34 Synthesis of t-butoxycarbonylglycine. 818
HO
B0C2O
O
. Aho.c^ n-
dioxane (24)
O'
A solution of glycine (1.5 g, 20 mmol) in a mixture of dioxane (40 cm^), water 
(20 cm^) and NaOH solution (IM, 20 cm^) was stirred and cooled in an ice water
170 ■-I
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bath. Di-t-butyl pyrocarbonate (4.8 g, 22 mmol) was added and the mixture was 
stirred at room temperature for 1 hour then concentrated to 30 cm .^ The solution 
was cooled to 0 °C and covered with a layer of ethyl acetate (60 cm^). The 
mixture was acidified with a dilute solution of KHSO4 to pH 2.5 before the 
aqueous phase was extracted with ethyl acetate (30 cm  ^ x 2). The ethyl acetate ç
extracts were washed with water (60 cm  ^ x 2 ), dried (MgS0 4 ) and concentrated 
under reduced pressure to give a white solid which was recrystaUised fi'om ethyl 
acetate/hexane to give t-butoxycarbonylglycine (24) as white crystals (1.44 g,
41%), m.p, 85 - 87 °C (Lit."'" 8 6  - 8 8  °C). Ôh (200 MHz, C^HCb) 1.4 (9H, s, 3 x 
B0 C-CH3), 3.9 (2H, m, CH2), 5.1 (IH, bs, NH or OH) and 6.7 (IH, bs, NH or 
OH); ÔC (50 MHz, C^HCb) 28.77 (3 x B0 C-CH3), 42.69, 53.89 (CH2 and 
C(CH3)3) 154.06 (COBoc) and 175.49 (COO).
8.35 Synthesis of t-butoxycarbonyl-L-alanine."'" j
;
o
HO,cA ^ N H , HO.cA ^ N ' ^ O '
dioxane (25)
t-Butoxycarbonyl-L-alanine (25) was prepared using the same method as for t- 
butoxycarbonylglycine (Reaction 8.34) but using L-alanine (1.78 g, 20 mmol) 
yielding the product (25) as a white crystalline solid (2.28 g, 60%), m.p. 84 - 86  
°C (Lit.*'* 82 - 84 °C). 8h  (200 MHz, C^HClj) 1.3 (12H, s, 3 x Boc-CHj and Â
CHs), 4.2 (IH, m, CH), 5.2 (IH, d, J = 7.7 Hz, NH) and 11.4 (IH, bs, OH); 8c 
(50 MHz, C'HCb) 18.84 (CHj), 28.74 (3 x B0 C-CH3), 48.57, 50.07 (CH and C- 
Boc), 156.31 (COBoc) and 173.51 (COO).
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8.36 Synthesis of t-butoxycarbonyl-L-phenylalanine 818
\  /
HQ
(26)
O'
t-Butoxycarbonyl-L-phenylalanine (26) was prepared using the same method as 
for t-butoxycarbonylglycine (Reaction 8.34) but using L-phenylalanine (3.3 g, 20 
mmol), yielding the product (26) as a white crystalline solid (3.04 g, 53%), m.p. 
87 - 89 °C (Lit.*”  84 - 8 6  °C). Sh (200 MHz, C'HCk) 1.3 (9H, s, 3 x B0 C-CH3),
3.2 (2H, m, CH2), 4.6 (IH, m, CH), 6 .6  (IH, d, J = 7.7 Hz, NH), 7.3 (5H, m, 
aromatics) and 8 .8  (IH. bs, OH); Sc (50 MHz, C^HCb) 28.41 (3 x B0 C-CH3),
38.32 (CH;), 54.71, 58.79 (C(CH3)3 and CH), 127.25, 127.52, 129.98, 135.35 
(aromatics), 155.85 (COBoc) and 176.46 (COO).
8.37 Synthesis of t-butoxycarbonyl-L-valine.^^ ^
Y Y ?B0C2O i  I
,cr    HOoCr ^HOo H,0,NaOH dioxane
O'H (27)
t-Butoxycarbonyl-L-valine (27) was prepared using the same method as for t- 
butoxycarbonylglycine (Reaction 8.34) but using L-valine (2.34 g, 20 mmol) 
yielding the product (27) as a white crystalline solid (2.27 g, 52%), m.p. 77 - 78 
°C (Lit.*“  77 - 79 °C). Sh (200 MHz, C^HCb) 1.0 (6H, m, 2 x CH,), 1.4 (9H, s, 3 
X B0 C-CH3), 2.2 (IH, m, CH(CH3)2), 4.3 (IH, m, CHNH), 5.1 (IH, d, J = 7.7 Hz, 
NH) and 6.4 (IH, bs, OH); Sc (50 MHz, C^HCb) 17.91 (2 x CH3), 28.76 (3 x
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Boc-CHs), 31.52 (C^CHs);), 58.88, 58.92 (C(CH3)3 and CHNH), 156.36 (CO) 
and 177.68 (COO).
8.38 Synthesis of t-butoxycarbonylglycinyl glycine methyl ester.818
HOoC"
O
A .
MeO HN"
CHME,DCM,H3N
(24)
C02CH3.HC1
(28) I
t-Butoxycarbonylglycine (Reaction 8.34, 0.35 g, 2 mmol) was dissolved in DCM 
(10 cm^) at 0 °C. Glycine methyl ester hydrochloride (0.25 g, 2 mmol) and 
triethylamine (0.28 cm ,^ 2 mmol) were added. After the addition of CHME (0.85 
g, 2 mmol) the solution was stored at 0 °C overnight. The reaction mixture was 
washed with water, citric acid solution (IM), saturated sodium bicarbonate 
solution, and water (30 cm  ^ of each), dried (MgS0 4 ), filtered and concentrated 
under reduced pressure to yield t-butoxycarbonylglycinyl glycine methyl ester (28) 
as a white solid (0.49 g, 8 8 %), m.p 116 - 118 °C. Ôh (200 MHz, C^HCb) 1.5 (9H, 
m, 3 X B0 C-CH3), 3.7 (3H, s, OCH3), 3.9 (2H, s, CH2) and 4.1 (2H, s, CHz); ôc 
(50 MHz, CfHCb) 27.25 (3 x B0 C-CH3), 40.05, 43.18 (2 x CH2), 51.43 (CH3),
58.88 (C(CHa)3), 152.15 (CO), 167.29 (COBoc) and 171.98 (COO).
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8.39 Synthesis of t-butoxycarbonylalaninyl alanine methyl ester 818
HOoC
MeO-
CHME, DCM, Et.N
(25)
CO.CHg.HCiNH2.HC1 hN' -►
t-Butoxycarbonylalanyl alanine methyl ester (29) was prepared using the same 
method as for t-butoxycarbonylglycinyl glycine methyl ester (Reaction 8.38) but 
using t-butoxycarbonyl-alanine (Reaction 8.35, 0.38 g, 2 mmol) and alanine 
methyl ester (0.28 g, 2 mmol), yielding the product (29) as a white solid (0.54 g, 
87%), m.p 119 - 121 °C. Ôh (200 MHz, C^HCb) 1.5 (15H, m, 3 x B0 C-CH3 and 2 
X CH3), 3.8 (3H, s, OCH3), 4.2 (IH, m, CH) and 4.6 (IH, m, CH); ô c  (50 MHz, 
CfHCb) 18.26 (CH3), 18.76 (CH3), 28.75 (3 x B0C-CH3), 46.46 (CH), 51.42 
(CH3), 52.93 (CH), 58.94 (C(CH3)3), 151.29 (CO-Boc), 169.41 (CONH) and
173.62 (COO).
8.40 Synthesis of t-butoxycarbonylphenylalanyl phenylalanine methyl ester.818
HN'
.NH,DCM, CHME, Et^ N
(26) (30)
t-Butoxycarbonylphenylalanyl phenylalanine methyl ester (30) was prepared using 
the same method as for t-butoxycarbonylglycinyl glycine methyl ester (Reaction
174
'"'I
8.38) but using t-butoxycarbonyl-phenylalanine (Reaction 8.36, 0.53 g, 2 mmol) 
and phenylalanine methyl ester (0.43 g, 2 mmol), yielding the product (30) as a 
white solid (0.81 g, 95%), m.p 112- 114 °C (Lit.'" 114-115 °C). Sh (200 MHz, 
C^HCh) 1.3 (9H, s, 3 X  Boc-CHj), 3.3 (4H, m, 2 x CHj), 3.8 (3H, s, OCH3), 4.2, 
4.5 (2 X  IH, 2 X  tn, 2 X  CH), 6 .8  (IH, d, J = 7.6 Hz, NH), 7.1 - 7.4 (lOH, m, 2 x 
aromatics) and 8.4 (IH, d, J = 7.6 Hz, NH); Sc (50 MHz, C'HCL) 28.40, 28.46, 
28.75 (3 X  B0 C-CH3), 38.36, 38.77 (2 x CHjPh), 52.71 (COjCft), 53.76 
(CCO2CH3), 56.17 (CHNHBoc), 58.21 (C(CH3)3), 127 - 129, 136.12, 136.95 
(aromatics), 155.84 (COOBoc), 171.39 and 172.54 (2 x CO).
8.41 Synthesis of t-butoxycarbonylvalinyl valine methyl ester.*^^
HO,CXx'N"H MeO. NH2.HCI  ►CHME, DCM, EtgN HN''^^C02CH3.HCI
(27)
t-Butoxycarbonylvalinyl valine methyl ester (31) was prepared using the same 
method as for t-butoxycarbonylglycinyl glycine methyl ester (Reaction 8.38) but 
using t-butoxycarbonyl-valine (Reaction 8.37, 0.43 g, 2 mmol) and valine methyl 
ester (0.33 g, 2 mmol) yielding the product (31) as a white solid (0.59 g, 89%). 
m,p 115-117 °C. ÔH (200 MHz, C^HClg) 1.0 (12H, m, 2 x CH(C7 &)2), 1.4 (9H, 
s, 3 X  B0 C-CH3), 2.0 - 2.2 (2H, m, 2 x Ci7(CH3)2), 3.8 (3H, s, OCH3), 3.9 (IH, 
m, CH) and 4.3 (IH, m, CH); ôc (50 MHz, C^HCb) 17.24, 19.17 (2 x 
(CH(Œ6 )2), 28.24 (3 x B0 C-CH3), 31.26 (2 x C7f(CH3)2), 58.24 (C(CH3)3),
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76.14, 77.29 (2 x CHNH under C^KCh), 156.26 (CO-Boc), 162.41 (CONH) and 
177.25 (COO).
8.42 Synthesis of glycine anhydride.®^^
^  D2CH3.HCi ______ ^
1. formic acid ^nh
2. butan-2-ol, O' 
toluene (32)
t-Butoxycarbonylglycinyl glycine methyl ester (Reaction 8.38, 0.4 g, 1.4 mmol) 
was dissolved in formic acid (40 cm ,^ 98%) and the solution was kept at room I
temperature for 2 hours. The excess formic acid was removed under reduced 
pressure, keeping the temperature below 30 °C. The residue containing the crude 
dipeptide ester formate was then dissolved in butan-2 -ol (sec-butyl alcohol, 80 
cm^) and toluene (2 0  cm^) and the mixture was heated under reflux conditions for 
2.5 hours. The mixture was concentrated under reduced pressure to 20 cm  ^ and 
then cooled to 0 °C. The resulting white crystals of glycine anhydride (32) were 
filtered off and dried over P2O5 (0.11 g, 71%), m.p. >250 °C (Lit.*^  ^ 311 - 312 
°C). ÔH (200 MHz, ^He-DMSO) 3.7 (4H, s, 2 x CH2) and 8.05 (2H, bs, 2 x NH);
ÔC (50 MHz, DMSO) 36.42 (2 x CH2) and 171.79 (2 x CO).
1 7 6  I
8,43 Synthesis of alanine anhydride.821
HN'
O
CO2CH3.HCI HN
1. formic acid
2. butan-2-ol Q 
toluene
O
NH
(29) (33)
Alanine anhydride (33) was prepared using the same method as for glycine 
anhydride (Reaction 8.43) but using t-butoxyearbonylalanyl alanine-methyl ester 
(Reaction 8.39, 0.44 g, 1.4 mmol), yielding the product (33) as a white solid (0.14 
g, 70%), m.p. >250 °C (Lit.*^  ^291 °C). 8» (200 MHz, ^Hs-DMSO) 1.3 (6H, m, 2 
X CHs), 3.9 (2H, m, CH) and 8.15 (2H, bs, NH); 8 c  (50 MHz, ^Hj-DMSO) 24.15 
(2 X CH3), 55.55 (2 X CH3) and 174.78 (2 x CO).
8.44 Synthesis of phenylalanine anhydride.821
HN' HN
1. formic acid
2. butan-2-ol, o' 
toluene
^NH
(34)
Phenylalanine anhydride (34) was prepared using the same method as for glycine 
anhydride (Reaction 8.42) but using t-butoxycarbonyl-L-phenylalanyl 
phenylalanine-methyl ester (Reaction 8.40, 0.6 g, 1.4 mmol), yielding the product
(34) as a white solid (0.36 g, 86%), m.p. >250 “C (Lit.*“  311 - 312 “€). 8 h  (200
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MHz, %-DM SO) 2.3 (4H, m, 2 x CHz), 4.0 (2H, m, 2 x CH), 7.1 - 7.3 (lOH, m, 
2 X aromatics) and 8.0 (2H, bs, 2 x  NH); ôc (50 MHz, ^H«-DMSO) 28.76 (2 x 
CH:), 60.12 (2 x CH), 132.21, 133.41, 134.62, 134.88, 135.54 (2 x  aromatics) 
and 172.61 (2 x CO).
8.45 Synthesis of valine anhydride 821
HN'
NH.
/ \(31)
\ y
HN
1. formic acid
2. butal-2-ol, O 
toluene
O
NH
(35)
Valine anhydride (35) was prepared using the same method as for the glycine 
anhydride (Reaction 8.42) but using t-butoxycarbonylvalinyl valine-methyl ester 
(Reaction 8.41, 0.43 g, 1.4 mmol) yielding the product (35) as a white solid (0.20 
g, 71%), rap. >250 °C (Lit.*“  263 °C). 5h (200 MHz. ^Hs-DMSO) 0.9 - 1.0 
(12H, m, 2 X CH(CH)):), 2.2 (2H. m. 2 x CfflfCHs):), 3.7 (2H, m, 2 x CHNH) 
and 8.0 (2H, bs, 2 x NH); §c (50 MHz, ^%-DMSO) 17.54, 18.94 (2 x 
CH(C%):), 51.28 (2 x (CH(CH3):). 62.45 (2 x CH) and 172.45 (2 x CO).
8.46 Synthesis of 2,5-dihydro-2,5-dimethoxypyrazine. 825
HN
o
O Me^ O+BF, 
►
3^ ^^  4DCM N
NH
oca
CH3 0 N(32)  ^ (36)
A suspension of glycine anyhydride (Reaction 8.42, 0.11 g, 1 mmol), 
trimethyloxonium tetrafluoroborate (0.44 g, 3 mmol) and DCM (9 cm^) was
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stirred at room temperature for 1 day then heated under reflux conditions for 4 
days. A further quantity of trimethyloxonium tetrafluoroborate (0.074 g, 0.5 
mmol) was added after 2 days. The resulting sticky suspension was cooled to 0 °C 
and NaOH solution (4 cm ,^ 2.5 M) was added. The layers were separated and the 
aqueous layer was extracted with DCM (2 x 10 cm^). The combined organic 
layers were re-extracted with water (3 x 10 cm^), dried (MgS0 4 ), filtered and 
concentrated under reduced pressure to give 2,5-dihydro-2,5-dimethoxypyrazine 
(36) as a light brown coloured solid (0.05 g, 35%), the melting point was not 
recorded due to the sensitivity of the product to aerial oxidation. Ôh (200 MHz, 
CfHCb, C^HsO^H or % -DM SO) 3.6 (6H, s, 2 x OCH3) and 4.0 (4H, s, 2 x 
CH2); ÔC (50 MHz, CfHCb, C^HaO^H or %-DM SO) 46.77 (2  x CH2), 53.21 (2  x 
OCH3) and 159.60 (2 x C-OMe).
8.47 Synthesis of 2,5-dihydro-2,5-dimethoxy-3,6 -dimethylpyrazine 825
. 0  MegO+BF^ -
HN DCM N OCH3
"Y" CH3O
(33) (3 7 )
2,5-Dihydro-2,5-dimethoxy-3,6-dimethylpyrazine (37) was prepared using the 
same method as for 2,5-dihydro-2,5-dimethoxypyrazine (Reaction 8.46) but using 
alanine anhydride (Reaction 8.43, 0.14 g, 1 mmol), yielding the product (37) as an 
off white solid (0.064 g, 38%), the melting point was not recorded due to the 
sensitivity of the product to aerial oxidation. Ôh (200 MHz, ^He-DMSO) 1.3 (6H, 
m, 2 X CH3), 3.6 (2H, m, 2 x CH) and 4.1 (6H, m, 2 x OCH3); 8 c (50 MHz, ^Hg-
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DMSO) 14.62, 14.68 (2 x CH3), 49.24, 49.31 (2 x OCH3), 61.02, 61.22 (2 x 
CH), 160.80 and 161.76 (2 x C-OMe).
8.48 Synthesis of 3,6-dibenzyl-2,5-dihydro-2,5-dimethoxypyrazine 825
,0 ocaHN
(38)
3 ,6 -Diben2yl-2 ,5 -dihydro-2 ,5 -dimethoxypyrazine (38) was prepared using the 
same method as for 2,5-dihydro-2,5-dimethoxypyrazine (Reaction 8.46) but using 
phenylalanine anhydride (Reaction 8.44, 0.29 g, 1 mmol) yielding the product (38) 
as an off white solid (0.085 g, 42%), the melting point was not recorded due to 
the sensitivity of the product to aerial oxidation. Ôh (200 MHz, ^Hg-DMSO) 2.7 
(4H, m, 2 X CH2), 3.4 (6H, m, 2 x OCH3), 3.6 (2H, m, 2 x CH) and 7.0 - 7.4 
(lOH, m, aromatics); 6c (50 MHz, % -DM SO) 46.03, 46.91 (2 x OCH3), 62.13, 
63.06 (2 X  CH), 65.08, 65.13 (2 x CH;), 131.61, 131.70, 131.74, 131.85, 131.89, 
132.23, 132.31, 132.48, 133.47, 133.56 (2 x aromatics), 141.63, 143.36 (2 x 
aromatics), 163.38 and 163.92 (2 x C-OMe).
8.49 Synthesis of 2,5-dihydro-2,5-dimethoxy-3,6-dipropylpyrazine. 825
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oY Y
CH3O - Y "/ \  A
(35) (39)
2,5-Dihydro-2,5-dimethoxy-3,6-dipropylpyrazme (39) was prepared using the 
same method as for 2,5-dihydro-2,5-dimethoxypyrazine (Reaction 8.46) but using 
valine anhydride (Reaction 8.45, 0.19 g, 1 mmol), yielding the product (39) as an 
off white solid (0.084 g, 37%), the melting point was not recorded due to the 
sensitivity of the product to aerial oxidation. Ôh (200 MHz, ^He-DMSO) 1.2 (6 H, 
m, 2 X CH (Œ i)2), 2.0 - 2.2 (2H, m, 2 x CHiCRs)!), 3.6 (2H, m, 2 x CH) and 4.2 
(6H, m, 2 X  OCH3); 5c (50 MHz, % -DM SO) 21.02, 21.64 (2 x CH(OT)2), 
31.41, 31.62 (2 X  C/f(CH3)2), 163.14 and 163.26 (2 x C-OMe).
8268.50 Synthesis of 2,5-diethoxy-2,5-dihydropyrazine.
A suspension of glycine anhydride (Reaction 8.42, 0.11 g, 1 mmol) and 
triethyloxonium tetrafluoroborate (0.62 g, 4.22 mmol, 3.3 cm  ^of a IM solution in 
DCM) was vigorously stirred at room temperature under an atmosphere of 
nitrogen for 72 hours. The mixture was cooled to 0 °C and NaOH solution (2.5M, 
5 cm  ^ was added. The layers were separated. The aqueous layer was extracted 
with DCM (2x10  cm^). The combined DCM extracts were washed with water (3
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X 10  cm^) dried (MgS0 4 ), filtered and concentrated under reduced pressure to 
give 2,5-diethoxy-2,5-dihydropyrazine (40) as an off white solid (0.08 g, 47%), 
the melting point was not recorded due to the sensitivity of the product to aerial 
oxidation. (200 MHz, % -DM SO) 1.3 (6H, m, 2 x CHs), 3.5 (4H, m, 2 x CH2) 
and 4.1 (4H, m, 2 x CH2); ôc (50 MHz, %-DM SO) 14.69, 14.72 (2 x CH3), 
45.12, 16.32, 50.99, 51.52 (2 x CH2), 162.82 and 163.06 (2 x COEt).
8.51 Synthesis of 2,5-diethoxy-2,5-dihydro-3,6 -dimethylpyrazine. 826
, 0  EtgO+BF^ - 
HN DCM N OCH2CH
,NH !■ ]sj
O'" ^
(33) (41)
2,5-Diethoxy-2,5-dihydro-3,6-dimethylpyrazine (41) was prepared using the same 
method as for 2,5-diethoxy-2,5-dihydropyrazine (Reaction 8.50) but using alanine 
anhydride (Reaction 8.43, 0.14 g, 1 mmol) yielding the product (41) as an off- 
white solid (0.10 g, 50%), the melting point was not recorded due to the 
sensitivity of the product to aerial oxidation. (200 MHz, ^He-DMSO) 1.3 - 1.5 
(12H, m, 4 X  CH3), 3.5 - 3.7 (2H, m, 2 x CH) and 4.0 - 4.1 (4H, m, 2 x CH2); ôc 
(50 MHz, %-DM SO) 14.72, 14.61, 16.22, 16.84 (4 x CH3), 52.03, 52.57 (2 x 
CH2), 61.35, 31.65 (2 x CH), 164.94 and 164.99 (2 x COEt).
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8.52 Synthesis of ethyl 5-bromolevulinate.
O
807
% o
C02H EtOH Br (42) CO2 CH2 CH3
Ethyl 5-bromolevulinate (42) was prepared using the same method as for methyl 
5-bromolevulinate (Reaction 8.1) substituting ethanol for methanol, giving the 
product (42) as a clear oil (5.25 g, 27%). 8h (200 MHz, C^HCfc) 1.3 (3H, t, J =
7.1 Hz, CH3), 2.5 (2H, m, CftCOO), 2.9 (2H, m. COCftCHj), 3.9 (2H, m, 
BrCHj) and 4.0 (2H, m, C/6 CH3); 8c (50 MHz, C^HCU) 14.77 (CH,). 27.15 
(CftCOO), 34.81 (COCH2CH2), 48.21 (BiCHg), 62.16 (CH2CH3), 174.12 
(COO) and 203.51 (CO).
8.53 Synthesis of ethyl 5-phthalimidolevuIinate. 807
DMF(42) (43)
Ethyl 5-phthaiimidolevulinate (43) was prepared using the same method as for 
methyl 5-phthalimidolevulinate (Reaction 8.4) but using ethyl 5-bromolevuIinate 
(Reaction 8.52, 1.11 g, 5 mmol), yielding the product (43) as a white solid (0.81 
g, 56%), rap. 80 - 82 °C (Lit.®" 79 °C). 8h (200 MHz, C^HCL) 1.2 (3H, m, 
CHs). 2.6 (2H, t, J = 7.5 Hz, C%COO), 2.8 (2H, t, J = 7.5 Hz, COCHjCHi), 4.2 
(2H, m, CH2CH3), 4.6 (2H, s, NCH2) and 7.8 to 7.9 (4H, m, aromatics); 8c (50 
MHz, C^HClj) 14.65 (CH3), 28.33 (CftCOO), 35.02 (COCH2CH2), 47.02
183
(NCHz), 61.38 (Œ 6 CH3), 112.80, 124.08, 132.54, 134.67 (aromatics), 173.21 
(COO) and 203.10 (CO).
8.54 Synthesis of 5-aminolevulinic acid methyl ester.
Et3N,MeOH
GOgCH)
HCI.H2N /
(44) (45)
CO2CH3
Methyl 5-phthalimidolevulinate (Reaction 8.4, 0.47 g, 1.7 mmol) was dissolved in 
dry methanol (20 cm^). Triethylamine (0.23 cm ,^ 1.7 mmol, 0.17 g) and N,N- 
dimethyl-1,3-propanediamine (0.64 cm ,^ 5.1 mmol, 2.2 equivalents) were added 
and the mixture was stirred at room temperature overnight causing it to go blue. 
The methanol was removed under reduced pressure and the mixture was purified 
by column chromatography, using a 19:1 solution of DCM : methanol with 0.5% 
HCl as the eluant giving a very small amount of the required product 
(approximately 10%) and a large amount of 2,5-di-(p-carboxyethyl) pyrazine 
dimethyl ester (approximately 90%). NMR spectroscopy identifies two products: 
5-Aminolevulinic acid methyl ester (44); Ôh (200 MHz, C^HsO^H) 2.6 (2H, m, 
Œ 6C 00), 2.8 (2H, m, COC^CHz), 3.6 (3H, s, CH3) and 4.1 (2H, m, NH2CH2); 
ÔC (50 MHz, C^H3 0 ^H) 28.91 (C7&C00), 35.64 (COC^CHg), 49.81 (NH2CH2), 
52.13 (CH3), 175.32 (COO) and 203.42 (CO). 2,5-di-((3-carboxyethyl) pyrazine 
dimethyl ester (45); Ôh (200 MHz, 2.8 (2H, t, J = 5.0 Hz, CH2), 3.0
184
(2H, t, J = 5.0 Hz, CH2), 3.6 (3H, s, CH3) and 8.4 (IH, s, aiomatic); Ôc (50 MHz, 
C^HaO^H) 30.12, 33.24 (C ^C ^C O O ), 52.15 (CH3), 143.12 (aromatic CH),
154.1 (NCCH2) and 173.02 (CO).
8.55 Synthesis of 5-aminolevulinic acid ethyl ester.
CH3CH2O2C,\
CO2CH2Œ 3
EtgN, MeOH  ►
(43)
D2CH2CH3
(46)
N'
(47)
HCLH 'CO2CH2CH3
5-Aminolevulinic acid ethyl ester was prepared using the same method as for 5- 
aminolevulinic acid methyl ester (Reaction 8.54) but using ethyl 5- 
phthalimidolevulinate (Reaction 8.53, 0.5 g, 1.7 mmol), yielding a small amount 
of 5-aminolevuhnic acid ethyl ester (approximately 10%) and a large amount of
2,5-di-(p-carboxyethyl) pyrazine diethyl ester (approximately 90%). NMR 
spectroscopy identifies two products: 5-Aminolevulinic acid ethyl ester (46); Ôh 
(200 MHz, CfHsO^H) 1.3 (3H, t, J = 7.1 Hz, CH;), 2.6 (2H, m, CH2CO), 2.8 
(2H, m, COCH2CH2) and 4.0 - 4.2 (4H, m, NH2CH2 and CH2CH3); 6c (50 MHz, 
C^HsO^H) 14.77 (CH3), 28.88 (CftCOO), 35.62 (COCH2CH2), 49.84 
(NH2CH2), 62.16 (CHjCHa), 174.41 (COO) and 203.45 (CO). 2,5-di-p- 
(carboxyethyl) pyrazine diethyl ester (47); 8h (200 MHz, C^HsO^H) 1.2 (3H, m, 
CH3), 2.8 (2H, t, J = 5.1 Hz, CH2), 3.0 (2H, t, J = 5.1 Hz, CH;), 4.1 (2H, t, J =
5.1 Hz, CH2) and 8.4 (IH, s. aromatic); 8c (50 MHz, C^HsO^H) 14.61 (CH3),
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30.02, 33.23 (Cf^C^COg), 60.92 (Œ 6 CH3), 144.02 (aromatic CH), 153.47 
(NCCH2) and 173.08 (CO).
8.56 Synthesis of carbobenzyloxyglycinyl valine methyl ester. 818
CO2CH3
HgN
CO2H HN
CO2CH3
NMM,IBC  ►DMF,Et3N
THF
(48)
A solution of valine methyl ester (3.0 g, 18 mmol) in dry DMF (30 cm^) was 
prepared by gentle warming. This solution was cooled to room temperature and 
treated wth triethylamine (2.1 cm ,^ 15 mmol, 1.5 g). A solution of 
carbobenzyloxyglycine (3.75 g, 18 mmol) in dry THF (75 cm^) was cooled in an 
ethanoFcardice bath and neutralised with N-methyl morpholine (2.04 g, 1.65 cm ,^ 
15 mmol). Isobutyl chloroformate (1.74 g, 1.98 cm^ 15 mmol) was added 
followed by, 3 minutes later, the valine methyl ester solution and the reaction 
mixture was allowed to warm to room temperature overnight. The hydrochlorides 
of N-methyl morpholine and triethylamine were removed by filtration and washed 
with THF. The combined filtrate and washings were concentrated under reduced 
pressure to approximately 15 cm  ^ and diluted with water (75 cm^). This solution 
was cooled to 0 °C and filtered. The resulting white solid was washed with water, 
0.5 M KHCO3 solution and water (75 cm  ^ of each) then dried to give 
carbobenzyloxyglycinyl valine methyl ester (48) as white crystals (2.7 g, 46 %),
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m.p. 78 - 80 °C (Lit.*“  78 °C). 6h (200 MHz, ^Hs-DMSO) 0.9 (6H, m, 
CH(Cft)2), 2.0 (IH, m, CH(CH^)2), 3.4 (2H, s, CHjNHZ), 3.7 (3H, s, CHs), 4.2 
(IH, t, J = 7.0 Hz, CHNH). 5.05 (2H, s, CHzPh) and 7.4 - 7.6 (5H, m, aromatics); 
8c (50 MHz, "Hs-DMSO) 18.43, 19.19 (CH(C%)2), 30.32 (CH(CHj)2,, 43.35 
(CHîNH), 51.97 (CHj), 57.58 (CHNH), 65.67 (CHaPh), 127.74, 127.94, 128.04, 
128.16, 134.21 (aromatics). 169.65 and 172.26 (2 x COO).
8.57 Synthesis of carbobenzyloxyglycinyl valine.818
HN
HN 1. NaOH, MeOH
2. HCl
(49)(48)
A solution of carbobenzyoxyglycinyl valine methyl ester (Reaction 8.56, 2.0 g, 
6.24 mmol) in methanol (24 cm^) was surrounded by a water bath at room 
temperature and IM NaOH (24 cm^) added. The mixture was stirred at room 
temperature for 2 hours. Dilute HCl (24 cm ,^ IM) was added and the methanol 
was removed under reduced pressure. The aqueous solution was cooled to 0 °C 
and stirred dui'ing acidification to pH 2 (approximately 16 cm  ^ of IM HCl was 
required). The mixture was stirred at 0 °C for 2 hours and the resulting precipitate 
was filtered, washed with water and dried over P2O5 to give 
carbobenzyloxyglycinyl valine (49) as a white solid (1.52 g, 79%), m.p. 148 - 150 
°C (Lit.""" 146 X ). ÔH (200 MHz, "Hô-DMSO) 0.9 (6H, m, C H (Œ )2), 2.1 (IH,
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tn, CH(Cni)2), 3.7 (2H, s, CH2NHZ), 4.2 (IH, t, J = 7.6 Hz, CHNH), 5.05 (2H, 
s, CHzPh) and 7.4 - 7.8 (5H, m, aromatics); 6c (200 MHz, %-DM SO) 18.16, 
19.35 {CXUCHih), 30.28 (CH(CH3)2), 41.9 (CH2NH), 57.30 (CHNH), 65.66 
(CH2PI1), 127.84,127.97,128.02, 128.59, 135.02 (aromatics), 169.47 and 173.15 
( 2 x 0 0 0 .
8.58 Synthesis of 2-[(benzyloxycarbonylamino)methyl]-4-isopropyl-5-oxo-3- 
oxazolin-2-propanoic acid ethyl ester.®^ *
HN
1. AC2O
2. ethyl aciylate, EtgN
(49) (50)
Carbobenzyloxyglycinyl valine (Reaction 8.57, 1.5 g, 2 mmol) was warmed to 80 
°C for 50 minutes in acetic anhydride (3.75 cm^). The solvent was then removed 
under reduced pressure, using toluene (10 cm  ^x 3) as an azeotrope. The resulting 
orange oil was mixed with freshly distilled ethyl acrylate (3.75 cm^) and 
triethylamine (0.7 cm^) was added dropwise with vigorous stirring at -10 °C. The 
mixture was allowed to warm to room temperature and was stirred at 50 °C for 5 
days. The solvent was removed under reduced pressure and the residue was 
purified using a polyamide (poly[dimer acid-co-alkyl] polyamine Tm 95 °C d = 
0.970) column using 40:60 petroleum ether (150 cm^) as the eluant. The solvent 
was passed through the column repeatedly for 12 hours resulting in the orange
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colour remaming on the column. The solvent was removed under reduced 
pressure giving 2-[(benzyloxycarbonylamino)methyl]-4“isopropyl-5-oxo-3- 
oxazolin-2-propanoic acid ethyl ester (50) as an ofiF white coloured solid (1.21 g, 
62%), m.p. 60 - 62 °C (Lit.®^ * 58 - 61 °C). 8» (200 MHz, %-DM SO) 1.0 - 1.4 
(9H, m, CH)), 1.7 - 1.9 (2H, m, CHj), 2.1 - 2.4 (4H, m, 2 x CH:), 2.6 - 2.8 (IH, 
m, CH), 3.4 - 3.5 (2H, m, CH,), 5.0 (2H, s, CH^Ph) and 7.2 - 7.4 (5H, m, 
aromatics); 8 c (50 MHz, % 6-DMSO) 15.90 (CH2CH3), 19.56 , 19.65 
(CH(C%)2), 32.86 , 34.92 (C ftC ftC O ), 45.01 (CH(CH3)2), 51.08 (NHCftC), 
65.68, 65.78 (CHaPh and CH2CH3), 71.11 (NCO), 133.20, 133.32, 133.47, 
133.99, 136.96 (aromatics), 141.02 (CCH(CH3);), 155.97 (COOCH2) and 166.14 
(CCOOC).
8.59 Synthesis of carbobenzyoxy-5-aminolevulinic acid ethyl ester.*“
(51)(50)
2 -[(Ben2yloxycarbonylamino)methyl]-4 -isopropyl-5 -oxo“3 -oxazolin-2 -propanoic 
acid ethyl ester (Reaction 8.58, 1 g, 2.56 mmol) was stirred in ethanol (20 cm^) 
and saturated sodium bicarbonate solution (20 cm^) at 60 °C over antibumping 
granules for 36 hours. The organic solvent was removed under reduced pressure
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and the mixture was extracted with DCM (2 x 25 cm^). The extracts were dried 
(MgS0 4 ), filtered and concentrated under reduced pressure to give 
carbobenzyloxy 5-aminolevulinic acid ethyl ester (51) as a fight brown coloured 
solid (0.26 g, 35%), m.p. 59 - 61 °C (Lit.®'  ^58.5 °C). Ôh (200 MHz, C^HCh) 1.2 
(3H, t, J = 7.2 Hz, CH3), 2.5 - 2.9 (4H, m, C0 C76Cj%C0 ), 4.1 - 4.3 (4H, m, 
CJT2NH and C7 6 CH3), 5.1 (2H, s, CHgPh), 5.4 (IH, s, NH) and 7.4 - 7.6 (5H, m, 
aromatics) ; ôc (50 MHz, C^HCb) 14.62 (CH2CH5), 29.86(Œ COO), 32.41 
(COCH2CH2), 43.36 (COCH2NH), 60.01 (CH2CH3), 65.52 (CH2?h), 127.42, 
127.90, 128,92 (aromatics), 156.24 (COOCH2), 172.04 (CO;Et) and 204.06 
(COCH2CH2).
8.60 Attempted synthesis of 5-aminolevufinic acid ethyl ester.
CO2CH2CH3
Ho. Pd/C
CO2CH2CH3 CH3CH2O2C,\
(47)
•CO2CH2CH3
Carbobenzyloxy-5-aminolevufinic acid ethyl ester (Reaction 8.59, 0.2 g, 0.68 
mmol) was dissolved in methanol (10 cm^). 10% Pd/C catalyst (100 mg) was 
added and the mixture was stirred under an atmosphere of H2 at room 
temperature and atmospheric pressure for 6 hours. The catalyst was removed by 
filtration through Cefite and the methanol was removed under reduced pressure 
leaving a pale yellow coloured oil. NMR data suggested the formation of 2,5-di-
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(P-carboxyethyl) pyrazine diethyl ester (47) and not the required product. Data as 
for Reaction 8.55.
8,61 Synthesis of 5-aminolevulinic acid ethyl ester. (ALA-OEt).®^^
HO2C
^ EtOH, SOCI2
NH2.HCI --------►
(46)
NH2.HCI
An excess of ethanol (3 cm^) was cooled to 0 °C. Thionyl chloride (0.5 cm ,^ 6.85 
mmol) was added dropwise followed by ALA.HC1 (Reaction 8.15» 0.5 g, 3.0 
mmol). The mixture was heated to 70 °C for approximately 15 minutes until a 
solution formed and then for a Anther 10 minutes. After cooling to room 
temperature, the solvent was removed under reduced pressure. The resulting 
mixture was dissolved in a small amount of warm ethanol (approximately 5 cm^). 
Diethyl ether (10 cm^) was added and the mixture was cooled to 0 °C overnight. 
The resulting white crystals of 5-aminolevulinic acid ethyl ester (46) were 
collected on a sinter (0,32 g, 58%), m.p. 105 - 107 °C. 6h (200 MHz, C^HaO^H)
1.3 (3H, t, J = 7.1 Hz, CHa), 2.6 (2H, m, C%COz), 2.8 (2H, m, COC^CHz) and 
4.0 - 4.2 (4H, m, NHaCiT  ^ and C%CHa); Ôc (50 MHz, C^HaO^H) 14.77 (CHa),
28.89 (CH2COO), 35.63 (C O Œ 2CH2), 49.85 (NH2CH2), 62.16 (CH2CH3), 
174.45 (COO) and 203.4 (CO).
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8.62 Synthesis of 5-aminolevulinic acid hexyl ester (ALA-OHex),829
HO2C
O hejanoL,SOCI2
(3) ^
An excess of hexanol (3 cm^) was cooled to 0 °C. Thionyl chloride (0.5 cm ,^ 6.85 
mmol) was added dropwise followed by ALA.HCl (Reaction 8.15, 0.5 g, 3.0 
mmol). The mixture was heated to 70 and stirred for approximately 30 minutes 
until a solution formed. After a further 10 minutes the mixture was cooled to 
room temperature. Excess hexanol was removed by silica gel flash column 
chromatography using acetone (100 cm^) and then methanol (150 cm^) as the 
eluant. Fractions of methanol containing the product were evaporated under 
reduced pressure. The resulting mixture was dissolved in a small quantity of warm 
methanol (5 cm^) and diethyl ether (10 cm^) was added causing a white precipitate 
to form. After 12 hours at 0 °C the white crystals of 5-aminolevulinic acid hexyl 
ester (52) were collected on a sinter (0,51 g, 6 8 %), m.p. 100 -102 °C. ôh (200 
MHz, C'HsO^H) 1.0 (3H, m, CH3), 1.4 (6 H, m, 3 x CHg-Hex), 1.6 (2H, m, CH2- 
Hex), 2.6 (2H, m, CH2CO2), 2.8 (2H, m, COCH2CB2 ) and 4,1 (4H, m, NH2C/ 6  
and CH2-Hex); ôc (50 MHz, C^HaO^H) 14.69 (CH3), 23.92 (CHa-Hex), 26.97 
(CH2-Hex), 28.29 (CHa-Hex), 28.83 (C%COO), 29.96 (CHa-Hex), 32.91 (CHa- 
Hex), 35.68 (COC^CHa), 48.01 (NH2CH2), 66.29 (CH2COO), 174.55 (COO) 
and 204.16 (CO).
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8.63 Synthesis of 5-aminolevnlinic acid benzyl ester (ALA-OBn).829
o
H02C NHj-HCI-
(3)
BnOH,SOCI2 NH2.HCI
5-Aminolevulinic acid benzyl ester (53) was prepared using the same method as 
for 5-aminolevulinic acid hexyl ester (Reaction 8.62) but using an excess of 
freshly distilled benzyl alcohol (3 cm^), yielding the product (53) as a white solid 
(0.52 g, 67%), m.p. I l l  - 113 X . Ôh (200 MHz, C % 0 "H) 2.7 (2H, m, 
CH2COO), 2.9 (2H, m, COŒ6 CH2), 4.0 (2H, s, NH2CF2), 5.2 (2H, s, CHzPh) 
and 7.4 (5H, m, aromatics); ôc (50 MHz, C^HsO^H) 28.86 (C%COO), 35.59 
(C0 C%CH2), 48.0 (NH2CH2), 67.85 (CH2?h), 129.44, 129.84 (aromatics), 
174.18 (COO) and 202.16 (CO).
8.64 Synthesis of carbobenzyloxyglycinyl 5-aminolevulinic acid benzyl ester.818
(53)
o
cq%H
(55)
5-Aminolevulinic acid benzyl ester (Reaction 8.63, 0.5 g, 1.94 mmol) was 
dissolved in DCM (10 cm^) at 0 °C. Carbobenzyoxyglycine (0.41 g, 1.94 mmol)
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and CHME (0.82 g, 1.94 mmol) were added and the mixture was allowed to 
warm to room temperature overnight. The resulting reaction mixture was then 
cooled to 0 °C, filtered to remove any urea produced, washed with water, citric 
acid (IM), saturated sodium bicarbonate solution and then water (50 cm^  of each) 
and dried (MgS04). Filtration followed by evaporation under reduced pressure 
yielded carbobenzyloxyglycinyl 5-aminolevulinic acid benzyl ester (54) as a white 
solid (0.52 g, 65%), m.p. 100 - 102 °C. m/z (EC) 412 (MT). A correct elemental 
analysis could not be obtained due to the product being contaminated with a small 
amount (<5%) of piperadine-2,5-dione (55). NMR spectroscopy identifies two 
products: carbobenzyloxyglycinyl 5-aminolevulinic acid benzyl ester (54); 6h (200 
MHz, C^HCU) 2.5 (2H, m, C/fcCOO), 2,8 (2H, m, COCftCHs), 3.9 (2H, m, 
NH2CH2), 4.2 (2H, m, NHCH2COCH2), 5.0, 5.1 (4H, 2 x s, 2 x CH2PI1), 5.6 (IH, 
bs, NH), 6.8 (IH, bs, NH) and 7.3 - 7.5 (lOH, m, 2 x Ph); 8c (50 MHz, (fHCb) 
28.31 (CH2COO), 34.96 (COCH2CH2), 44.79 (NHCttCONH), 49.52 
(NHCH2COCH2CH2), 67.22, 67.75 (2 x CftPh), 128.51, 128.74, 128.62, 
129.11, 135.10 (aromatics), 156.61 (NHCOO) 169.67 (NHCH2CO), 172.74 
(CH2COOCH2) and 204.09 (COCH2CH2). Piperadine-2,5-dione (55); 8» (200 
MHz, C^HCb) 2.7 (4H, m, 2 x CH2), 4.0 (2H, d, J = 3 Hz, CH;) and 7.1 (IH, m, 
NH); 8c (50 MHz, C^HClj) 28.15 (CH;), 30.21 (CH;), 51.31 (CH;), 154.57 and
204.62 (2 X  CO).
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8,65 Alternative synthesis of carbobenzyloxyglycinyl 5-aminolevulinic acid 
benzyl ester,^ *®
0(53)
o
NMM, m e 
THF, DMF 
Et,N
•CO^H
N'
(54)
A solution of 5-aminolevulinic acid benzyl ester (Reaction 8.63, Ig, 3.9 mmol) in 
dry DMF (7.8 cm^) was treated with triethylamine (0.54 cm \ 0.39 g, 3.9 mmol). 
A solution of carbobenzyloxyglycine (0.81 g, 3.9 mmol) in dry THF (20 cm^) was 
cooled to -15 °C. Isobutyl chloroformate (0.51 cm ,^ 10 mmol) and N-methyl 
morpholine (0.43 cm \ 10 mol) were added followed by, 3 minutes later, the 5- 
aminolevuhmc acid benzyl ester solution. The mixture was allowed to warm to 
room temperature overnight and was then filtered to remove the hydrochloride 
salts. These were washed with THF and the combined THF fractions were 
concentrated under reduced pressure to approximately 10 cm .^ Water was added 
but, after cooHng to 0 °C, no crystals precipitated out. The mixture was extracted 
into DCM (100 cm^), washed with water, potassium hydrogen carbonate solution 
(0.5M) then water (100 cm  ^of each), dried (MgS0 4 ), filtered and concentrated 
under reduced pressure to give carbobenzyloxyglycinyl 5-aminolevulinic acid 
benzyl ester (54) as a brown oil (0.14 g, 17.5%). Data as for Reaction 8.64.
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8.66 Attempted synthesis o f glycinyl 5-aminolevulinic acid.818
1
Ô (54)
%Pd/C
MeOH
NH
HN
Carbobenzyloxyglycinyl 5-aminolevulinic acid benzyl ester (Reaction 8.64, 0.4 g, 
0.97 mmol) was dissolved in methanol (15 cm^). 10% Pd/C catalyst (100 mg) was 
added and the mixture was stirred under an atmosphere of Ha at atmospheric 
pressure and room temperature for 10 hours. The catalyst was removed by 
filtration through Celite and the methanol was removed under reduced pressure 
giving a white solid which, from NMR data, was not the required product.
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8.67 Synthesis of t-butoxycarbonylglycinyl 5-aminolevulinic acid ethyl ester.
(56)CHME, DCM
(55)
HC1.B
(46) H
t-Butoxycarbonylglycinyl 5-aminolevulinic acid ethyl ester (56) was prepared by a 
CHME coupling reaction using the same procedure as for carbobenzyloxyglycinyl 
5-aminolevulinic acid benzyl ester (Reaction 8.64) but using t- 
butoxycarbonylglycine (Reaction 8.34, 0.44 g, 2.5 mmol) and 5-aminolevulinic 
acid ethyl ester (Reaction 8.61, 0.5 g, 2.5 mmol), yielding the product (56) as a 
white solid (0.24 g, 31%), m.p. 92 - 94 °C. m/z (EC) 316 (M^). A correct 
elemental analysis could not be obtained due to the product being contaminated 
with a small amount (<5%) of piperadine-2,5-dione (55). NMR spectroscopy 
identifies the two products: t-butoxycarbonylglycinyl 5-aminolevulinic acid ethyl 
ester (56); Ôh (200 MHz, C^HCh) 1.3 (3H, m, CHa), 1.5 (9H, s, 3 x CHa-Boc),
2.7 (4H, m, CH2CH2CO2), 3.8 (2H, d, NHC76), 4.1 (2H, m, CHg), 4.2 (2H, d, J =
4.8 Hz, NHCH2) and 5.1 (IH, s, C/f(CH3)3); 6c (50 MHz, C^HCh) 14.77 
(CH2C%) 28.77 (3 x CH3-B0 C), 34.95 (COCT^CHa), 35.82 (CH2CH3), 44.56 
(NHC76CONH), 157.12 (CO-Boc), 170.25, 172.72,(CONH and COO) and 
204.21 (CO-ALA). Piperadine-2,5-dione (55); Data as for Reaction 8.64.
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8.68 Synthesis o f glycinyl 5~aminolevulimc acid ethyl ester.
O O
.O,
O (56)
N ^ O  HO
HQ gas, EtOAc
(57) H(55)
t-Butoxycarbonylglycinyl 5-aminolevulinic acid ethyl ester (Reaction 8.67, 0.2 g, 
0.65 mmol) was dissolved in ethyl acetate (10 cm^) and cooled to 0 °C. HCl gas 
was bubbled through the solution for 30 minutes then the mixture was stirred for 
1 hour. Nz gas was bubbled through the solution to remove any excess HCl and 
the solvent was removed under reduced pressure giving glycinyl 5-aminolevulinic 
acid ethyl ester (57) as a clear oil (0.16 g, 94%). m/z (E r) 216 (M^ - HCl salt). A 
correct elemental analysis could not be obtained due to the product being 
contaminated with a small amount (<5%) of piperadine-2,5-dione (56), NMR 
spectroscopy identifies two products: glycinyl 5-aminolevulinic acid ethyl ester 
(57); 8 h  (200 MHz, CPHCk) 1.3 (3H, m, CH;), 2.5 (2H, m, CHjCOO), 2.7 (2H, 
m, COCftCHj), 3.9 (2H, d, NHCft), 4.1 (2H, m, CH;) and 4.3 (2H, d, J = 4.8 
Hz, NHCift); 5c (50 MHz, C^HCk) 14.92 (CH;Cffi), 34.72, 35.91 (COCHjCH; 
and CH2CH3), 45.12 (NHCftCONH), 170.36, 173.14 (CONH and COO) and 
203,96 (CO-ALA). Piperadine-2,5-dione (55); Data as for Reaction 8.64.
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8.69 Synthesis of carbobenzyloxyglycine (Z-Gly),818
(58)Na0H,H20 (5Î
A solution of glycine (11.1 g, 0.1 mol) in 2 M NaOH (50 cm^) was cooled in an 
ice/water bath and stirred. Benzyl chloroformate (18.7 g, 15,8 cm ,^ 0.11 mol) and 
2M NaOH (55 cm^) were added in ten alternating portions, ensuring the pH 
remained alkaline throughout, and the temperature was kept between 5 and 10 °C. 
The mixture was stirred vigorously at room temperature for 30 minutes before the 
alkaline solution was extracted four times with diethyl ether (4 x 50 cm^). The 
diethyl ether extracts were discarded and diethyl ether remaining in the aqueous 
layer was removed by bubbling a stream of Na through the solution. The mixture 
was acidified using 5 M HCl (22 cm^) causing a precipitate to form. This product 
was filtered, washed with water and dried under reduced pressure at room 
temperature yielding carbobenzyloxyglycine (58) as a white solid (12.2 g, 58%), 
m.p. 122 - 123 °C (Lit.*^ ® 120 °C). Ôh (300 MHz, %-DMSO) 3.6 (2H, d, J = 8.1 
Hz, CH2), 5.0 (2H, s, CH2), 7.3 (4H, m, aromatics) and 7.5 (IH, t, J = 7.3 Hz, 
NH); ÔC (75 MHz, ^Hg-DMSO) 37.21 (CH2), 60.62 (CH2), 122.92, 123.02,
123.57, 132.26 (aromatics), 151.77 (C=0) and 166.85 (C=0).
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8.70 Synthesis of carbobenzyloxy-L-phenylalanme (Z-L-Phe).818
COoH C^) COoH
fl nh= NHj-HCl
NaOH, H .0
Carbobenzyloxy-L-phenylalanine (59) was prepared using the same method as for 
carbobenzyloxyglycine (Reaction 8.70) using L-phenylalanine (16.5 g, 0.1 mol) 
yielding the product (59) as a white solid (19.4 g, 65%), m.p. 100 - 102 °C 
(Lit.“ “ 103 °C). 8h  (200 MHz/%-DMSO) 3.2 (2H, m, Ph-CHj), 4.2 (IH, m, 
CH), 5.0 (2H, s, 0 CH2?h), 7.3 (lOH, m, 2 x aromatics) and 7.6 (IH, d, J ~ 8.7 
Hz. NH); 5c (50 MHz, ^Hs-DMSO) 36.82 (PhCHj), 56.14 (CH), 65.55 (CHjO),
126.58, 127.76, 127.96, 128.39, 128.56, 129.40, 137.32, 138.37 (aromatics),
156.23 (COO) and 173.76 (CO).
8.71 Synthesis of carbobenzyloxy-D-phenylalanine (Z-D-Phe) 818
Carbobenzyloxy-D-phenylalanine (60) was prepared using the same method as for 
carbobenzylojQ^glycme (Reaction 8.70) using D-phenylalanine (16.5 g, 0.1 mol) 
yielding the product (60) as a white solid (16.5 g, 55%), m.p. 98 - 100 °C (Lit.^ ^® 
103 °C). Data as for Reaction 8.70.
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8.72 Synthesis of carbobenzyloxyglycinyl 5-aminolevulinic acid ethyl ester (Z-
Gly-ALA-OEt) (ALAI).
O
HCI.H2N.
•CO^HDCM,CHME
(58)
o
H (55)(61)
Carbobenzyloxyglycinyl 5-aminolevulinic acid ethyl ester (61) was prepared by a 
CHME coupling using the same procedure as for carbobenzyloxyglycinyl 5- 
aminolevulinic acid benzyl ester (Reaction 8.64) but using 5-aminolevulinic acid 
ethyl ester (Reaction 8.61, 0.38 g, 1.94 mmol), yielding the product (61) as a 
white solid (0.32 g, 49%), m.p. 8 8 - 90 °C. m/z (E t)  350 (IVT). A correct 
elemental analysis could not be obtained due to the product being contaminated 
with a small quantity (<5%) of piperadine-2,5-dione (55). NMR spectroscopty 
identifies two products: carbobenzyloxyglycinyl 5-aminolevulinic acid ethyl ester 
(61);Ôh (200 MHz, C'HCk) 1.2 (3H, t, J = 7.7 Hz, CH3), 2.7 (4H, m, 
COCH2CH3), 3.9 (2H, m, CH2), 4.1 (4H, m, 2 x CH2), 5.1 (2H, s, CH2PI1), 5.6 
(IH, bs, NH), 6 .8  (IH, bs, NH) and 7.4 (5H, m, aromatics.); ôc (50 MHz, 
C^HClj) 14.68 (CHs), 28.34 (CftCOO), 34.99 (COCftCHjCO), 44.83 
(NHCftCONH), 49.41 (NHCftCOCHz), 61.41 (C^CH ;), 67.74 (PhCH;),
128.46, 128.70, 128.89, 129.03 (aromatics), 157.12 (CHjOCONH), 169.68
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(CONH), 172.91 (COO) and 204.15 (NHCH2COCH2). Piperadine-2,5-dione 
(55); Data as for Reaction 8.64.
8.73 Synthesis of carbobenzyloxy-L-phenylalanyl 5-aminolevulinic acid ethyl 
ester (Z-L-Phe-ALA-OEt) (ALA2).
O
HCLH2N,
(46) O
DCM,CHME
CO,H
(62)
Carbobenzyoxy-L-phenylalanyl 5-aminolevulinic acid ethyl ester (62) was 
prepared by a CHME coupling reaction using the same procedure as for 
carbobenzyloxyglycinyl 5-aminolevulinic acid benzyl ester (Reaction 8.64) using 
carbobenzyloxy-L-phenylalanine (Reaction 8.70, 0.58 g, 1.94 mmol) and 5- 
aminolevulinic acid ethyl ester (Reaction 8.61, 0.38 g, 1.94 mmol), yielding the 
product (62) as a white solid (0.46 g, 54%), m.p. 110 - 111 °C. m/z (EE) 440
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(M^). Found: C, 65.1; H, 6.3; N, 6.4; Calculated for C24H2&N2O6: C, 65.4; H, 6.4; 
N, 6.4%. Sh (200 MHz, C^HCls) 1.1 (3H, t, J = 7.7 Hz, CH3), 2.3 (2H, m, 
CHCftPh), 2.5 (4H, m, COCftCftCO), 3.8 (2H, d, NHCft), 4.0 (2H, m, CH2),
4.3 (IH, m, OH), 5.0 (2H, s, CmPh), 5.6 (IH, bs, NH), 6 .8  (IH, bs, NH) and 7.2 
(lOH, m, 2 X aromatics); 6 c  (50 MHz, C^HCb) 14.31 (CH3), 28.29 (CH2COO),
34.99 (COC%CH;CO), 38.91 (CHCffjPh), 49.46 (NHCH2COCH2), 56.41 (CH), 
61.50 (C/6 CH3), 67.51 (PhCHzO), 127.47, 128.18, 128.44, 128.68, 129.00, 
129.11, 129.46, 129.76, 136.63, 136.86 (2 x aromatics), 156.53 (CONHCH),
171.86 (CHCONHCH2), 173.37 (COOEt) and 204.06 (NHCH2COCH2).
8.74 Synthesis of carbobenzyloxy-D-phenylalanyl 5-aniinolevulmic acid ethyl 
ester (Z-D-Phe-ALA-OEt) (ALAI 1).
o
HCI.H2N.
(46) o
DCM, CHME
ÇOjFI
(60)
(63)
- X
H
(55)
Carbobenzyloxy-D-phenylalanyl 5-aminolevulinic acid ethyl ester (63) was 
prepared by a CHME coupling procedure using the same procedure as for 
carbobenzyloxyglycinyl 5-aminolevulinic acid benzyl ester (Reaction 8.64) but
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using carboben2yloxy-D-phenylalanine (Reaction 8.71, 0.58 g, 1.94 mmol) and 5- 
aminolevulinic acid ethyl ester (Reaction 8.61, 0.38 g, 1.94 mmol), yielding the 
product (63) as a white solid (0.41 g, 48%), m.p. 108 - 1 1 0  °C. m/z (EC) 440 
(M^). A correct elemental analysis could not be obtained as the product was 
contaminated with a small quantity (<5%) of piperadine-2.5-dione (55). NMR 
spectroscopy identifies two products: carbobenzyloxy-D-phenylalanyl 5-
aminolevulinic acid ethyl ester; ôh (200 MHz, C^HCb) 1.2 (3H, t, J = 7.7 Hz, 
CHs), 2.3 (2H, m, CHC%Ph), 2.6 (4H, m, COCH2CH2CO), 3.7 (2H, s, NHŒ 6 ),
4.1 (2H, m, CH2), 4.5 (IH, m, CH), 5.1 (2H, s, 0 CH2Ph), 5.4 (IH, bs, NH), 6 .6  
(IH, bs, NH) and 7.3 (lOH, m, 2 x aromatics); ôc (50 MHz, C^HCb) 14.08 
(CH3), 28.03 (C%COO), 34.95 (COC/72CH2), 38.85 (CHC/^Ph), 49.45 
(NHŒ6 COCH2), 56.65 (CH), 60.39 (C^CHs), 67.56 (PhC%OCO), 127.59,
128.54, 128.87, 129.03, 129.48, 129.93, 136.68, 136.72 (2 x aromatics), 155.41 
(OCONHCH), 171.56 (CONHCH2CO), 173.06 (COOEt) and 203.70 
(NHCOCH2CH2). Piperidine-2,5-dione (55); Data as for Reaction 8.64.
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8.75 Synthesis of carbobenzyloxyglycinyl 5-aminolevulinic acid hexyl ester (Z-
Gly-ALA-OHex) (ALAIO).
HCI.H2N.
(CHz)^
o
K K C H » ,
(64)
o.
Carbobenzyloxyglycinyl 5-aminolevulinic acid hexyl ester (64) was prepared by a 
CHME coupling reaction using the same procedure as for carbobenzyloxyglycinyl 
5-aminolevulinic acid benzyl ester (Reaction 8.64) but using 5-aminolevulinic acid 
hexyl ester (Reaction 8.62, 0.25 g, 0.9 mmol), yielding the product (64) as a white 
solid (0.20 g, 53%), m.p. 82 - 84 °C. m/z (EC) 406 (M"). Found: C, 62.2; H, 7.4; 
N, 6 .8 ; Calculated for C21H30N2O6: C, 62.1; H, 7.4; N, 6.9%. Ôh (200 MHz, 
CHCI3) 0 .9  (3H, t, CH3), 1.3 (4H, m, 2 X CHa), 3.9 (2H, d, C%), 4.1 (2H, t, 
CHj), 4.2 (2H, d, CH2), 5.2 (2H, s, CH2PI1), 5.6 (IH, bs, NH), 6 .8  (IH, bs, NH) 
and 7.4 (5H, m, aromatics); Sc (50 MHz, CfHCb) 14.21 (CH3), 23.02 (CH2CH3), 
26.02 (CH2-Hex), 28.29 (CHz-Hex), 28.98 (CftCOO), 31.89 (CH2-Hex), 35.00 
(COCH2CH2), 44.85 (NHCftCONH), 49.53 (NHCH2COCH2), 65.66 
(PhCHjOCO), 67.76 (COOCH2CH2), 128.58, 128.62, 128.76, 128.86, 129.06 
(aromatics), 157.14 (OCONHCH2), 169.63 (NHCH2CONH), 173.03 (COOHex) 
and 204.21 (COCH2CH2CO).
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8.76 Synthesis of phthalimidolevulinic acid (ALA4).831
6MHC^
1 hour
O (4) (9)
Methyl 5-phthalimidolevulinate (Reaction 8 .6 , 0.5 g, 1.8 mmol) was heated under 
reflux conditions in 6M HCl (5 cm^). The solid dissolved slowly over 30 minutes. 
After 1 hour the mixture was cooled to room temperature, refridgerated overnight 
and the resulting solid was filtered off, dried and recrystaUised from water to give 
phthalimidolevulinic acid (9) as white crystals (0.22 g, 47%). Data as for Reaction 
8.14.
8.77 Synthesis of2-amino-2-deoxy-N-anisylidene-p-D-glucopyranose.
OH
832
CHO HO-
OH
HO— J---------
-O
HO-
-O
N OH
NH2.HCI OH
NaOH, H2O (65)
OMe
Glucosamine hydrochloride (10 g, 47 mmol), IM NaOH solution (47 cm ,^ 47 
mmol) and p-anisaldehyde (5.7 cm ,^ 6.37 g, 47 mmol) were shaken vigorously. 
After 10 minutes a white precipitate formed and the mixture was cooled to 0 °C 
for 30 minutes. The solid was filtered off, washed with ice cold water, then ice 
cold diethyl ether and dried thoroughly yielding 2-amino-2-deoxy-N-anisylidene-
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p-D-glucopyranose (65) as a white soHd (11.5 g, 83%), m.p. 158-161 °C (Lit.^ ^^  
166 °C). ÔH (200MHz, % -DM SO) 2.8 (IH, t, J = 8  Hz, 2-H), 3.2 (IH, m, 5-H),
3.8 (3H, s, OCHs), 4.5 (IH, t, J = 8.5 Hz, 4-H), 4.6 (IH, t, J = 8.5 Hz, 3-H), 4.8 
(IH, d, J = 8.0 Hz, 6  or 6 ’-H), 4.9 (IH, d, J = 8.0 Hz, 6  or 6 ’-H), 6.5 (IH, s, 1- 
H), 7.0 (2H, d, J = 10.0 Hz, aromatics), 7.6 (2H, d, J = 10.0 Hz, aromatics) and
8.1 (IH, s, N=CH); ôc (50 MHz, % -DM SO) 55.54 (OCH3), 61.51 (C2), 70.60, 
74.83, 77.10, 78.43 (C3-C6), 95.88 (Cl), 114.17, 115.25, 129.90, 130.65 
(aromatics) and 161.55 (N=CH).
8.78 Synthesis of 1,3,4,6-tetra-0-acetyl-2-amino-2-deoxy-N-anisyl-P-D- 
glucopyranose.^^^
OAc
AcO
AcO
OH OAc
pyridine
acetic anhydride ^
OMe OMe
2-Amino-2-deoxy-N-anisyhdene-p-D-glucopyranose (Reaction 8.77, 11.2 g, 37.8 
mmol) was dissolved in dry pyridine and cooled to 0 °C. Acetic anhydride (35 
cm ,^ 37.8 mmol) was added and the mixture was stirred at room temperature 
overnight then poured onto ice and stirred. The resulting precipitate was filtered, 
dried and recrystallised from ethanol yielding 1,3,4,6-tetra-0-acetyl-2-amino-2- 
deoxy-N-anisyl-p-D-glucopyranose (66) as white crystals (11.2 g, 64%), ra.p. 189
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- 190 °C (Lit.*’  ^188 °C). ÔH (200 MHz, C^HCla) 1.8 - 2.0 (12H, m, 4 x COCK,),
3.8 (3H, s, OCH3), 4.0 (IH, t, J = 9.3 Hz, 2-H), 4.2 (IH, m, 5-H), 4.3 (2H, m, 6 
and 6’-H), 5.0 (IH, t, J = 9.3 Hz, 3 or 4-H), 5.4 (IH, t, J = 9.3 Hz, 3 or 4-H), 6.0 
(IH, d, J = 9.3 Hz, 1-H), 7.0 (2H, m, aromatics), 7.6 (2H, m, aromatics) and 8.2 
(IH, s, N=CH); 8c (50 MHz, C^HCb) 18.95, 21.03, 21.21, 21.33 (4 x COCHs),
55.92 (OCH3), 62.30 (C2), 68.48, 73.22, 73.43, 73.72 (C3-C6), 93.63 (Cl), 
114.56, 115.12, 128.72, 130.78 (aromatics), 164.89 (N=CH), 169.23, 169.65, 
170.14 and 170.79 (4 x COCH3).
8.79 Synthesis of 1,3,4,6"tetra-0-acetyl-2-amino-2-deoxy-p-D-glucopyranose 
hydrochloride.^^^
OAc
AcO
AcO
O , OAcacetone,
water, c-HCI AcO OAc ----------^
AcO
NH2.HCI OAc
(67)
OMe
1,3,4,6-Tetra-o-acetyl-2-amino-2“deoxy-N-anisyl-p-D-glucopyranose (Reaction
8.78, 6 g, 0.01 mol) was dissolved in the minimum amount of hot acetone 
(approximately 20 cm^). A small quantity of water (1 cm^) was added and the 
mixture was cooled to 0 °C. c-HCl (5 cm^) was added dropwise until a precipitate 
appeared. The mixture was washed at 0 °C with diethyl ether to remove the 
anisaldehyde, filtered, and washed with ice cold diethyl ether to give 1,3,4,6-tetra-
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0-acetyl-2-amino-2“deoxy-p-D-glucopyranose hydrochloride (67) as a white solid 
(4.4 g, 87%), m.p. 222 - 224 °C (dec.) (Lit.*”  230 °C (dec.)). 5h (200 MHz, 
% 0 )  2.0 - 2.2 (12H, m, 4 X COCH3), 3.8 (IH, t, J = 10.6 Hz, 2-H), 4.3 (3H, m, 
5, 6  and 6 ’-H), 5.2 (IH, t, J = 10.6 Hz, 4-H), 5.4 (IH, t, J = 10.6 Hz, 3-H) and 
6.0 (IH, d, J = 9.1 Hz, 1-H); ôc (50 MHz, ^HsO) 19.85, 23.03, 23.08, 23.21 (4 x 
COCHs), 55.33 (C2), 64.44 (C6 ), 71.01, 73.81, 75.16 (C3-C5), 93.36 (Cl), 
174.2, 175.67, 176.01 and 176.56 (4 x COCH3).
8.80 Synthesis of 1,3,4,6-tetra-0-acetyl-2-amino-2-deoxy-p-D-
glucopyranose
OAc
AcO
AcO
OAc
sodium acetate
AcO
NH2.HCI OAc NH. OAc(67) (68)
1,3,4,6-Tetra-o-acetyl-2- amino- 2- deoxy -p - D- glucopyranose hydrochloride 
(Reaction 8.79, 1.18 g, 2.6 mmol,) was dissolved in water (10 cm^). Sodium 
acetate (0.85 g, 5.2 mmol) was added resulting in the formation of a white 
suspension. This was extracted with DCM (30 cm  ^ x 3), dried (MgS0 4 ) and 
concentrated under reduced pressure to give a white sohd which was 
recrystallised from diethyl ether (0.74 g, 6 8 %), m.p. 144 - 146 °C (Lit.®^  ^143 °C). 
ÔH (200 MHz, C'HCla) 1.9 - 2.2 (12H, m, COCH3), 3.0 (IH, m, 2-H), 4.1 (2H, m, 
5 and 6 -H), 4.2 (IH, dd, J = 13 Hz and 4 Hz, 6 ’-H), 5.0 (IH, m, 4-H), 5.4 (IH, 
m, 3-H) and 5.8 (IH, m, 1-H); ôc (50 MHz, C^HCh) 19.61, 19.71, 19.75, 19.93
209
(4 X COCHs), 54.00 (C2), 60.79 (C6), 67.28, 71.62, 73.96 (C3-C5), 94,07 (Cl), 
168.25, 168.71, 169.65 and 169.70 (4 x COCH3).
8.81 Synthesis of phthalimido-5-ammolevulinyl glucosamine tetraacetate
(Phthal-ALA-Gluc-OAc) (ALA3).
OAc
AcO
AcO
OAcNH
OAc
AcC
(68)
AcO- O (69)
DCM. CHME
Phthalimidolevulinic acid (Reaction 8.14, 0.25 g, 0.96 mmol) was dissolved in 
DCM (20 cm^) and cooled to 0 °C. l,3,4,5-tetra-0-acetyl-2-ammo-2-deoxy-p-D- 
glucopyranose (Reaction 8.80, 0.40 g, 0.96 mmol) and CHME (0.41 g, 0.96 
mmol) were added and the mixture was warmed to room temperature overnight. 
The reaction was cooled to 0 °C and filtered to remove the resulting urea by­
product. The DCM layer was washed with water, IM HCl solution, saturated 
sodium bicarbonate solution and water (50 cm  ^ of each), dried (MgS0 4 ), filtered 
and concentrated under reduced pressure to give a white solid (0.48 g, 76%), 
m,p. 186 - 188 °C (dec.), m/z (EC) 530 (M^ - phthalimide). Elemental analysis on 
sugar derivatives are unreliable as the molecules tend to be very wet. CHN data
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for this compound suggested the presence of water in the molecule. Ôh (200 MHz, 
dH C k) 2.0 (12H, m, 4 X COCHs), 2.4 (2H, m, CH2CO2), 2.9 (2H, m, 
COCT6 CH2), 3.8 (2H, m, CH2), 4.1 (IH, m, 2-H), 4.3 (3H, m, 5,6 and 6 ’-H), 4.5 
(2H, s, NCH2), 5.2 (2H, m, 3 and 4-H), 5.7 (IH, m, NH), 6.2 (IH, m, 1-H) and
7.8 (4H, m, aromatics); 8c (50 MHz, CfHCk) 19.21, 19.92, 21.07, 21.23 (4 x 
COCHi), 29.79 (CH2CONH), 35.14 (COCftCHa), 46.81 (NCH2), 53.26 (C2 ), 
62.21 (C6 ), 68.49, 72.89, 73.11 (C3-C5), 92.83 (Cl), 124.02, 124.36, 133.71,
134.74 (aromatics), 168.05 (NCOPhthal), 169.83, 170.10, 171.22, 171.699,
171.99 (CONH and 4 X COCH3) and 201.02 (CO-ALA).
8.82 Attempted synthesis of 5-aminolevuIinyl glucosamine acetate.
OAc
OAc EtgN, MeOH
Phthalimido-5-aminolevulinyl glucosamine tetraacetate (Reaction 8.81, 0.1 g, 0.14 
mmol) was suspended in dry methanol (5 cm^). Triethylamine (0.02 cm ,^ 0.14 
mmol) and N,N-dimethyl-1,3-propanediamine (0.04 cm ,^ 0.33 mmol) were added 
and the mixture was stirred at room temperature overnight. The mixture was
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separated by column chromatography yielding piperadine~2,5-dione (55) and 
other products but not the required product. Data as for Reaction 8.67.
8.83 Attempted synthesis of 5-aminolevulinyl glucosamine acetate.
OAc
AcO
AcO
1. methanolic hydrazine
A cO
OAc
AcO
-O
NH
2. HCl / ion exchange 0=
-OAc + NaCl
=0
\ NHj.HCl
Phthalimido-5-arninolevulinyl glucosamine acetate (Reaction 8.81, 0.25 g, 0.35 
mmol) was dissolved in methanolic hydrazine (50 cm ,^ 0.2M, 1 g in 100 cm  ^
methanol) with gentle warming. The mixture was stirred at room temperature 
overnight. Excess methanol and hydrazine were removed under reduced pressure 
leaving a white sohd which was purified using ion exchange column 
chromatography (Amberlyst 100, strongly acidic resin). The column was washed 
with water, 0.1, 0.5, 1,0 and 6 M HCl solutions and no product was fovmd. 
Washing with 0.5 M NaOH solution yielded a very small quantity of the required 
product contaminated with a large quantity of NaCl so this approach was 
abandoned.
212
8.84 Attempted synthesis of piperidine-2,5-dione.
CH3CH2O2C,\
NaOMe
MeOHH
N '
(47) \ CO2CH2Œ 3
5-Aminolevulinic acid ethyl ester (Reaction 8,61, 0.25 g, 1.27 mmol) was 
dissolved in a small quantity of methanol (5 cm^). Sodium (0.029 g, 1.27 mmol) 
was added causing a white precipitate of NaCl to form. The mixture was stirred 
for 2 hours, filtered and the solvent removed under reduced pressure to give an 
oily solid. From NMR data the product was 2,5-di-(p-carboxyethyl) pyrazine 
diethyl ester (47) and not the required product. Data as for Reaction 8.55.
8.85 Attempted synthesis of piperidme-2,5-dione
CH3CH2O2C,\
o. NaOMe \
N O MeOH H (47) \ CO2CH2CH3
5-Aminolevulimc acid ethyl ester (Reaction 8.61, 0,2 g, 1.0 mmol) was dissolved 
in a large excess of methanol (200 cm ,^ 1000 fold excess). Sodium (0.023 g, 1.0 
mmol) was added and the mixture was stirred at room temperature for 24 hours. 
The excess methanol was removed under reduced pressure, DCM (20 cm^) was 
added and the mixture was washed with water to remove the NaCl. The organic 
layer was dried (MgS0 4 ), filtered and concentrated under reduced pressure to
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give 2,5-di-(P-carboxyethyi) pyrazine diethyl ester (47) and not the required 
product.
8338 .8 6  Synthesis of 2,5-dihydroxypyridine.
NaOttH^O 
ferrous sulfate.
potassium
N”^  ^OH perojydisulfete ^OH
(70)
2-Hydroxypyridine (3.8 g, 0.04 mol) and sodium hydroxide (8  g, 0.2 mol) were 
dissolved in water (150 cm^). The solution was cooled to 0 °C and ferrous sulfate 
(0 .2  g) dissolved in water (2  cm^) was added causing the mkture to go green. 
Potassium peroxydisulfate (13.5 g, 0.05 mol) was added and the resulting orange 
mixture was stirred at room temperature for 20 hours. The mixture was filtered, 
cooled, acidified to pH 1 by the addition of C-H2SO4. The acidified mixture was 
then hydrolysed at 100 °C for 30 minutes under N2. The red / brown mixture was 
cooled and brought to pH 6  with lOM NaOH solution under N2 and the excess 
water was removed under reduced pressure. The resulting brown solid was dried 
thoroughly over P2O5, then extracted with isopropyl alcohol in a Soxhlet 
apparatus for 8 hours. Decolourising charcoal failed to remove the brown colour 
so the excess solvent was removed under reduced pressure to give a brown solid 
which was recrystallised fi*om ethanol to remove the 2,3 -dihydroxypyridine by­
product. Column chromatography using DCM as the eluant yielded an off white 
solid which darkened upon standing in air. The brown crystals of 2,5- 
dihydroxypyridine (70) were, therefore, used (1.2 g, 27%), m.p. 230 °C (dec.) 
(Lit.'" 230 °C (dec.)). 5h (200 MHz, 'Hs-DMSO) 6.3 (IH, d, J = 9.5 Hz, CH),
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7.0 (IH, d, J = 3.2 Hz, CH) and 7.2 (IH, dd, J = 3.2 and 9.5 Hz, CH) 8c (50 
MHz, 'H s-DMSO) 123.17, 136.99, 138.92, 146.88 and 164.88 (aromatics).
8.87 Synthesis of 2,5-dihydroxypyridine.833,834
NaOHHjO
potassium 
“OH peiojiy disulfate N '
(70)
“OH
2,5-Dihydroxypyridine (70) was prepared using the same method as in Reaction
8.86 but omitting the ferrous sulfate®^ '^  yielding the product (70) as brown crystals 
(2.1 g, 47%). Data as for Reaction 8.86.
8.88 Synthesis of piperadine-2,5-dione. 835
o.
N"
(70)
‘OH
%Pd/C
MeOH
H
(55)
2,5-Dihydroxypyridine (Reaction 8.87, 1.1 g, 10 mmol) was dissolved in methanol 
(150 cm^). 10% Pd/C catalyst (200 mg) was added and the mixture was stirred 
under an atmosphere of Hz at 30 °C and atmospheric pressure for 5 hours. The 
catalyst was removed by filtration through Celite and the solvent was removed 
under reduced pressure. The mixture was purified by silica gel flash column 
chromatography using DCMimethanol 9:1 as the eluant then recrystallised from 
acetonitrile to give piperadine-2,5-dione (55) as an off white solid (0.12 g, 11%), 
m.p. 139 -141 °C (Lit.*" 139 °C). 8» (200 MHz, C^HCL) 2.7 (4H, m, 2 x CH;),
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4.0 (2H, d, J = 3.0 Hz, CHz) and 7.1 (IH, m, NH); ôc (50 MHz, CHCI3) 28.15 
(CH2), 36.21 (CH2), 51.31 (CH2), 174.57 (CO) and 204.62 (CO)
8,89 Attempted synthesis o f N-acetylglycinyl 5-aminolevulinic acid hexyl ester.
CP2(CH2)5CH3 CH3(CH2)$02C, 
,C02(Œ2)5CH3 \
CHME, DCM
A - 0='CO,H (71)
HC1.H2N \ 002(CH2);CH3
(52)
Acetyl glycine (0.12 g, 0.99 mmol) was suspended in DCM (5 cm )^. N-Methyl 
morpholine (0.11 cm^ , 0.1 g, 0.99 mmol) was added along with CHME (0.51 g,
1.2 mmol) at 0 °C and the mixture was stirred for 30 minutes to activate the acid. 
5-Aminolevulinic acid hexyl ester (Reaction 8.62, 0.25 g, 0.99 mmol) was added 
along with another equivalent of N-methyl morpholine (0.11 cm^ , 0.1 g, 0.99 
mmol) and the mixture was allowed to warm to room temperature overnight. The 
mixture was cooled, filtered, washed with brine, IM citric acid solution, saturated 
sodium bicarbonate solution and water (50 cm^  of each), dried (MgS04 ), filtered 
and concentrated under reduced pressure to give a yellow oil which, firom NMR 
data was 2,5-di-(P-carboxyethyl) pyrazine dihexyl ester (71) and not the required 
product. ÔH (200 MHz, CPHCb) 0.9 (3H, m, CH3), 1.2 - 1.4 (6H, m, 3 x CH2- 
Hex), 1.6 (2H, m, CHz-Hex), 2.8 (2H, t, J= 5.1 Hz, CH2C/6 COO), 3.1 (2H, t, J 
= 5.1 Hz, COŒ6 CH2), 4.0 (2H, m, CHz-Hex) and 8.3 (IH, s, aromatic); ôc (50 
MHz, C^ HCla) 14.52 (CH3), 23.46 (CF6 CH3), 28.15 (CHz-Hex), 29.84 (CH2-
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Hex), 31.85 (CftCH), 33.26 (CftCHaCH), 65.21 (CO 2 CH 2 ), 144.02 (aromatic 
CH), 153.41 (NCCH), 173.25 (COO).
8.90 Synthesis of N-acetyl-5-ammolevulic acid benzyl ester. (N-Acetyl-ALA- 
OBn).'"
o
5“Aminolevuliiîic acid benzyl ester (Reaction 8.63, 0.25 g, 0.97 mmol) was 
dissolved in pyridine (5 cm )^ at 0 °C. Freshly distilled acetyl chloride (0.11 g, 0.10 
cm ,^ 1.45 mmol) was added carefiilly, causing a fairly violent reaction and 
formation of an orange solution. The reaction was stirred at room temperatuie 
overnight. Ethyl acetate (50 cm^ ) was added and the mixture was washed with 
water, IM HCl solution, saturated sodium bicarbonate solution and water (50 cm^  
of each), dried (MgS04 ), filtered and concentrated under reduced pressure to give 
sMghtly yellow coloured crystals of N-acetyl-5-aminolevulinic acid benzyl ester 
(72) (0.21 g, 81%), m.p. 76 - 78 °C. Ôh (200 MHz, C^HCh) 2.1 (3H, s, CH3), 2.8 
(4H, m, COCH2CH2CO), 4.2 (2H, d, J = 5.1 Hz, NHCT^), 5.1 (2H, s, CHgPh),
6.3 (IH, bs, NH) and 7.4 (5H, m, Ph); ôc (50 MHz, C^HCb) 23.42 (CH3), 28.31 
(CH 2 COO), 34.94 (COCH2CH2), 49.75 (NHCH2), 67.25 (CH2Ph), 128.49,
128.54, 128.76, 129.13 (aromatics), 170.59 (CH3CO), 172.65 (COO) and 204.78 
(COCH2CH2).
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8.91 Synthesis ofN-acetyl-5~aminolevulinic acid (N-Acetyl-ALA)
g  Î  H2,Pd/C ^
836
CO^ Bn MeOH y
Ô (72) “ 6
N-Acetyl-5-ammolevulmic acid benzyl ester (Reaction 8.90, 0.2 g, 0.76 mmol) 
was dissolved in methanol (10 cm^). 10% Pd/C catalyst (10 mg) was added and 
the mixture was stirred at room temperature and atmospheric pressure, under an 
atmosphere of for 12 hours. The catalyst was removed by filtration through 
Celite and the solvent was removed under reduced pressure yielding N-acetyl-5- 
aminolevulinic acid as a clear oil (0.11 g, 85%). Ôh (200 MHz, C^HsO^H) 2.0 
(3H, s, CHa), 2.6, 2.8 (2 x 2H, 2 x m, COCH2CH2CO) and 4.1 (2H, s, NHCH2); 
ÔC (50 MHz, C^HsO^H) 22.58 (CH3), 29.08 (Œ&COO), 35.72 (COC/6CH2),
49.02 (NHCH2), 173.91 (CH3CO), 177.21 (COO) and 204.12 (COCH2CH2).
8.92 Synthesis of N-butanoyl-5-aminolevulinic acid benzyl ester (N-But-ALA 
OBn).836 I
o o
HCI.H2N.. JL H ^
(53) ^CO^Bn
O
N-Butanoyl-5-aminolevulinic acid benzyl ester (74) was prepared using the same 
method as for N-acetyl-5-aminolevuUnic acid benzyl ester (Reaction 8.90) but 
using freshly distilled butanoyl chloride (0.15 g, 1.45 mmol), yielding the product 
(74) as a slightly yellow coloured oily solid (0.19 g, 68%), m.p. 62 - 63 °C. Ôh 
(200 MHz, C^HCk) 1.0 (3H, t, J =  7.5 Hz, CH;), 1.7 (2H, m, CftCHs), 2.2 (2H,
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t, J = 7.5 Hz, CaCHîCHs), 2.7 (4H, m, COCftCftCO), 4.2 (2H, d, J = 5 Hz. 
CHsNH), 5.2 (2H, s, CHjPh), 6.2 (IH, bs, NH) and 7.4 (5H, m, aromatics); Sc 
(50 MHz, C'HCb) 14.26 (CH3), 19.52 (CH2CH3), 28.33 (CftCOO), 35.06 
(C76CON), 38.74 {COCHi), 49.67 (NHCftCO), 67.14 (CHjPh), 128.38,
128.46, 128.83, 129.05, 136.09 (aromatics), 172.68 (C=0), 173.54 (C=0) and
204.47 (NHCH2COCH2).
8,93 Synthesis of N-butanoyl-5-aminolevulinic acid (N-But-ALA) (ALAI2).836
(74) (75)MeOH 
H., Pd/C
N-Butanoyl-5-aminolevulinic acid (75) was prepared using the same method as 
for N-acetyl-5-arnmolevuîinic acid (Reaction 8.91) but using N-butanoyl-5- 
aminolevuMc acid benzyl ester (Reaction 8.92, 0.15 g, 0.76 mmol), yielding the 
product (75) as an off-white solid (0.11 g, 78%), m.p. 114 - 116 °C. Ôh (200 
MHz, C% 0'H) 0.9 (3H, m, CH3), 1.7 (2H, m, CH2CH3), 2.2 (2H, ra, 
C/Ï2CH2CH3), 2.6 (2H. m. CH2CO2H), 2.8 (2H. m. CH2CH2CO2H) and 4.1 (2H, 
s, NH); 8c (50 MHz, C^HjO^H) 17.04 (CH3), 23.21 (€ % % ), 32.03 
(CftCOO), 38.41 (CffiCON), 41.69 {COCHi), 49.75 (HNCftCO), 179.48 
(CH2CONH), 181.35 (CO2H) and 203.15 (NHCH2COCH2).
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8.94 Synthesis of N-pentanoyl-5-aminolevulinic acid benzyl ester. (N-Pent-
ALA-OBn).*“
\  A  oCl H
OHCI.H2N. JL 'W /  l 
(53) (76)
o
CO^ Bn
N-Pentanoyl-5-aminolevulinic acid benzyl ester (76) was prepared using the same 
method as for N-acetyl-5-aminolevulinic acid benzyl ester (Reaction 8.90) but 
using freshly distilled pentanoyl (valeryl) chloride (0.17 cm^ , 0.17 g, 1.45 mmol), 
yielding the product (76) as a slightly yellow coloured oily solid (0.26 g, 90%), 
m.p. 60 - 62 X . ÔH (200 MHz, C^HCh) 0.9 (3H, t, J = 7.7 Hz, CH3), 1.2 - 1.5 
(2H, m) and 1.5 - 1.8 (2H, m, C%C%CHa), 2.2 (2H, t, J = 7.7 Hz, NCOCH2),
2.8 (4H, m, C 0 CH 2 CH 2 C 0 \  4.2 (2H, d, J = 5.1 Hz, COCH2N), 5.1 (2H, s, 
CHsPh), 6.2 (IH, bs, NH) and 7.4 (5H, m, aromatics); ôc (50 MHz, C^HCb)
14.23 (CH3), 22.87 (Œ 2CH3), 28.16 (Œ 6 CH2CH3), 28.33 (Cj%COOBn), 35.06 
(CH2CONH), 36.61 (COCj^CHgCO), 49.69 (NHŒ/2COCH2), 67.19 (CHgPh), 
128.73, 128.85, 128.98, 129.08, 129.26 (aromatics), 170.15 (C=0), 171.22 
(C=0) and 204.46 (NHCH2COCH2).
8.95 Synthesis of N-pentanoyl-5-arninolevulinic acid (N-Pent-ALA) (ALA6).836
(76) (77)
N-Pentanoyl-5-aminolevulinic acid (77) was prepared using the same method as 
for N-acetyl-5-aminolevulinic acid (Reaction 8.91) but using N-pentanoyl-5-
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aminolevulinic acid benzyl ester (Reaction 8.94, 0.23 g, 0.76 mmol), yielding the 
product (77) an off white solid (0.12 g, 86%), m.p. 112-114 °C. Ôh (200 MHz, 
C^HjO^H) 0.9 (3H, t, J = 6.8 Hz, CH,), 1.4 - 1.6 (4H, m, CiïjCftCHj), 2.3 (2H, 
t, J = 6.8  Hz, NCOCft), 2.5 - 2.7 (4H, m, COCftCftCO) and 4.1 (2H, s, 
COCHjN); 8c (50 MHz, C%O^H) 14.24 (CH;), 22.92 (CftCHj), 28.21 
(CH2CH2CH3), 29.51 (CftCOaH), 35.01 (CftCONH), 36.51 (COCftCHjCO), 
49.69 (NHCftCOCHj), 170.31 (C=0 ), 177.54 (CO2H) and 204.62
(NHCH2COCH2).
8.96 Synthesis of N-hexanoyl-5-aminolevulinic acid benzyl ester (N-Hex-ALA- 
OBn).*“
\  A  o
(53) ''CO^Bn
o
N-Hexanoyl-5-aminolevulinic acid benzyl ester (78) was prepared using the same 
method as for N-acetyl-5-aniinolevulinic acid benzyl ester (Reaction 8.90) but 
using freshly distilled hexanoyl (caproyl) chloride (0.2 cm^ , 0.19 g, 1.45 mmol), 
yielding the product (78) as a slightly yellow coloured solid (0.29 g, 94%), m.p. 
56-58 °C. ÔH (200 MHz, C^HClj) 0.9 (3H, m, CH3) 1.3 (4H, m) and 1.7 (2H, m, 3 
X CHî-Hex), 2.2 (2H, t, J = 7.1 Hz, NCOCH2), 2.7 (4H, m, COCH2CH2CO), 4.2 
(2H, d, J = 4.8 Hz, COCH2N), 5.1 (2H, s, CH2PI1), 6.2 (IH, bs, NH) and 7.4 (5H, 
m, aromatics); Sc (50 MHz, C^HCb) 14.40 (CH;), 22.85 (CH3CH2), 25.8 (CH2- 
Hex), 28.31 (CftCOOBn), 31.89 (CH2-Hex), 35.04 (CH2-Hex), 36.85 
(COCH2CH2CO), 49.68 (NHCH3COCH2), 67.17 (CHiPh). 128.57, 128.70,
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128.78, 128.84, 129.06 (aromatics), 172.67 (COHex), 173.69 (COOBn) and 
204.44 (NHCH2COCH2).
8.97 Synthesis of N-hexanoyl-5-aminolevulinic acid (N-Hex-ALA) (ALA7).836
(78) (79)
N-Hexanoyl-5-aminolevulinic acid (79) was prepared using the same method as 
for N-acetyl-5-aminolevulinic acid (Reaction 8.91) but using N-hexanoyl-5- 
aminolevulinic acid benzyl ester (Reaction 8.96, 0.2 g, 0.63 mmol), yielding the 
product (79) as an off white solid (0.12 g, 86%), m.p. I l l  - 113 °C. ôh (200 
MHz, tfHsO^H) 0.9 (3H, t, J = 6.25 Hz, CH,), 1.4 (4H, m, 2 x CHj-Hep), 1.6 
(2H, m, CH2-Hep), 2.2  (2H, t, J = 8.3 Hz, NCOC%), 2.7 (4H, m, 
COCH 3 CH 2C O ) and 4.1 (2H, s, COCH2N); 5c (50 MHz, C%O^H) 14.50 (CH3), 
23.68 (CH2CH3), 26.91 (CH2-Hex), 28.99 (COCH2CH2CO), 32.78 (CHj-Hex),
35.47 (CH2-Hex), 37.01 (COCH2CH2CO), 48.02 (NHCHiCO), 174.37 
(NHCOHex), 177.04 (CO2H) and 206.52 (NHCH2COCH2).
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8.98 Synthesis of N-heptanoyl-5-aminolevulimc acid benzyl ester (N-Hep-
ALA-OBn).
O
836
OHaH,N- JL H "
(80)
N-Heptanoyl-5-aminoIevulinic acid benzyl ester (80) was prepared using the same 
method as for N-acetyl-5-aminolevulinic acid benzyl ester (Reaction 8.90) but 
using freshly distilled beptanoyl chloride (0.23 cm^ , 0.22 g, 1.45 mmol), yielding 
the product (80) as a sbgbtly yellow coloured solid (0.26 g, 81%), m.p. 55-57 °C, 
ÔH (200 MHz, C^ HCla) 0.9 (3H, m, CH3), 1.3 (3 x 2H, m, 3 x CHz-Hep), 1.6 (2H, 
m, CHz-Hep), 2.2 (2H, t, J = 7.5 Hz, NCOCH2), 2.8 (4H, m, COCH2CH2CO),
4.2 (2H, d, J = 5 Hz, COCH2N), 5.1 (2H, s, CH^Pb), 6.2 (IH, bs, NH) and 7.4 
(5H, m, aromatics); 8c (50 MHz, C^HCb) 14.48 (CH3), 26.05 (CHs-Hep), 28.42 
(COCH2CH2CO), 29.42 (CHz-Hep), 31,99 (CHa-Hep), 35.06 (CHg-Hep), 36.90 
(COC7 6 CH2CO), 49.69 (NHC%C0CH2), 67.19 (CH2Pb), 128.52, 128.73, 
128.80, 128.83, 129.04 (aromatics), 172.68 (COHep), 173.74 (COOBn) and 
204.46 (NHCH2COCH2).
8.99 Synthesis of N-beptanoyl-5-aminolevulinic acid (N-Hept-ALA)
(ALA8)."""
(80) (81)
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N-Heptanoyl-5-aminoIevulinic acid (81) was prepared using the same method as 
for N-acetyl-5-aminoîevulimc acid (Reaction 8.91) but using N-heptanoyl-5- 
aminolevulinic acid benzyl ester (Reaction 8.98, 0.2 g, 0.6 mmol), yielding the 
product (81) as an off white solid (0.15 g, 90%), m.p. 110 - 112 °C. Ôh (200 
MHz, CfmO^H) 0,9 (3H, m, CH3), 1.4 (6H, m, 3 x CHj-Hep), 1.6 (2H, m, CHj- 
Hep), 2.2  (2H, t, J = 7.7 Hz, NCOCft), 2.7 (4H, m, COCftCftCO) and 4.0 
(2H, s, COCftN); 8c (50 MHz, C^ HaO^ H) 14.69 (CH3), 23.90 (CftCHj), 27.19 
(CHî-Hep), 29.73 (COCH^C^CO), 30.26 (CHj-Hep), 33.01 (CHj-Hep), 35.46 
(CHî-Hep), 37.07 (COŒ6 CH2CO), 48.02 (NHCftCO), 172.51 (NHCOHep), 
177.01 (CO2H) and 204.01 (NHCH2COCH2).
8.100 Synthesis ofN-acetyl-5-aminolevulinic acid (N-Ac-ALA) (ALA9).
HO2C
1.H3N
2, acetonitrile, 
acetic anhydride ». = 0
=0
829
-OH
(73)
NH 1
NH2.HC1 0 = /  I
(3)
Triethylamine (1.74 cm^ , 1.26 g, 12.5 mmol) was added to ALA.HC1 (Reaction 
8.15, 0.42 g, 2.5 mmol). This mixture was sonicated for 15 minutes before 
acetonitrile (10 cm^ ) was added. The solution was stirred and acetic anhydride 
(0.5 cm^ ) was added dropwise. The reaction was stirred at room temperature 
overnight resulting in formation of a black solution. A smaU quantity of 
decolourising charcoal was added and the mixture was refluxed for 30 minutes, 
filtered through Celite and concentrated under reduced pressure. The mixture was
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purified by column chromatography using ethyl acetate as the eluant yielding N- 
acetyl-5-aminolevulinic acid (73) as a white solid (0.24 g, 56%), m.p. 150 - 152 
°C. 8 h  (200 MHz, CfHCb) 2.1 (3H, s, CHj), 2.8 (2H, t, CRiCHiCO), 2.9 (2H, t, 
CH2CH2CO), 6.3 (IH, d, J = 10.1 Hz, NHCH=COH - enol) and 7.1 (IH, bs, 
NH); 8c (50 MHz, C^HCb) 23.41 (CH;). 28.17 and 28.51 (CHiCftCOzH), 
101.52 (CH), 135.48 (C-OH), 167.48 (CH3CO), 174.41 (COjH) and 203.12 
(NHCH2CO). Peaks corresponding to lit.*^ ’ were observed but there were some 
unidentified signals.
8.101 Attempted synthesis of N-acetyl 5-aminolevulinyl glycine methyl ester.
o C^QjMe O
H H H
O DCM, CHME o O
An attempt was made to prepare N-acetyl-5-aminolevulinyl glycine methyl ester 
using the same method as for N-acetyl-glycmyl-5-aminolevulinic acid hexyl ester 
(Reaction 8,89) but using N-acetyl-5-aminolevulinic acid (Reaction 8.100, 0.1 g, 
0.58 mmol) and glycine methyl ester (0.052 g, 0.58 mmol). This yielded only a 
very small amount (>2%) of impure product so the attempt was abandoned.
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8.102 Synthesis of N,N-dimethyî-5-aininolevulmic acid (ALA5). 837
HO2C HO2C
NH2.HCI
O HgO, fonmldehyde ) = 0  
H2,Pd/C
ALA.HC1 (Reaction 8.15, 0.84 g, 0.5 mmol) was dissolved in water (100 cm^). 
Formaldehyde (0.6 g, 0.02 mmol) and 10% Pd/C catalyst (0.084 g) were added 
and the mixtui'e was stirred at room temperature and atmospheric pressure, under 
an atmosphere of Hz for 20 hours. The mixture was heated to reflux then filtered 
through Celite to remove the catalyst. The filtrate was evaporated under reduced 
pressure and impurities of paraformaldehyde were removed by coevaporation with 
water. The product was recrystaUised fi*om acetone/ether giving N,N dimethyl-5- 
aminolevulinic acid (82) as a slighly yellow coloured solid (0.55 g, 56%), m.p. 
2 0 1  - 204 °C (Lit.*”  202 - 204 °C). Sh (200 MHz, ^HjO) 2.7 (2H, t, J = 6  Hz, 
CftCOO), 2.8 (2H, t, J = 6  Hz, COCftCHj), 2.9 (6 H, s, N(CH,)2), 4.4 (2H, s, 
NCHj) and 7.2 (IH, bs, NH); 5c (50 MHz, 'H^O) 30.54 (CiïjCOO), 37.44 
(CH2COCH2), 46.51 (NCffiCO), 67.22 (2 x CH3), 179.81 (COO) and 206.15 
(CO).
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